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Social constructionism posits that the dominant discourses embedded within society 
limit what can be written, spoken and thought about Alcohol and Other Drug (AOD) 
issues whilst maintaining ‘truth’ value. In turn, these discourses influence the way 
AODs are perceived within society, which has implications for research, policy 
debates and AOD-related behaviours. While there are some good examples of 
specific AOD issues being examined from a discursive perspective, there are few 
local examinations of the broad dominant discourses and narratives regarding AODs. 
I aimed to describe those Australian dominant discourses and narratives within 
which language concerning AODs is situated. It is possible that the internalisation of 
these discourses, and the subsequent impact on an individual’s perception, are salient 
variables that influence people’s use of AODs, co-morbidity and policy debate. The 
series of papers contained in this thesis explore the Australian discursive landscape 
in relation to AODs and describe the development of a psychometric tool that can be 
used in future research. 
The first paper describes a Foucauldian discourse analysis that was conducted of 
Australian media regarding AOD. Newspaper articles spanning a 12-month period 
(April 2005–2006) were analysed with the analysis triangulated with visual media 
and newspapers from five years prior. Six dominant discourses were found which 
framed AOD issues in Australia: Legal, Medical, Moral, Political, Economic and 
Glamorous (or ‘popular culture’). Consistent with previous analyses, the first four 
discourses primarily allowed only for negative and pathological narratives of drugs 
and drug use. Economic discourse, which allowed for neo-liberal constructions of 
AOD use, was limited to alcohol within the dominant culture. Meanwhile, 
Glamorous discourse provided an opportunity for a wide variety of narratives that 
serves people’s curiosity regarding celebrity culture. 
Whilst the research was being conducted, the phenomenon of novel psychoactive 
substances (e.g., synthetic cannabis) emerged as drugs of concern. This provided a 
unique opportunity to apply the first analysis of the broader AOD discourses to a 
specific issue. The second paper describes an exploration of the role that the media 
played in the emergence of synthetic cannabis. It was found that there was an 
intersection between the media, drug-related harm and policy reactions that was 
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limited by those dominant discourses by which media reporting was constrained. A 
literature review of synthetic cannabis and other newly emerging drugs is included in 
the appendices.   
Finally, a psychometric tool was developed that might be helpful in understanding 
how the internalisation of dominant discourses by individuals affects AOD-related 
behaviours (e.g., use, addiction, behaviour change, co-morbidity and policy debate). 
The third paper describes the development of the Dominant Discourses of Drugs 
Scale (DDDS), which was constructed to measure the degree to which each of the 
six Australian dominant discourses of drugs are internalised. This involved first 
developing and refining an item-set through substantive validity analysis. 
Confirmatory Factor Analysis (CFA) of the resulting items supported a six-factor 
model that was congruent with the six dominant discourses of drugs.  
To examine the construct validity of the DDDS, correlations between the six scales 
and locus of control were explored. Locus of control was measured using the Locus 
of Control of Behaviour Scale (LCBS). Since the factors structure of the LCBS has 
not been properly examined, CFA was conducted on the LCBS. The fourth paper 
describes these results, which suggest that while the internal locus of control scale is 
robust, the external scale appeared to fragment. Consequently, only the internal scale 
of the LCBS was examined in relation to the DDDS. The direction of the correlation 
between the DDDS and the internal scale of LCBS that is reported in the third paper 
was unexpected. Specifically, while it was predicted that endorsement of pathogenic 
narratives would be negatively correlated with internal locus of control, the medical 
scale of the DDDS was positively correlated with internal locus of control. While 
this does not necessarily reduce the validity of the DDDS, it is suggested that further 
research be conducted on the DDDS and that our understanding of the relationship 
between the internalisation of certain dominant discourses and locus of control might 
be more complex than previously believed.  
The research contained in this thesis has extended our understanding of the dominant 
drug discourses in Australia, and their relationship to media reporting, policy and 
AOD-related harm. It has led to the development of the DDDS, a psychometric tool 
that can be used in future research to further understand how the internalisation of 
certain dominant discourses affects policy development, AOD-related harm and 
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AOD treatment. In addition, the results of the fourth paper will be valuable for future 
researchers who use the LCBS.  
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Introduction 
Psychoactive drugs have been used throughout history to alter consciousness. 
Alcohol is thought to be one of the first psychoactive substances to have been used, 
with evidence of beer being brewed as early as 10,000 BC (Hanson, 1995). There is 
also evidence of a rich history of psychedelic plants being used to alter 
consciousness in both ancient Greece (Wasson, Hofmann, & Ruck, 2008) and by 
Indigenous people in the Americas (Bussmann & Sharon, 2006). In the late 
nineteenth and early twentieth century, technological advances led to the isolation 
and modification of the psychoactive chemicals in plants that led to an increase in 
the number of drugs available, including: morphine, heroin, amphetamine, cocaine 
and lysergic acid diethylamide (LSD). In the twenty-first century, there has been a 
rapid and exponential increase in the number of psychoactive drugs that have 
become available that are easily accessible through the internet.   
There has been significant variability in the types of drugs that have been 
used in cultures and the attitudes that have been held by individuals and institutions 
within those cultures toward these drugs (McAllister, Moore, & Makkai, 1991). 
These attitudes are embedded within the culture and reflect the socio-political milieu 
of both past and present (for discussion, see Palin & Beatty, 2000, pp. 11-22). 
Therefore a social constructionist paradigm has been used in the consideration of 
Alcohol and Other Drugs (AOD) in this research, because this paradigm asserts that 
both culture and history determine what is considered to have ‘truth-value’ within a 
consensual reality. Social constructionism assumes that people’s understanding of 
the world is not objective; rather, conceptual understanding is a fluid construction of 
individuals within a culture or society. Hence, while AODs have distinct objective 
pharmacological properties, a person’s understanding of AODs is influenced by 
various institutional and individual actors within that person’s culture, each of whom 
have particular interests and ideologies (Dingelstad, Gosden, Martin, & Vakas, 
1996). 
This thesis will first provide an overview of the social constructionist 
paradigm, and then consider how AODs have been socially constructed in Australia. 
It will examine the impact that Australian social constructions of AODs have on 
policy development and AOD-related behaviours, highlighting the need for 
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additional research to better understand the discursive frameworks that limit what 
can be written, spoken and thought about AOD issues whilst maintaining ‘truth’ 
value.  
Social Constructionism 
As a paradigm for investigation, two salient debates exist regarding social 
constructionism. First, Burr (2003) contends that there are essentially two forms of 
social constructionism, micro- and macro-constructionism. Shwandt (2000) has 
referred to these as ‘weak’ and ‘strong’ social constructionist paradigms, 
respectively. Within micro-social constructionism, the realities of individuals are 
seen as being primarily constructed through interactions in which discourse is 
exchanged. Alternatively, macro-social constructionism is concerned with how 
social structures and institutions influence individuals’ realities, and hence, is 
concerned with power. That is, since “views of reality are … culturally embedded, 
those views dominant at any time and place will serve the interests and perspectives 
of those who exercise the most power in a particular culture” (Patton, 2002, p. 100). 
Hence, the macro-social constructionism perspective would be most relevant to the 
investigation of the culturally and historically bound nature of attitudes regarding 
AOD. 
The second debate pertains to ontology and is referred to by Burr (2003) as 
the realism-relativism debate. While there has been extensive debate regarding the 
degree to which the scientific endeavour is able to determine the nature of reality, 
this debate has extended into social constructionism. Relativists have contended that 
the existence of an objective reality is unascertainable since the enquirer can only 
access his or her reality, and hence, can only consider this reality in the context 
within which it was constructed (Edwards, Ashmore, & Potter, 1995; Potter, 1998). 
Alternatively, critical realists assert that our representations of the world are an 
approximation of a single objective reality (Nightingale & Cromby, 1999; Parker, 
1998). Critical realists have argued that relativists forgo opportunity for social 
critique since neither the social structures that produce inequality nor concepts such 
as power and morality can be considered because there are “no grounds for 
adjudicating between different views” (Willig, 2001, p. 124). However, rather than 
being dichotomous opposing perspectives, relativism and critical realism might 
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better be considered as a two ends of a continuum. That is, while Foucault (1972) 
argues that “discourse form the objects of which they speak” (p. 49), this does not 
deny the existence of objects or institutions, but rather, highlights the way in which 
discourse influences how objects are perceived. Hence, relativists are still able to 
consider the role of social institutions and power; though acknowledge that 
discussion of such concepts involves discourse and thus is socially constructed.  
Given that social constructionism considers language to be the foundation of 
the human experience, Burr (2003) logically surmises that explanations of the social 
world be sought from the ‘linguistic space’ in which people co-exist rather than from 
within the individual. This ‘linguistic space’ has been investigated through 
examining either the way in which individuals purposefully utilise interpretive 
repertoires in social interactions (Potter & Wetherell, 1987), or the nature of 
culturally-shared dominant discourses that represent events or objects in particular 
ways (Foucault, 1969/1972).   
Macro-social constructionists are concerned with the discourses perceived by 
individuals as holding the most truth (Burr, 2003). These dominant discourses are 
entrenched ways of representing the world that “privilege those versions of social 
reality which legitimate existing power relations and social structures” (Willig, 2001, 
p. 107). Gergen (1985) argues that this dominance of the powerful creates social 
tension and it is this contested world that is socially constructed. In doing so, 
dominant discourses become salient in the construction and maintenance of 
dominant narratives – suggested by Rappaport (2000) to be “overlearned stories 
communicated through mass media or other large social and cultural institutions and 
social networks” (p.4). That is, dominant narratives are the prevailing stories and are 
constrained by the available dominant discursive frameworks. Hence from the 
macro-social constructionist perspective, the way that individuals perceive issues 
such as AOD use are constrained by the dominant discourses within a society, and 
expressed through dominant narratives. 
3 
Dominant Drug Discourses: Medicines, Non-drugs and Drugs   
Tupper (2008) has noted that within Western society, the word ‘drug’ has 
three discrete meanings that are implicit to discursive context within which the word 
is used: 
(i) Medicines: chemicals that are deemed to have therapeutic benefits, 
typically by medical authorities who restrict their use; 
(ii) Non-drugs: psychoactive substances regardless of their legal status 
and medical utility that are permitted to be used recreationally and are 
perceived to have low potential for harm (caffeine, nicotine, alcohol, 
etc.); and 
(iii) Drugs: psychoactive substances that are perceived to have a high 
potential for harm and are consequently subjected to control (typically 
criminalisation) and some Non-Drugs in certain circumstances (e.g., 
when they are used outside of the parameters that are deemed socially 
acceptable). 
It is the third meaning that is typically implicit to the use of the word ‘drug’ within 
dominant discourses regarding drugs. This meaning is evident in the dichotomous 
distinction that is often made between drugs and alcohol, such as that made within 
the titles of a number of Australian organisations, such as the “Western Australian 
Drug and Alcohol Office”, “Next Step Drug and Alcohol Services” and the 
Australian “National Drug and Alcohol Research Centre”. The term AOD will be 
used throughout this thesis to emphasise that alcohol is also a drug. Further, given 
the ambiguity regarding the meaning of the word drug, Tupper’s convention of 
distinguishing between Medicine, Non-drugs and Drugs will be used to clearly 
articulate the intended meaning.   
 In Australia, like most Western countries, the dominant discourses within 
which this third meaning of drugs (i.e., Drugs) is framed only allows for drugs to be 
constructed as pathological. For example, researchers have demonstrated how drugs 
are constructed as dangerous (Room, 2006), harmful (Lancaster & Ritter, in press; 
David Moore, 2008), corruptive and criminogenic (Stevens, 2007). Such 
constructions seem to suggest that drugs themselves have agency; however, a drug is 
simply a chemical compound until a person interacts with it. Nonetheless, certain 
drugs are ascribed more pathogenic agency than others. For example, Moore (2004) 
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has highlighted how each drug is constructed as a subject with a distinct personality, 
or ‘drugality’. Thus, while alcohol might be constructed as a larrikin, heroin is 
constructed as oppressive and crack as perverse.   
Within any discourse, certain subject positions are available in which the 
social roles of individuals are specifically defined. These subject positions demarcate 
what those individuals framed within the discourse are able to say and limit their 
actions. Consequently, dominant discourses can be considered to influence people’s 
identity and agency. For example, within neoliberal discourse, individuals are 
defined as rational and ascribed significant agency to ‘self-care’ – that is, “provide 
for their own needs and service their own ambitions” (Brown, 2005, p. 42). The 
dominant narratives regarding alcohol and other licit drugs (or Non-drugs; Tupper, 
2008) are typically framed within neoliberal discourse. Consequently, most 
individuals who use Non-drugs are afforded significant agency as neoliberal 
subjects.  
In contrast, the subject positions available within the dominant discourses for 
people who use illicit drugs (and also those who use licit drugs ‘abnormally’) have 
limited agency since their behaviour is being ‘controlled’ by a Drug, or they have 
certain deficits in personality or social status that ‘cause’ them to use Drugs 
(Southgate & Hopwood, 1999). For example, Elliott and Chapman (2000) have 
examined the dominant discourses surrounding a debate regarding the establishment 
of a proposed trial to provide medically-prescribed heroin as a treatment option for 
people with heroin dependence in the Australian Capital Territory (ACT). They 
focused on the way in which people who use heroin were portrayed through a 
discourse analysis of 412 letters and articles appearing ACT newspapers between 
1992 and 1997.  Elliott and Chapman found that people who use heroin were 
constructed by proponents of the trial as having a medical problem (i.e., sick), 
whereas opponents of the trial constructed people who use heroin as social pariah 
(i.e., deviants). 
The National Drug Strategy Household Survey, conducted by the Australian 
Institute of Health and Welfare (AIHW, 2011), estimated that in 2010 87.9% of 
Australians had consumed alcohol at some point in their lifetime, while 39.5% drank 
alcohol on a weekly basis. In contrast, the AIHW estimated that only 2.1% of 
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Australians had used amphetamines in the year prior to the survey and 0.2% reported 
using heroin or other opiates in the week prior to the survey. Since there is a 
comparatively low incidence of illicit substance use in contrast to licit substance use 
(AIHW, 2011), people who use illicit substances can be considered a minority group 
within Australian society. As such, dominant narratives concerning illicit substance 
use within Australia would be expected to be negative. That is, it is in the interest of 
the majority group to divert attention away from the harms attributable to their drugs 
(or Non-drugs) through the use of dominant discourses to construct negative 
narratives of illicit substance use. By controlling the language, and thus, “the very 
categories of reality that are opened to consciousness, those in power are served” 
(Patton, 2002, p.100).  
Those drugs that are used by the majority of Australian’s overwhelmingly 
cause the most harm. The 2010 National Drug Strategy Household Survey estimated 
that 15.9% of Australians drank at levels that placed them at-risk of experiencing an 
alcohol-related injury on a weekly basis (AIHW, 2011). It also estimated that 8% of 
Australians have experienced physical abuse by a person who has been drinking, and 
21.4% of Australian’s aged under 18-years had been harmed by another person’s 
drinking. A recent report by the Australian National Council on Drugs (2013) found 
that 13% of deaths of Australians aged under 25 are attributable to alcohol. Tobacco, 
which is smoked by 15.1% of Australians daily (AIHW, 2011), is associated with 
more deaths (Ridolfo & Stevenson, 2001) and morbidity (Das, 2003) than any other 
drug in Australia. 
Despite this, the 2010 National Drug Strategy Household Survey found that 
most people perceived heroin to be the drug most associated with a ‘drug problem’ 
(AIHW, 2011). Meanwhile, 6.5% and 2.2% of respondents nominated alcohol and 
tobacco respectively as the drug most associated with a ‘drug problem’ (AIHW, 
2011). Partly this discrepancy between harms and community attitude might be due 
to the question in the survey being framed in such a way that it excluded Non-drugs. 
Consequently, alcohol would not have been considered by many respondents to be a 
valid answer.  However, research worldwide has shown that attitudes towards licit 
drug use are overwhelmingly more favourable than attitudes towards illicit substance 
use (for discussion, see Room,2005). This is likely to be related to the legal status of 
the substances, since “by criminalizing the production, distribution, and use of 
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particular drugs, drug prohibition fundamentally transforms the … lenses through 
which much of society views the drug problem” (Nadelmann, 1992, p. 35).  
Put differently, prohibition creates a binary opposition. Brook and Stringer 
(2005) conceptualise a binary opposition as a hierarchical relationship that exists 
between two phenomena that is a structure of language such that the meaning of one 
phenomenon is determined by that which is not. In doing so, binary logic makes one 
phenomenon appear inherently good and its counterpart bad. The binary opposition 
between legal and illegal drugs means that legal drugs are attributed opposite 
properties to those attributed to illegal drugs. Consequently, legal drugs are 
perceived to be good, safe and innocent.   
The automatic contrast that occurs between these Non-drugs and Drugs 
might facilitate the psychodynamic process referred to as splitting. Smith and Berg 
(1997) have noted that splitting allows majority groups to project negative 
representations onto a scapegoat in order to maintain positive representations of 
themselves. That is, the negative aspects and harms associated with Non-drugs are 
projected onto Drugs, leading to a certain sense of denial regarding the harm 
potential of the substances. In turn, this increases the acceptability of these Non-
drugs and could increase the frequency and quantity that are consumed.        
Implications of Dominant Discourses of Drugs on Policy  
Australia’s AOD policy ostensibly aims to minimise the harm individuals 
and society experience from AODs (Ministerial Council on Drug Strategy, 2011). 
While Australia has had success in reducing some AOD-related harm (e.g., the 
incidence of AOD-related HIV), it could be argued that Australia’s policy response 
to AODs could be improved. Almost one in six Australian deaths is related to the use 
of AODs and AODs continue to contribute to numerous morbidities (Collins & 
Lapsley, 2008). The economic cost of AODs to Australian society has been 
estimated to be $55 billion annually (Collins & Lapsley, 2008).  
Some (e.g., Hughes, 2007; Nutt, 2012) have suggested that drug policy 
would be more effective if politicians payed more attention to the evidence; 
however, there are a range of factors that limit the use of evidence in developing 
policy in Australia. First, Ritter (2009) has noted that policy makers are often 
required to make decisions quickly. This limits the degree to which they are able the 
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synthesise research to inform policy decisions. Ritter found that among 32 
Australian health and policy makers, while most sought expert advice, decisions 
were also informed by “political viability, degree of community support and other 
non-evidentiary aspects of decision making” (p. 72). She noted that it is unclear how 
much impact each of these inputs have on the decision making process. Further, 
where evidence is used to develop AOD policy, Hughes (2007) has suggested that 
the process might be better described as policy-based evidence rather than evidence-
based policy, since evidence is often used selectively to support a predetermined 
policy direction.       
Evidence-based drug policy is also difficult to achieve since politicians are 
constrained by the available dominant discourses and perceptions of the extent to 
which these influence public perceptions. Through interviewing UK policy makers 
and reviewing key documents, MacGregor (2013) has highlighted how policy 
decisions are shaped by cognitive bias, ideology and pre-existing ideas about AODs. 
Further, the impetus for policy change is often driven by the media, who set the 
agenda for debate and define (and respond to) public interest (Brosius & Weimann, 
1996). The way in which the media defines the problem is also limited by the 
available dominant discourses. Consequently, the policies that are most likely to be 
enacted are those that are consistent with the dominant discourses (Stevens, 2011), 
and thus there is a tendency for policy to maintain the status quo. This tendency is 
evident in the policy responses to the rapid emergence of new drugs that has 
occurred over the past few years. 
Between 2009 and 2012 the European Monitoring Centre for Drugs and Drug 
Addiction (2013) identified the availability of 188 new drugs. The rate at which 
these drugs are entering the market is increasing exponentially. While this increase 
has been facilitated by technological advances that have led to easier access to drug 
synthetisation, the prohibition of illegal drugs has undoubtedly also been a 
contributing factor. Specifically, prohibition has led to the demand for cheaper and 
more potent drugs that are not scheduled and thus have fewer risks associated with 
distribution. Further, supply control does little to reduce the demand to use 
psychoactive substances (Werb et al., 2013). Yet most policy responses to these new 
drugs entering the market, including those in Australia, have been reactive to media 
hysteria (Lancaster, Hughes, Spicer, Matthew-Simmons, & Dillon, 2011) and 
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consistent with the status quo – the newly identified substances are banned and 
tougher analogues laws introduced. This has led to new drugs entering the market to 
replace those that have become illegal, while some newly illegal drugs have emerged 
on the black-market (see Appendix A).     
To minimise harm, the degree of regulation placed on a psychoactive 
substance should be directly proportional to its potential to cause harm (Mugford, 
1993). A group of researchers in the UK had experts rank the harms of numerous 
drugs using multi-criteria decision analysis (Nutt, King, & Phillips, 2010; Nutt, 
King, Saulsbury, & Blakemore, 2007). They consistently found that drugs such as 
alcohol and tobacco were ranked as more harmful than most illicit drugs. Hence, the 
legal status of a drug is not necessarily related to its potential to cause harm. Rather 
than being evidence-based, current drug laws are historically bound. Szasz (2003) 
has stated that the prohibition of a substance is not a consequence of its 
dangerousness, but rather, we regard a certain substance “as harmful in order to 
maintain our justification for prohibiting it” (p. 34). 
Second, rather than simply providing solutions to AOD-related issues, drug 
policy first constructs these as problems, which then limits the responses that will be 
considered acceptable (Fraser & Moore, 2011). Through conducting a discourse 
analysis of the Australian National Drug Strategy documents from 1985-2012, 
Lancaster and Ritter (in press) have been able to show the way in which the 
construction of the AOD problem has changed over time. For example, early 
documents constructed the problem in terms of AOD-related harm, whereas later 
documents constructed the problem in terms of the use of AOD. Acceptable policy 
responses to the problem of drug use focus on preventing the initiation of drug use 
and supply control; whereas the construction of the problem in terms of harm leads 
to strategies that address “the structures around the subject to reduce harms which 
may be experienced by the individual and the community” (Lancaster & Ritter, in 
press, p. 14).  
Finally, evidence-based drug policy is also problematic in practice since 
dominant discourses lead to a skewed ‘objective’ understanding of drugs. Within 
contemporary Western society, drug researchers have typically focused on 
understanding the harms associated with drug use. This dominant framework has 
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been referred to by Mugford (1991) as the ‘pathological paradigm’. Since research 
that is underpinned by the pathological paradigm is consistent with the dominant 
narratives of drug use, it is more likely to receive funding. The research findings then 
serve to perpetuate the dominant discourses since they consolidate the pathological 
narratives of drug use and indicate the need for further research to reduce use and 
harm. Such research aims to describe how individual and cultural deficits lead to the 
initiation and perpetuation of drug use (Karlsson, 2010). Yet many people who use 
drugs do not experience harm, and their use of drugs is not driven by deficits 
(Alexander, 2008; Hart, 2013; Reinarman & Levine, 1997; Shewan & Dalgarno, 
2005; Zinberg, 1984). 
As a dominant framework for AOD research, the pathological paradigm 
creates an absence of discussion regarding the role of pleasure in AOD use (Moore, 
2008). In turn, this limits the scope of drug policy. For example, because pathogenic 
narratives cannot coherently acknowledge pleasure, the notion of moderation (or 
controlled drug use) cannot be rationally discussed (Duff, 2008). Further, by not 
focusing on those individuals who do not experience problems associated with their 
use of AODs, there are also missed opportunities for research to understand factors 
that provide these individuals with resilience to harmful use.  
Implications of Dominant Discourses of Drugs on the Behaviour of 
People who use AODs   
While dominant discourses indirectly affect AOD-related behaviours as a 
consequence of policy development, they might also directly affect AOD-related 
behaviours through influencing people’s patterns of use, openness to seeking 
treatment and other behaviours associated with AOD-related harm. One process that 
might mediate these effects is internalisation. Burr (2003) has asserted that social 
constructionism is anti-essentialist, and thus, rejects the notion of a coherent and 
unified sense of self. Rather, an individual’s identity is an effect of language, and 
hence fragmented since individuals are continually constructing themselves through 
the discourse inherent to any given context. Consequently, it is reasonable to assume 
that behaviours associated with the use of legal drugs (e.g., binge drinking, drunk 
and disorderly behaviour, etc.) are perpetuated by the internalisation of dominant 
discourses that provide a neo-liberal subject position. 
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The internalisation of dominant discourse is consistent with Hacking’s notion 
of the ‘looping effect’ (Hacking 1995; 2006). Hacking posits that social science 
categorises people in order to understand human phenomena, such as those who 
consume AODs. Institutions are then established that create ‘knowledge’ about the 
categories with the view that research regarding these categories will help and/or 
subvert these individuals. The knowledge that is created then informs how people 
who fit within the categories think about themselves. Hence, some people who use 
drugs will internalise the constructions of the ‘drug user/abuser’ that emerge from 
research. Given that research on drugs is typically framed within the ‘pathological 
paradigm’ (Mugford, 1991), some people who use Drugs will internalise the 
aforementioned negative projections and the various subject positions and 
pathogenic narratives that are inherent to the dominant discourses of drugs. These 
dominant narratives might become part of a person’s identity, and could lead him or 
her to having a negative sense of self – feeling “trapped, restricted or oppressed by 
their identity” (Burr, 2003, p. 56). 
The internalisation of dominant narratives might be considered analogous to 
self-stereotyping (Hogg & Turner, 1987). As such, people who use a Drug could 
self-identify with those subject positions available within pathogenic narratives of 
drugs, such as deviants (Elliott & Chapman, 2000), addicts (Davies, 1997a; Rødner, 
2005), irresponsible (Barratt, 2012) or chaotic and disordered (Fraser & Moore, 
2008). In turn, this self-stereotyping could lead to people who use Drugs 
experiencing negative affect as a result of stereotype threat (Steele, 1997). 
Stereotype threat is the anxiety that emerges when “a negative stereotype about a 
group to which one belongs becoming self-relevant” (Steele, 1997, p. 616). For 
example, a dominate narrative pertaining to heroin users being social pariah, such as 
that which emerged from Elliott and Chapman’s (2000) analysis, might lead a person 
who uses heroin to perceive a degree of stigma and become anxious when 
confronted with social situations involving non-heroin users. This anxiety would 
conceivably result in the individual performing poorly during such interaction. 
Perceptions of stigma among people who use drugs have been found to be associated 
with reduced access to healthcare, increased experiences of discrimination and 
poorer mental health (Ahern, Stuber, & Galea, 2007).  
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Self-stereotyping (or the internalisation of dominant narratives) would also 
conceivably evoke self-fulfilling prophecies (Merton, 1948), leading to an increased 
likelihood of Drug users engaging in maladaptive behaviours that are consistent with 
the dominant narratives. Consistent with Merton’s notion of self-fulfilling 
prophecies, a comprehensive literature review by Archibald (1974) found 
overwhelming empirical evidence that individuals’ expectations about the outcome 
of an event reliably predict the occurrence of that outcome. An extensive review of 
social psychology experiments by Hilton, Darley, and Fleming (1989) highlight that 
an individual who believes that the outcome of an event will be negative is likely to 
engage in self-defeating behaviour, thus ensuring a negative outcome that is 
congruent with his or her expectancy.  
Consequently, self-stereotyping might decrease an individual’s self-efficacy 
(Bandura, 1982, 1997). Bandura’s model of self-efficacy involves: (a) efficacy 
expectancies, or an individual’s belief that he or she is capable of performing a 
behaviour; and, (b) outcome expectancies, or an individual’s belief regarding the 
subsequent outcome of a behaviour. Research has demonstrated that positive 
outcome expectancies predict intention to change behaviour (e.g., Dijkstra, De Vries, 
& Bakker, 1996; Dijkstra, Tromp, & Conijn, 2003). Hence, it would appear that 
individuals’ confidence in being able to successfully engage in behaviour change is 
diminished as a function of their perceived probability of a negative outcome. 
Perhaps then, self-stereotyping of dominant narratives concerning a lack of self-
control, such as those associated with being an ‘addict’, would reduce a Drug user’s 
intention to engage in abstinence or controlled use. It could also contribute to the 
person sabotaging his or her cessation attempt. Indeed, Miller (1996) has noted that 
negative beliefs are a salient contributing factor in relapse. 
The maladaptive behaviours associated self-stereotyping and the subsequent 
anxiety associated with stereotype threat could contribute to mental health co-
morbidities among people who use Drugs. Up to 50% of individuals with a 
substance use disorder concurrently experience one or more additional psychological 
disorders (Henderson, Andrews, & Hall, 2000; Teesson, Hall, Lynskey, & 
Degenhardt, 2000). Mueser (2003) describes four models of co-morbid mental health 
and AOD-related problems aetiology:  
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(i) the common factor model, in which common factors predispose the 
onset of both conditions factors; 
(ii) the secondary substance abuse mode, in which the onset of the 
AOD-related problem is caused by the psychiatric condition (cf. 
self-medication hypothesis and the alleviation of dysphoria 
model); 
(iii) the secondary psychopathology model, in which the onset of the 
psychiatric condition is caused by AOD use; and, 
(iv) the bi-directional model in which both conditions reciprocally 
perpetuate each other, but there no clear aetiology.  
While the pharmacological effects of psychoactive substances are generally 
proposed to precipitate the onset of the psychiatric disorder within the secondary 
psychopathology model, the role of being a minority group member could also 
precipitate the onset of a psychiatric disorder among people who use Drugs. Indeed, 
the incidence of mental illness is significantly higher among minority groups such as 
Indigenous Australians. That is, the onset, maintenance and even the exacerbation of 
pre-existing of co-morbid psychiatric disorders among people who use Drugs might 
be partly related to the negative effects of being a minority member, such as 
exposure to negative dominant narratives and the aforementioned behavioural and 
affective consequences of internalising these narratives. Indeed, negative affect has 
been shown to be a salient aetiological factor for a range of mental health problems 
(Brown, Chorpita, & Barlow, 1998; Chorpita, Brown, & Barlow, 1998).  
In support of this proposal, Pasion, Templer, and Walker (2001) found that 
self-reported illicit substance use was more strongly associated with affect than self-
reported licit substance use among a sample of 23 non-psychotic outpatients. Given 
that level of use was not controlled for, this outcome might be an artefact of Pasion 
et al.’s (2001) methodology. Nonetheless, prospective research has shown that the 
incidence of depression and anxiety subsequent to substance use disorders is also 
higher among people who use illicit substance than licit substance users (Merikangas 
et al., 1998; Regier et al., 1990). Further, Merikangas et al. found that the number of 
psychological disorders individuals experience was a function of their level of illicit 
substance use. While Merikangas et al.’s results could also be interpreted as 
supporting the bi-direction model of aetiology, in which there is mutual influence 
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between illicit drug use and mental health; together, these findings suggests that 
factors common to illicit substance use, discriminative from licit substance use, 
appear to increase negative affect and the incidence of psychological disorders. 
Stigma and the effects of exposure to negative dominant narratives regarding such 
illicit drug use could be one such factor (as could others such as legal and financial 
problems which tend to be more common to illicit than licit drug disorders). 
People who use Drugs who internalise the pathogenic narratives might also 
be more likely to have an external locus of control. Therapists from a range of 
perspectives (e.g., Beatch et al., 2009; Teyber, 2000; Yalom, 2002) have contended 
successful behaviour change requires individuals to take personal responsibility for 
their behaviour. Hence, internalisation of medical discourse by individuals 
experiencing problems associated with their substance use could hinder their 
behaviour change efforts. However, Keene and Raynor (1993) found that 
internalisation of pathogenic narratives, such as the disease model of addiction, was 
associated with positive treatment outcomes in 12-step programs (e.g., Alcoholics 
Anonymous). Similarly, Hammer, Dingel, Ostergren, Nowakowski, and Koenig 
(2012) found that many of the participants that they interviewed who were engaged 
in treatment believed that a genetic/medical understanding of their behaviour had 
utility in assisting their effects to change their behaviour. Hammer et al. (2012) noted 
a range of narratives that had diverse outcomes. Perhaps then, people who internalise 
certain dominant discourses might have better outcomes when they are matched to a 
particular treatment that shares this understanding of addictive behaviour. For 
example, people who endorse medical narratives of AOD-related problems might 
respond better to pharmacotherapy. 
The degree to which people internalise negative dominant narratives might 
vary considerably depending on an individual’s personality, the type of drugs they 
use and the frequency and quantity of their use. For example, Rødner’s (2005) 
examination of Swedish illicit substance users’ identity using micro-constructionist 
discourses analysis found that some people who use illicit substance might avoid 
internalising negative dominant narratives by emphasising alternant narratives. Many 
of Rødner’s participants presented themselves as having good self-control, 
differentiating themselves from ‘drug abusers’. Indeed, Sonn and Fisher (1998) have 
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postulated that it would appear that there are differences in resilience to dominant 
narratives.  
Like politicians and policy makers, psychologists are not impervious to the 
negative dominant narratives. The Australian Psychological Society (APS, 2003) has 
expressed a concern that many psychologists are reluctant to work with people who 
experience problems with AOD use since they are often perceived as being difficult 
clients. Internalisation of negative dominant narratives by psychologists would 
conceivably reduce the efficacy of treatments provided to people who use illicit 
substances as a result of the Pygmalion effect – the consistent finding that an 
individual will often behave in ways that are consistent with others’ expectations (for 
review, see Rosenthal, 1995). For example, Hakan (1990) has illustrated that 
clinicians’ perception of clients who use AODs as motivated or unmotivated to 
change can have an impact on treatment outcome.  
Aims 
The dominant narratives embedded within Australian society have the 
potential to impact upon people who use AODs, AOD-related behaviours, policy 
debate and health professionals’ interactions with people who use AODs, including 
the way in which they develop treatments. Hence, it is important that the role 
dominant discourses play in constructing AODs is well understood. While previous 
research has added to this understanding, it has often focused on specific issues, 
including: prescription heroin programs (Elliott & Chapman, 2000; Lawrence, 
Bammer, & Chapman, 2000), people who inject drugs (Fraser, Hopwood, Treloar, & 
Brener, 2004), celebrity drug use (Seear & Fraser, 2010a, 2010b), methamphetamine 
(Dwyer & Moore, 2013; Dwyer et al., 2012), para-methoxyamphetamine (Barratt, 
Allen, & Lenton, in press), policy (Lancaster & Ritter, in press) and rave culture 
(Gibson & Pagan, 2000). I aimed to synthesise and extend this research to develop 
an overarching description of the Australian dominant discursive landscape within 
which AOD use is situated. I also sought to enhance our understanding of the 
processes by which people internalise dominant discourses. To assist in this 
endeavour, I aimed to develop a psychometric tool that measured the degree to 
which individuals internalise dominant discourses of AODs since such a tool would 
allow for quantitative analysis of the interaction of discourse with psychological 
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constructs, such as locus of control. The resultant tool could then be used in future 
research to examine how the internalisation of the internalisation of dominant 
discourses affect AOD-related behaviour, addiction treatment, substance use co-
morbidity and policy debate.     
Design 
A two-phase sequential mixed design was used. Creswell (2003) asserts that 
mixed design research capitalises on the flexibility and vividness of qualitative 
methodology whilst preserving the structure of quantitative methodology. Thus, 
mixed design research captures the best of both methods. An exploratory sequential 
procedure (Creswell, 2003) was conducted in which the inductive nature of 
qualitative inquiry was used to explore the concept of dominant narratives pertaining 
to substance use, followed by quantitative inquiry to develop a psychometric tool 
that can be used in future quantitative inquiry, whilst also providing an iterative 
method of ensuring the credibility of the qualitative results. In the first phase of the 
research, the dominant narratives pertaining to AOD in Australia were elucidated 
through Foucauldian discourse analysis. In the second phase of the research, a short 
psychometric instrument was developed, which is proposed to measure the 
congruence between individuals’ beliefs and the dominant narratives that emerged 
from the first phase of the research. Development of this instrument involved item 
generation, substantive validity analysis, confirmatory factor analysis, and an 
examination of validity.  
In conducting mixed design research, Creswell (2003) has highlighted the 
possible complications that could arise as a result of contradictory qualitative and 
quantitative paradigmatic assumptions. In an endeavour to reduce such 
complications, the overarching paradigm of the proposed research was consistent 
with that which Creswell has presented as being conducive to mixed methodology. 
This paradigm can be articulated through addressing each of the four axiomatic 
features that Lincoln and Guba (2000) suggest are inherent to any paradigm.  
First, the ontological perspective can be considered to be relativistic, in that 
while I assume the existence of an objective reality, the nature of this reality cannot 
be ascertained due to the influence of discourse in producing objects (Nightingale & 
Cromby, 1999; Parker, 1998). Nonetheless, through the use of multiple methods, an 
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array of perspectives that describe reality can be considered. Consequently, 
relativism does not preclude quantitative enquiry, though does limit the conclusions 
that can be drawn from such methodology. Second, the epistemology within this 
research is pragmatic – the pursuit of knowledge is problem-focused and is directed 
by the researcher’s anticipated consequences of pre-existing knowledge 
(Cherryholmes, 1992). As such, in relation to the third paradigmatic axiomatic 
feature of axiology, research is necessarily reflexive. That is, because research is a 
value-laden process it is important that the enquirer reveal pre-suppositions and 
motives. While in the past subjectivity has been viewed as having a negative impact 
on research results, it can also be acknowledged and used to help understand the way 
in which objects are constructed. In interpreting the research presented in this thesis, 
it is thus important to note that the author values freedom of choice and believes that 
people who use AODs have the ability to make rational decisions regarding the use 
of AODs if provided with the opportunity to do so. Finally, the methodology 
involves both emergent and predetermined methods. That is, the type of information 
collected is both specified in advance of the study and develops from participants in 
the project.   
Outline of papers included in this thesis 
 Four papers emerged from this research. These papers are outlined in the 
following section.  
The first paper in this thesis (Paper 1) presents a discourse analysis of 
Australian media that sought to elucidate the dominant discourses that are available 
to frame AOD in Australia. A search for articles that referred to AOD in The West 
Australian and The Australian between April 2005 and April 2006 was conducted 
using Factiva using the key words: alcohol, amphetamines, beer, caffeine, cannabis, 
coffee, drug, ecstasy, heroin, ice marijuana, meth, nicotine, pot, substance, smoking 
and wine.  
Of a total 2,576 AOD-related articles that were retrieved, a sample of 75 
articles was sought from each newspaper. Two articles were excluded due to 
ambiguous content. The remaining 148 articles were analysed with the analysis 
triangulated with visual media and newspapers from 5-years prior. The analysis 
involved an iterative process of identifying the discourses that were used through 
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consideration of the available subject positions, the way in which drugs were 
constructed, the implicit ideologies and the relationship of these ideologies with 
institutions. It revealed that six dominant discourses are available to frame AODs in 
Australia: medical, legal, economic, moral, political, and ‘glamorous’ (or popular 
culture). The paper describes the symbiotic relationships between these discourses 
and how they maintain the institutional structures that are dominant within 
Australian society. It also describes some of the narratives that are framed within 
these dominant discourses.        
The second paper (Paper 2) describes the application of the discursive model 
from Paper 1 to a specific issue that emerged during the research process. In 
Australia, synthetic cannabis emerged as drug of concern using 2011. The most 
notable brand of synthetic cannabis was Kronic. Through using Google Trends, 
Paper 2 describes how there was increased Google searches for synthetic cannabis 
and Kronic that had a strong relationship with news media being generated at the 
time. Data from a survey of 316 people who had used synthetic cannabis indicated 
that many used synthetic cannabis for the first time after the initial media attention.  
A discourse analysis of key news stories, as identified by Google Trends, 
highlighted how synthetic cannabis was initially framed outside of the dominant 
discourses identified in Paper 1. People who use synthetic cannabis were initially 
positioned as neo-liberal subjects. However, the subsequent media stories were 
framed within the dominant discourses – particularly medical and moral discourse. 
In doing so, a moral panic was created to which governments reacted contributing 
further to the moral panic. This highlights the dynamic interface between discourse, 
policy and drug-related harm, whilst providing further evidence of the underlying 
discursive structure within which AODs can be framed. 
 Paper 3 describes the development of a psychometric instrument that is 
hypothesised to measure the degree to which individuals internalise the dominant 
discourses from Paper 1. A total of 60 items were developed to measure the six 
dominant discourses. Each item reflected a potential narrative that constructed drugs 
in a manner that would be congruent with the relevant discourse and included (either 
implicitly or explicitly) at least one of the subject positions to that discourse. A 
substantive validity analysis was conducted among 20 people seeking treatment at a 
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Perth residential facility. At least four items were retained for each discourse and 
used to construct the Dominant Drug Discourses Scale (DDDS). The DDDS was 
administered to 348 people attending Perth treatment agencies. Several plausible 
models were tested using Confirmatory Factor Analysis (CFA). The best fitting 
model had six correlated factors that corresponded with the six dominant discourses. 
It was hypothesised that since certain discourses produced pathological 
narratives with subject positions in which agency was limited, these scales of the 
DDDS would be negatively correlated with internal locus of control. Meanwhile, 
since economic discourse positions people as neoliberal subjects, it was hypothesised 
that this scale would be positively correlated with internal locus of control. Such 
findings would provide evidence of the DDDS’s construct validity. Hence, the Locus 
of Control of Behaviour Scale (LCBS) was additionally administered to participants.  
However, the LCBS has not been subject to CFA. The final paper (Paper 4) 
describes the CFA of the LCBS. Contrary to the proposed factor structure that is 
described by the authors of the LCBS (Craig, Franklin, & Andrews, 1984), a single 
factor structure did not fit the data. Alternative models were examined that were 
consistent with a multidimensional conceptualisation of locus of control. The best 
fitting model consisted of an internal locus of control factor and four external loci of 
control factors; however, the fit is probably best described as ‘reasonable’ rather than 
‘good’. A subsequent exploratory factor analysis using parallel analysis indicated 
that while the Internality factor was cohesive, the Externality factor showed a 
tendency to fragment into smaller components. 
Consequently, the analysis of the correlations between the DDDS and locus 
of control only used the Internality factor of the LCBS. Contrary to prediction, the 
medical discourse scale of the DDDS was found to be negatively correlated with 
Internality factor of the LCBS. No other DDDS dimensions were correlated with the 
Internality factor of the LCBS. This could be construed as evidence against the 
validity of DDDS, or that the medical discourse does not limit agency. Alternatively, 
it is possible that individuals who endorsed items in the medical discourse scale, and 
indeed the other scales, might apply these narratives to others but not themselves 
since they are not personalised. However, the economic discourse scale of the DDDS 
was negatively correlated with the medical, moral, legal, and political discourse 
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scales. This could be considered further evidence of construct validity of the DDDS 
since economic discourse was hypothesised to provide individuals with increased 
agency, 
The results from Paper 3 provide increased credibility of the analysis from 
Paper 1, and also further our understanding of the structure of discourse. Despite 
medical, moral, legal and political discourse providing space for pathological 
narratives of drug use, the data did not support a single pathological discourse factor. 
This suggests that the four discourses are discrete and supports the way in which 
discourse is generally conceptualised (Burr, 2003; Dingelstad et al., 1996). The 
DDDS can be used in future research to further our understanding of the role that 
discourse plays in shaping policy, research, health professionals’ interactions with 
people who use AODs, including the way in which they develop treatments, and 
AOD-related behaviours.    
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narratives emergent from Australian media 
21 
Bright, S. J., Marsh, A., Bishop, B., & Smith, L. M. (2008). What can we say about 
substance use? Dominant discourses and narratives emergent from Australian media. 
Addiction Research & Theory, 16, 135-148. 
Addiction Research and Theory
April 2008; 16(2): 135–148
What can we say about substance use? Dominant
discourses and narratives emergent from
Australian media
STEPHEN J. BRIGHT, ALI MARSH, LEIGH M. SMITH,
& BRIAN BISHOP
School of Psychology, Curtin University of Technology, Perth, Western Australia
(Received 20 April 2007; revised 11 October 2007; accepted 26 October 2007)
Abstract
Discourses are conceptualised as context-specific frameworks that constrain what can be presented
as rational when considering psychoactive substances. Given the implications of this for Australian
policy debate and development, research and health promotion, an integrative analysis explored
the nature of the dominant discourses as they pertain to substance use. Newspaper articles spanning
a 12-month period (April 2005–2006) were analysed with the analysis triangulated with visual media
and newspapers from 5-years prior. We conclude that within Australia, psychoactive substance use is
framed within the dominant discourses of medicine, morality, law, economics, politics and popular
culture. The linguistic landscape circumscribed by each discourse is described and the power
dynamics underpinning the maintenance of the discourses considered, with each discursive framework
shown to delineate unique subject positions that define the numerous individuals concerned with
substance use issues (e.g. substance users, politicians, medical experts, etc.).
Keywords: Discourse, media, Australia, psychoactive substances, policy debate
Introduction
Many of the concepts, theories and definitions of substance use that are present within
Australian society can be considered socio-cultural constructions – linguistic products of a
particular set of historical circumstances (e.g. Keane 2002; Moore and Rhodes 2004;
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Spooner 2005). Foucault (1969, 1972) conceptualised such constructions in terms of
discourses, which are described by Hall (1997) as systems of statements that:
produce the objects of our knowledge [and] govern the way a topic can be meaningfully talked
about and reasoned about. [They] also influence how ideas are put into practice and used to
regulate the conduct of others (p. 44)
That is, in constructing an account of reality, discourses inherently make available specific
subject positions. Put simply, subject positions are social roles implicitly defined within
discourses that stipulate how the person being spoken about can or cannot talk, write or act.
Foucault’s (1984) later work emphasises the relationship between discourse and power, in
which constructions of reality are intimately related to the interests of particular institutions
that occupy positions of power within society. Hence, particular discourses will be more
dominant within any given context, relative to these social structures. The present article will
focus on Foucault’s earlier definition of discourse that regardless of the interests of
social institutions, dominant discourses becomes self-perpetuating due to the broad
acceptance of these constructive frameworks within society.
For example, in considering the rhetoric inherent to particular debates surrounding
substance use, Dingelstad et al. (1996) have illustrated that each debate tends to be framed
by distinct discourses (or dominant to the particular context), each of which functions to
privilege the interests of particular institutions. Thus, with regard to the issue of substance
use in sport, Dingelstad et al. (1996) proposed that debate is commonly framed within
a moral discourse that perpetuates a construction of the behaviour (e.g. drug use is wrong)
consistent with the interests of the sporting conglomerate whose aim is to promote the image
of sport as ‘fair’ and ‘pure’ to ensure the institution’s financial security. Moreover, this
discursive framework denies certain act (e.g. athletes who use drugs) from having a voice,
through the determined availability of a limited number of subject positions. In this case,
athletes who use drugs are denied a voice as a consequence of their being ‘immoral’, which is
diametrically opposed to the ‘sport as pure’ ideology implicit to the moral discourse.
From a psychological perspective, dominant discourses can be conceptualised
as worldviews, or schemas (Beck et al. 1979; Young et al. 2003) that are widely accepted
by the majority of people within society. That is, they pertain to the dominant cultural
group and provide members of society with the cognitive structures that organise
their perceptual information. Thus, each discursive framework will produce different (and
often incommensurate) approximations of the material reality that the institutions and
social structures from which discourses ultimately arise are operating. In this way,
discourses might be thought of as frames ‘within which representations of the reality of
drug use can be depicted . . . [and] influence the picture it encompasses’ (Martin and
Stenner 2004, p. 396).
This conceptualisation of discourses is consistent with Harre’s (1995) celebration
of discursive psychology as the second cognitive revolution and has wide-ranging
implications. For example, Australia’s emphasis upon the contribution of illicit substances
in creating problems within society, despite licit substances creating a larger social burden
(Australian Institute of Health and Welfare 2005), might be explained by dominant
discourses that maintain this version of reality. Specifically, once dominant discourses are
internalised by individuals, the resulting schemas frame their perception in such a way that
it ‘makes sense’ for licit substances to be less problematic. Similar processes are perhaps
salient in policy development, such that politicians’ dialogue, text and thoughts become
constrained by discursive frameworks, thus precluding deviations from the status quo.





























































That is, apparent variations in policy simply reflect fluctuations in the degree to which
incompatible discursive frameworks are favoured – same debate but a different winner. In
this respect, the content of debates concerning ‘harm-minimisation’ vs. ‘zero tolerance’
can be considered temporally static, such that changes in public opinion and policy with
regard to this debate only reflect the perception of substance use being viewed through a
different frame. Further, those discourses that are dominant at any given time will
influence the paradigmatic focus of research, such as that of the ‘addiction as a disease’
inherent to the biomedical paradigm (Reinarman 2005). It is reasonable to assume that the
relationship between discourses and research underpinned by particular paradigms is
reciprocal, such that research results further establish the dominance of particular
discourses.
Indeed, it becomes apparent that the maintenance of particular realities of substance use
exists within a dynamic system. Ultimately, individuals using substances are deeply affected
by this system, such that they may dismiss the harms associated with certain substances, or
become marginalised for using other substances such that they engage in risky behaviours.
Hence, in understanding numerous substance-related issues, it would be useful to articulate
the dominant discursive frameworks that substance users, researchers, politicians and the
public are immersed in.
Currently, however, there is a paucity of research that has investigated the dominant
discourses used to frame substance use within Australia in a comprehensive manner. Largely
such investigations have been confined to specific issues, and lack an integrative analytic
approach, with the analyses of discourses limited to particular discursive elements.
For example, the two most recent examinations of the discursive context within which
substance-related issues are constructed in Australia were limited to the exploration
of newspaper articles discussing a very specific issue (e.g. heroin prescription; Lawrence
et al. 1999) or a very specific subsection of the substance using population (e.g. heroin users,
Elliott and Chapman 2000). Moreover, the analytic procedures adopted were limited in
terms of their comprehensiveness, with Lawrence et al. (1999) failing to indicate the
theoretical underpinnings of their approach and conclusions; and Elliot and Chapman
limiting their analyses to the subject positions available in the texts without consideration
of the discourses within which these positions were situated, nor the institutions
being reinforced by these discourses. Indeed, as Hook (2001) noted this lack of
comprehensiveness when conducting discursive analyses renders superficial interpretations,
yet is frequently observed in the literature.
Consequently, despite the aforementioned implications of discursive formations upon the
way in which drug use is constructed, theorised, understood, talked about and experienced,
there remains a paucity of research exploring the content, nature and impact of the
dominant discourses in Australia. This investigation, was therefore conducted in response to
this dearth of information, with the authors hoping to provide a more comprehensive
articulation of the dominant discourses in which substance use is framed in Australian
society, as well as instigate more serious consideration of the practical and theoretical
implications of how the issue of drug use is typically spoken about.
Method
Both a major state and national Australian newspaper, The West Australian and
The Australian respectively (Roy Morgan 2005), were chosen for the analysis, since it





























































was believed that this would provide a representative sample of the dominant discourses
in Australia, with each newspaper having special editions and popular culture sections.
Given the geographic size of Australia, local community newspapers were not included
since the results could become confined to only a small section of Australian society.
A search for articles pertaining to substance use printed between April 2005 and April
2006 was conducted using the Factiva electronic database system. The search used an
array of keywords inclusive of the Australian cultural vernacular relating to substance use
including: alcohol, amphetamines, beer, caffeine, cannabis, coffee, drug, ecstasy, heroin,
ice, marijuana, meth, nicotine, pot, substance, smoking and wine. The search appeared to
have reached saturation at as no new articles were being found in the later searches.
A total of 1080 articles from The West Australian, and 1496 articles from The Australian
were retrieved. A random sample of 75 articles was taken from each newspaper. The
content of 53% of these articles concerned illicit substance use, 37% licit substance use,
and 8% included a reference to both illicit and licit substance use. Two articles contained
ambiguous content and could not be classified.
An analysis of the discourses and their content was conducted on the articles. Following
the suggestions of Parker (1992) and Willig (2001), this involved an iterative process
of distinguishing between discourses through considering the subject positions that were
made available within the text, the way in which objects (e.g. psychoactive substances)
were constructed and the ideologies inherent to the text. As these discourses emerged,
they were further explicated through determining how the inherent qualities of the
discourses reflected institutions and how might this serve to reinforce particular
institutions.
To ensure credibility (Nagy and Viney 1994), the data was triangulated with both an
episode of Insight that examined the prevalence of substance use among young people and
aired on SBS in May 2005, in addition to older newspaper articles. Using the procedure
for obtaining the first sample, eight articles were sampled from each newspaper that
appeared 5-years prior to the first sample to validate the final interpretation since discursive
formations are conceptualised by Foucault (1966, 1970, see also 1969/1972) as being
universal to an episteme. Further, inter-coder reliability testing was employed with
competing interpretations being constantly scrutinised. Finally, rigour was ensured through
an audit trail documenting the emergent analysis (Morse 1994).
Results and discussion
Overview
The analysis revealed dominant discourses that are reflective of the institutional structures
that dominate Australian society. Discourses were considered dominant in that other
discourses and narratives could be situated within these overarching frameworks. Further,
the discursive frameworks needed to adequately account for all psychoactive substance use
(despite differences in how substances were individually situated within the discourse).
Through carefully considering competing systems of classification, it was finally
determined that medical, legal, economic, moral and political discourses constituted the
primary discursive frameworks within which representations of substance use in Australia
is constructed. In addition, a ‘glamorous’ discourse emerged from the analysis that is less
reflective of any single institutional structure than of popular culture. The pattern in
which each dominant discourse and its various discursive constructions were used





























































(and associated narratives invoked) varied according to the type of substance being
considered within the text (e.g. licit vs. illicit).
Medical discourse
The medical discourse encapsulates the disease theory of addiction that has been popular
since the 1960s (Miller and Hester 1989). This discursive framework constructs
psychoactive substances as pathogens, and thus inherently dangerous. Typically this
framework makes available two categories of subject positions, those who are experts
(doctors, researchers, etc.) and those who are unwell (patients, drug users, etc.). These two
types of subject positions made available by the medical discourse are contrasted in terms
of the actors’ agency, with ‘experts’ imbued with an inherently active status, compared to the
passivity that is implicit to the subject status of those who are ‘unwell’. Hence, the medical
discourse functions to construct the drug user as passive/without agency and thus narrates
stories of how such subjects fall victim to the agent (substance/pathogen), the effects
of which are constructed to account for the difficulties such subjects experience.
Exemplified in the following excerpt is the manifestation of the ‘disease’ of addiction and
its explanatory power:
His addiction to amphetamines or speed was so strong that Mr Marquet would sometimes
inject himself while sitting in his Parliament House office after doing a drug deal at the West Perth
building. (The West Australian, 24 April 2006)
Within contemporary Western society, this discourse holds substantial ‘truth’ value since
the empirical essence is consistent with the current episteme in which reason and rationality
are given preference (Foucault 1970), and in which health can be conceptualised as
analogous to deity (Fleising 2000). Hence, medical discourse pervasively frames both illicit
and licit substances. In contrast to the previous quote, however, when licit substance use is
framed within this discourse, the pathogenic effects are typically confined to physiological
ailments (e.g. cancer, cirrhosis), with the exception of marginalised populations such as
indigenous Australians. That the disease of addiction is a reasonable and frequent
consequence of exposure to licit substances for these populations but not the dominant
group is implicit within the following excerpt:
Asked if his trust is doing anything to combat the scourge of alcoholism on [indigenous]
communities, Thorpe says he supports trying to create a society where people ‘‘do not have
a dependency on alcohol and use it as an out’’. (The Australian, 8 October 2005)
Further, physiological ailments are confined to individuals deviating from the normative
behaviour of the dominant group such as tobacco smokers and those consuming excessive
quantities of alcohol. This can serve to normalise the consumption of licit substances among
members of the dominant group, whose normative behaviours might even be expected to
benefit their health, despite contrary evidence (e.g., Fillmore et al. 2006). Thus, the position
of the medical institution within society is perpetuated through concurrently reinforcing
normative behaviours and marginalising minority groups.
That medical discourse serves to benefit the medical institution at a detriment to users
of substances less endorsed by the institution has been identified by Szasz (1985).
Specifically, Szasz has contended that it is in the interest of the medical institution to vilify
certain substances in the same way that witches were labelled as heretics by the religious





























































institution to ensure retention of power. Indeed, it is in a similar fashion to the hysteria
during the witch trials of Salem that the threat of exposure to pathogens is highlighted
through an epidemic narrative. Within this narrative, in which ‘drugs are like a spreading
cancer’ (The Australian, 29 August 2005), there is an implicit assumption that the medical
institution is required to curb this epidemic through their treatment/cures. This is evident in
the following extract:
Leading Australian psychiatrists are calling for a radical review of mental health care . . . [with]
the nation’s mental health crisis . . . bring driven by epidemic rates of methamphetamine use.
(The Australian, 29 July 2005)
In doing so, however, users must first be coerced to acquiesce, foregoing autonomy and
agency in order to be cured. Further, the epidemic narrative reinforces the legal institution
since preventing exposure to pathogens involves curbing the availability of substances
through supply control, evident in the statement ‘a binge-drinking epidemic [has resulted
from] easing licensing laws’ (The Australian, 7 January 2006).
Legal discourse
Legal discourse was identifiable from other discourses through the use of jurisprudent
language to demarcate certain substance using behaviours as illegal. Two primary subject
positions are available within this discursive formation; that of the law administrator (police
officer, lawyer, etc.) and that of the people whom the law affects. The subject position
of those affected by the law consisted of both those who do and do not abide by the law
(i.e. are criminals), with precedence given to the law abider. This extends to the
classification of substances, evident in the licit/illicit dichotomy, in which precedence is
given to the former.
Indeed, illegal behaviours related to the use of legal drugs (e.g. drink driving and under-
age drinking) tended to normalise the use of these substances through highlighting that
characteristics of offenders were not those of dominant society. For example, an article in the
West Australian on ‘alcohol fuelled beachfront brawls’, reported that ‘thousands of young
revellers – including many underage teenagers – flocked to Cottesloe beach from all parts
of Perth and kept police busy as several fights broke out after midnight’ (2 January 2006).
Hence, the perpetrators were discriminated from the wider population through highlighting
that most were not legally allowed to consume alcohol, thus exonerating the substance from
the incident. Notwithstanding this, Forsyth (2001) has contended that certain beverages
such as ‘alcopops’ can be portrayed as having agency in a similar way that illicit substances
are portrayed as pathogens, and thus are to blame for non-normative behaviour that can
serve to normalise alcohol in general (i.e. it is only certain drinks that are problematic);
however, this was not observed in the present analysis, though could be implied in the
references to under-age drinking since these individuals are generally associated with the
consumption of ‘alcopops’.
In contrast, illegal substances are implicated as being responsible for antisocial behaviour,
evident in the close in-text association between these substances and behaviours such as
murder, rape, and violent crimes. For example, it was reported that amphetamines were
‘implicated in offending behaviour generally’ (The Australian, 29 July 2005). Suppliers of
illicit substances are vilified in a similar fashion to that of the witches described earlier, since
as Szasz (1985) has suggested, these individuals threaten the practices of the dominant





























































medical institution who control their legitimacy to dispense substances. For example,
‘a Sydney-based drug syndicate’ was implicated in luring a previously decent citizen into
‘acting as a drug mule’ (The Australian, 28 October 2005). Similarly, it was reported that
‘Australia is facing increasing threats from both transnational criminal groups and local
manufacturers’ (The Australian, 27 March 2005).
Unlike medical discourse, however, the substance user has some agency since they must
be accountable for their actions. Consider the contrast within the following passage between
medical and legal discourse in which the less traditional legal institutions of sporting
agencies assume the position of law administrator:
The policy under which the [Australian Football League] has been operating considers the use
of cannabis, ecstasy and cocaine to be a social issue and prescribes confidential counselling for the
first two positives, with a six-game suspension for a third offence. Under the [World Anti-Doping
Agency] code, a first positive in-competition test for a recreational drug results in exposure and
anything between a warning and a 12-month ban (West Australian, 21 July 2005)
This excerpt highlights the differences between medical and legal discourse in that treatment
is ‘prescribed’ to aid an individual’s ‘recovery’ within the former, whilst punitive measures
are the focus of the latter, forcing a sense of responsibility upon the substance user.
However, the excerpt also highlights that there is a fine distinction between medical and legal
discourse given the advent of therapeutic jurisprudence, which is implicit to the Australian
Football League’s policy. In this sense, medical discourse complements legal discourse.
Indeed, in their analysis of the evolution of the psychiatric diagnosis of anti-social personality
disorder (cf. psychopath), Parker et al. (1995) note that the medical institution provided the
legal institution with the concept that criminal behaviour was related to a disease, and thus
could be treated. This re-conceptualisation was appealing since the focus of punishment had
begun to move away from the body to that involving ‘the heart, the thoughts, [and], the
inclinations’ of the criminal (Foucault 1977/1977, p. 16). As such, the criminal subject
position of the illicit substance user does not avail much opportunity for voice. Indeed, the
conviction subsequent to engaging in prohibited behaviours requires that an individual
revoke their right to certain societal privileges including expression, evident in recent
proposed changes to Australian law preventing incarcerated criminals from participating in
federal elections (‘Electoral and referendum amendment (electoral integrity and other
measures) act,’ 2006).
However, the relationship between medical and legal discourse might be considered
reciprocal. In addition to justifying the billions of dollars spent on enforcement, legal
proceedings and incarceration (Collins and Lapsley 2002), legal discourse can serve to
benefit the medical institution through maintaining the dangerousness of certain substances.
As Szasz (1985) has stated, the prohibition of a substance is not a consequence of its
dangerousness, but rather, we regard a certain substance ‘as harmful in order to maintain
our justification for prohibiting it’ (p. 34).
Moral discourse
Within moral discourse lie narratives of ethics, characterised by delimiting what is right and
wrong. This can be differentiated from legal discourse that defines correct conduct through
the legal/illegal dichotomy in that moral discourse is explicitly underpinned by a distinct
ideology. This ideology is informed by the institutions of Christianity and family, which are





























































subsequently reinforced by the proliferation of this discourse. Nonetheless, the two
discourses emphasise the responsibility of the individual with regard to their behaviour.
Indeed, a dialectical relationship exists between legal and moral discourse, with the use
of a particular substance both considered wrong since it is an illegal act and illegal because
using the substance is wrong.
The available subject positions within moral discourse include the deviant/irresponsible
substance user and the righteous. The deviant/irresponsible substance user is associated with
the religious contraindication of overt intoxication and has some agency within this
discourse, since like legal discourse, he or she is responsible for his or her actions. However,
this subject position is not authorised to speak. That is, the righteous individual assumes the
higher status within this discourse through his or her purity of character, and thus, is able to
condemn those whose behaviour is incongruent with their ideology. For example, consider
the following excerpt from an editorial piece on young Australians using substances in
Indonesia:
It is the result of a delusion, common among young adults that they are invincible,
invulnerable and possibly even immortal. Just for their sakes, then, let’s spell it out one more
time: Drugs. Bali. Bloody idiot. (The Australian, 29 August 2005)
Hence, moral discourse is consistent with an Aristotelian conceptualisation of ethics,
in which morality is a virtue of character (e.g. Bostock 2000).
The use of words such as ‘banning’ and ‘reform’ in moral discourse implies the public
condemnation of particular immoral behaviours that require attention and intervention.
With regard to cannabis, for example, the federal parliament secretary for health,
Christopher Pyne, was cited as stating ‘if something is bad for people and wrong,
it should be treated that way’ (West Australian, 14 November 2005). In this respect there are
some similarities with medical discourse, with the pathogen of medicine being synonymous
with immorality in moral discourse. Similar to the medical expert, the righteous person is an
advocate for change among deviant individuals, although change is sought through
repentance rather than treatment. As such, moral discourse might be palatable to users
that have changed their behaviour since they are able to assume a righteous subject position.
For example, Szsaz (1985) has suggested that the reformed user becomes a prophet. Indeed,
consider that a reformed individual is able to state:
They’re the street kids who survive by their wits and savvy, their means of survival often
supplemented by petty crime or by selling their bodies, the proceeds going on food, booze and
drugs. (West Australian, 29 October 2005)
As such, reformed users might ‘accept the myths and models of the ruling classes and
participate in the exploitation of their own groups’ (Albee 1992, p. 271).
A further parallel between the pathogenic narrative and moral discourse was evident in the
depravity narrative. Rather than portending the physiological harms that are consequential
to exposure to a pathogen, the moral discourse highlights perpetuating immorality as being
a manifestation of substance use. For example, a previously respected public servant’s
depravity following use of amphetamines was described:
Mr Marquet started to build a web of deceit inside the Parliament building he had proudly
represented for more than two decades, it was the beginning of the end for his otherwise
commendable career. (West Australian, 24 April 2006)





























































This narrative might preclude consideration for moderation, since as Duff (2004) has
indicated, pleasure is deemed sinful and cannot be considered. A dichotomy between
abstinence/purity and use/sin exists within this ideology, and thus, behaviour is defined as all
or nothing.
Nonetheless, at times alcohol is partially exonerated as a cause of depravity. Incidentally,
alcohol has been intimately associated with Christianity (Gossop 2000), perhaps explaining
this inconsistency. Hence, within moral discourse, problems associated with alcohol use
were typically the result of mitigating circumstances. In contrast with the ‘depravity’
subsequent to Mr Marquet’s amphetamine use, for example, prior to a man’s admission that
he ‘has become a drunk’, an extensive and explicitly poignant account of the man’s
misfortune was firstly presented (The Australian, 11 January 2006).
Economic discourse
Economic discourse is underpinned by a Capitalist ideology in which the psychoactive
substance is a commodity. Whilst it is conceptually plausible for any substance to be framed
as a commodity (Mugford 1991), only alcohol (and occasionally tobacco) appears to be
legitimately framed within this discourse, reflective of the multimillion dollar alcohol
producing industry. For example, while a young girl on Insight stated ‘It’s cheaper to take
one pill and not be messed the next day than spend however much on alcohol’, this would
presumably be deemed an irrational statement by a majority of Australians. As a result of the
position made available with this discourse for the manufacturing industry, the substance
user becomes a consumer. As consumers, substance users become active decision makers
(Willis 2004) and have considerable agency (Mugford 1991). Within our analysis, they
essentially determine the available commodities through their preference for particular
products. For example:
In April, Foster’s released a chardonnay to US consumers called White Lie . . . to make an
entirely new style of wine that reflected the taste profile and palates of Australian women
(The Australian, 1 August 2005)
It is reasonable to assume that this empowers the substance user since they are able to make
explicit their choices, reflective of their subjectivity. Further, consumption of the substance
can become normalised with advertisements portraying the archetypical consumer
endorsing the substance.
It is in the interests of manufacturers for substances that they produce to be normalised to
ensure increased profits. Since economic discourse is informed by a Capitalist ideology, the
primary concern is with fiscal issues. For example, within the following except pertaining to
trading policy, the fiscal issues appear foremost to social concerns:
They [publicans] fear that Sunday trading could cripple local family hotels and are also worried
[italics added] about increased social problems related to alcohol consumption in country towns
(West Australian, 16 July 2005)
Indeed, Capitalist ideology is conducive to the normalisation of substance use, since
the ability for companies to sell their product with minimal political interference is valued.
Thus, de-legitimising the use of a substance is antithetical to this discourse.






























































Political discourse was distinct from the previously discussed discourses in that the
narratives pertain to policy and the institution of governance. As such, the primary subject
positions are that of the politician, who might be considered the ‘expert’, and that of the
community, the people, or the constituents. The nature of the latter subject position was
often not explicit, and might be best considered as the ‘us’. The notion of ‘us’ is defined
by what it is not rather than what it is through the ‘them’. The ‘them’ can be described as
those objects that deviate from an idealised norm and are considered a threat to the ‘us’.
For example, a political committee deliberates ‘whether Australia is doing enough to
combat the scourge of synthetic illicit drugs’, thus dismissing these substances and their
users from the ‘us’ (The Australian, 27 March 2006). Similarly, the burden of ‘them’ is
highlighted through an emphasis on the cost of these individuals and objects on ‘us’,
such as:
The North Korean freighter that has cost federal taxpayers more than $2 million to maintain
during the trial of its crew for heroin smuggling, has been sunk by a bomb dropped from an RAAF
F-111 fighter jet (The Australian, 24 March 2006)
In doing so, the use of such substances by the ‘them’ will be more closely monitored by the
‘us’, consistent with Foucault’s (1984) concept of surveillance.
Smith and Berg (1997) have postulated that the psychodynamic process of splitting and
projection maintains this societal dichotomy. That is, negative representations of society are
split from positive representations, with the former projected upon particular scapegoats
(e.g. certain substances and users), thus enabling all but the scapegoats to feel good about
themselves. Any change to the scapegoats’ status is a threat to society since it would force
the ‘us’ to examine these negative representations. Hence, it is in the interest of politicians,
and indeed society, to maintain the ‘them’.
It is not surprising then, that political discourse involved a confluence of the
aforementioned discourses. Since it is in the interest of the government to appeal to the
‘us’, it follows that other dominant discourses (i.e. those seen as holding the most truth
value) will be drawn upon to create and combat the ‘them’. In this way, substances that
are no longer perceived to be therapeutic by the medical institution become all
encompassing causes of myriad ailments in which politicians, members of the medical
community and members of the legal fraternity can unite in their cause to prohibit.
Further, through providing a taxonomy of mental illness (e.g. substance disorders), Parker
et al. (1995) suggest that the medical intuition provides governance through de-legitimis-
ing the ‘them’.
This confluence of dominant discourses within the political discursive formation provides
the contextual basis for a paternalistic narrative. For example, the medical discourse holds
that people cannot control their behaviour when under the influence of pathogens, so steps
must be taken to ensure the safety of the ‘us’. The extent to which there exists a threat to the
‘us’ might be reflected in the disproportionately large number of articles relating to illicit
substances in contrast to the actual number of people who use these substances (Australian
Institute of Health and Welfare 2005). Further, given that younger people represent the
majority of those who are using illicit substance, it could be suggested that this group
(in addition to other groups) become the target of the ‘them’. Indeed, younger people have
been implicated in a number of the excerpts presented, both as a threat to the ‘us’ and as
being threatened by exposure to substances. The implications of this paternalistic narrative





























































perhaps benefits the institution of governance since individual agency is the one threat to
governance. That is, an autonomous society does not require governance, rendering the
political authority limp.
Glamour discourse
In contrast to the previous discourses that are each reflective of particular Australian
institutions, ‘glamour’ discourse appears to be underpinned by a myriad of institutions that
are central to popular culture. Specifically, reality and fiction coalesce in a landscape
inhabited by celebrities that is broadcast to the populace through radio, television, and
magazines. This is particularly evident in a study by Trevithick et al. (1999) appearing in the
British Medical Journal examining the effects of shaking versus stirring on the anti-oxidant
properties of an alcoholic beverage in which the hypothesis was informed by the fictional
character James Bond. Similarly, The West Australian reported that consumption of
chardonnay wine decreased as a result of ‘TV icons Kath and Kim, along with chardonnay-
swilling desperate single Bridget Jones, [who] adopted the top-drop and made it a little
too common for some’ (25 November 2005).
Only celebrities and fictional characters are able to occupy the subject positions available
within glamour discourse. This exclusion highlights the disparity between the unfathomable
reality of glamour discourse and that of ordinary life, in which the:
Universal rules [do not] apply to . . . those in elevated states. At the big charity bash after the
premiere of Russell Crowe’s movie Cinderella Man in Sydney, anyone who wanted a quick smoke
was required to dash outside [however] at the end of the evening one table was definitely
a smoking zone. Which one? The one with Big Rusty, Kerry Packer, Young Jamie and his
model/actor/singer girlfriend Erica Baxter. (The Australian, 23 September 2005)
Through this disparity, psychoactive substances are often constructed as mysterious and
fascinating. For example, ‘think hotel heiress sex tapes, supermodels snorting cocaine and
royal affairs with riding instructors’ (The Australian, 23 December 2005). Use of substances
adds a further dimension to the celebrity’s persona, often viewed as being a reasonable and
rationale behaviour. This might be described as a privileged narrative in which recreational
use of psychoactive substances is not deemed irrational by certain people. Indeed:
Generation X roles models are lining up to admit that they have taken the drug – among them
Nicole Kidman, who told Marie Claire magazine last week that she had tried ‘‘everything anyone
could imagine’’, presumably including ecstasy. (The Australian, 21 April 2001)
This is in stark contrast with the previously discussed discourses in which such behaviours
cannot be rationalised, although the subject position within glamorous discourse is reserved
for those people who have the privilege to be allowed to indulge in recreational use.
Nonetheless, not all celebrities can be situated within this subject position. In particular,
sports stars appear to often occupy a separate semi-fictional landscape that is uncontami-
nated by the impurities of ordinary reality. As alluded to by Dingelstad et al. (1996), moral
discourse is congruent with this in which substance use is contraindicated, thus maintaining
a version of reality that is pure and untouched by ordinary reality. This version of reality
epitomes the contemporary notion that health is the modern equivalent of purity.






























































Through conducting an analysis founded on the assumption that the media’s presentation of
information will necessarily be integrated with those discursive frameworks that are
dominant within society, we have systematically described the dominant discourses within
Australian society with regard to psychoactive substances. In accordance with the
constructions inherent to these dominant discourses, illicit substances are legitimately
conceptualised in Australia as an epidemic that is dangerous to the body (medical),
corruptive to the soul (moral), a threat to normative society (political), and thus must be
outlawed (legal). The discourses also allow for licit substances to be conceptualised in this
way, although through economic and some medical discourse, significant additional space is
available for these substances to be considered a normative part of society. Many Australians
might not consider conceptualisations of substance use that fall outside of these discursive
frameworks to be rational. Further, it is possible that the availability of subject positions
within each of these discourses is limited by social structures. For example, consider the
contrast between the uses of moral discourse to describe the civil servant’s substance use,
medical discourse to describe indigenous Australian’s substance use, and glamorous
discourse to describe a celebrity’s use of a substance.
The way in which these discourses impact on our conceptualisations of substance use is
particularly evident through their role in providing the rationale that underpins policy. It is
only reasonable that illicit substances be prohibited given the aforementioned constructions
of these substances that are inherent to the discourses. However, it is important to remember
that these constructions are not objective, but rather, the effect of institutions attempting to
maintain their power within society. This becomes most evident when glamour discourse is
contrasted with the other dominant discourses. Thus, it is important that consideration is
given for how these discourses are being utilised within any discussion of substance-related
issues.
Future research might use these findings to develop more effective ways of promoting
health. For example, it is noteworthy that a narrative of harm-minimisation was not present
within the texts. Hence, whilst harm-minimisation might be widely accepted within the
academic and treatment community, this concept has not penetrated the dominant
Australian culture. In order to better ‘sell’ this and other health promotion concepts to the
public, it might be useful work within particular discursive frameworks to ensure that
information is integrated with individuals pre-existing schemas. For example, harm-
minimisation needs to be situated within discourse in which the subject position of
substance user has rationality (e.g. economic discourse and consumer safety).
Unfortunately, within Australia harm-minimisation has been typically associated with
medical discourse (Lawrence et al. 1999), which might explain the absence of this narrative
within dominant culture, since the pathogenic narrative of substance use within medical
discourse might be incongruent with harm-minimisation. It could be suggested that the
rationality of recreational substance use that is inherent to the glamorous discourse makes
available the space to provide a harm-minimisation message; however, the exclusion of the
general public from the privileged subject position of the celebratory precludes any such
integration.
Alternatively, an understanding of these global schemas might allow for more
sophisticated cognitive interventions involving cognitive restructuring (Beck 1995), such
as through challenging the ‘us’ and ‘them’ dichotomy of licit and illicit substance use.
Similarly, through highlighting how they are positioned within discursive frameworks,
political debates might be made more productive (although we cynically concede that such





























































improvements might require a utopian-like reflexive political atmosphere). However, given
the culturally dependant nature of discourse, any application of these findings beyond the
Australian context must proceed with caution since despite many of the discursive
frameworks appearing to reflect Western culture and ideology, the unique idiosyncrasies of
Australian culture will be implicit to the discourses described.
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a b s t r a c t
Background:Havingfirst appeared in Europe, synthetic cannabis emerged as a drug of concern inAustralia
during 2011. Kronic is the most well-known brand of synthetic cannabis in Australia and received
significant media attention. Policy responses were reactive and piecemeal between state and federal
governments. In this paper we explore the relationship between media reports, policy responses, and
drug-related harm.
Methods: Google search engine applicationswereused toproduce time–trendgraphsdetailing the volume
ofmedia storiesbeingpublishedonline about synthetic cannabis andKronic, andalso theamountof traffic
searching for these terms. A discursive analysis was then conducted on those media reports that were
identified by Google as ‘key stories’. The timing of related media stories was also compared with self-
reported awareness and month of first use, using previously unpublished data from a purposive sample
of Australian synthetic cannabis users.
Results: Between April and June 2011, mentions of Kronic in the media increased. The number of media
stories published online connected strongly with Google searches for the term Kronic. These stories were
necessarily framedwithin dominant discourses that served to construct synthetic cannabis as pathogenic
and created a ‘moral panic’. Australian state and federal governments reacted to this moral panic by
banning individual synthetic cannabinoid agonists. Manufacturers subsequently released new synthetic
blends that they claimed contained new unscheduled chemicals.
Conclusion: Policies implementedwithin in the context of ‘moral panic’, whilewell-intended, can result in
increased awareness of the banned product and the use of newyet-to-be-scheduled drugswith unknown
potential for harm. Consideration of regulatory models should be based on careful examination of the
likely intended and unintended consequences. Such deliberation might be limited by the discursive
landscape.
© 2012 Elsevier B.V. All rights reserved.
Synthetic cannabis refers to products containing a herbal mix-
ture that is then sprayed with synthetic cannabinoid agonists
(Dargan, Hudson, Ramsey, & Wood, 2011; Dresen et al., 2010;
Schifano et al., 2009). Synthetic cannabis first emerged in Europe
in 2004 with reports of a product called Spice producing effects
that were very similar to cannabis, such as euphoria, increased
sociability, relaxation, increased appetite, and sometimes anxiety
and paranoia (Castellanos, Singh, Thornton, Avila, & Moreno, 2011;
Psychonaut Web Mapping Research Group, 2009). These marked
psychoactive effects were unlikely to have been produced by the
largely inert herbal materials that Spice was purported to contain,
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which included: Althaea officinalis (Marshmallow), Canavalia mar-
itima (Beachbean), Leonotis leonurus (Wilddagga), Leonotis sibericus
(Siberian motherwort), Nelumbo nucifera (Pink lotus), Nymphaea
caerulea (Blue lotus), Pedicularis densiflora (Indian warrior), Rosa
cania (Dog rose), Scutellaria nana (Dwarf skullcap), and Zornia lati-
folia (Maconha brava) (Psychonaut Web Mapping Research Group,
2009).
Ananalysisof Spice (Auwärteret al., 2009; Lindigkeit et al., 2009)
revealed that it containeda rangeof synthetic cannabinoidagonists.
These chemicals included a homologue of CP 47,497, which within
the Australian Criminal CodeAct of 1995, is considered an analogue
of delta-9-tetrahydrocannabinol (9-THC) based on the similarity
of its structure to 9-THC. As such, possession of this product was
a breach of federal law. However, outside of federal jurisdictions
(e.g. airports, border control and universities), in those Australian
states without analogues clauses within their drug acts, products
containing this chemical were legal.
0955-3959/$ – see front matter © 2012 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.drugpo.2012.12.002
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JWH-018, or 1-pentyl-3-(1-naphthoyl) indole, is another syn-
thetic cannabinoid agonist thatwas identified to bepresent in Spice
(Auwärter et al., 2009; Lindigkeit et al., 2009). JWH is an abbrevi-
ation for John W. Huffman, the individual who first synthesised
these cannabinoid agonists. Later analyses have revealed a range of
JWH’s chemicals present in synthetic cannabis products including:
JWH-019, JWH-022, JWH-073, JWH-122, JWH-250, and JWH-398
(de Jager,Warner,Henman, Ferguson,&Hall, 2012; Fattore&Fratta,
2011; Hastie, 2011). These chemicals were structurally dissimi-
lar from 9-THC and other scheduled cannabinoid agonists, and
thuswere not considered analogueswithin the Australian Criminal
Code Act of 1995. Consequently, prior to legislative changes in
2011, products containing these chemicalswere legal to supply and
possess in all Australian states and territories.
While anecdotal reports of synthetic cannabinoid use in
Australia date back to 2005, it was in 2011 that synthetic cannabis
emerged as a drug of concern in Australia. Kronic has been themost
well-known brand of synthetic cannabis in Australia with various
blends produced, including Skunk, PurpleHaze, Tropical, Pineapple
Express, and Black Label. In April 2011, radio and tabloid newspa-
persfirst began reportingon theuseofKronic atWesternAustralian
(WA) mine sites as a means of evading drug testing (Macdonald,
2011).Media interest swiftly grew, andby June theWAgovernment
moved to schedule seven synthetic cannabinoid agonists: JWH-
018, JWH-073, JWH-122, JWH-200, JWH-250, CP 47,497, and the C8
Homologue of CP 47,497 (Misuse of Drugs (Amounts of Prohibited
Drugs) Order (No. 2) 2011, Western Australia).
Within days, new synthetic cannabis blends appeared that
claimed to contain new unscheduled synthetic cannabinoid
agonists. For example, Kronic released its ‘Black Label’ blend specif-
ically for itsWAcustomers. This is consistentwith the experience in
the UK (Dargan et al., 2011) and the USA (Shanks, Dahn, Behonick,
& Terrell, 2012) where analysis of synthetic cannabis blends avail-
able after bans found the presence of a range of new chemicals. de
Jager et al. (2012) have reported that blends of Kronic purchased
after bans in Australia contained chemicals previously unknown to
them that were later revealed via mass spectra to be JWH-022 and
AM2201.
Then in August 2011, the media reported on a Perth man with
a pre-existing heart condition who had a heart attack. While this
event is not something the media would normally report on, the
man had allegedly been smoking Kronic Black Label prior to his
death (Phillips, 2011). In a response to this alleged first ‘Kronic-
relateddeath’, theWAgovernment scheduled14more cannabinoid
agonists (Poisons (Appendix A Amendment) Order (No. 2) 2011).
Again, new blends appeared that claimed to contain new unsched-
uled chemicals.
Other Australian states followedWA’s lead. South Australia out-
lawed 17 cannabinoid agonists (Trans-Tasman Mutual Recognition
(South Australia) Variation Regulations 2011, South Australia). In
addition to the seven cannabinoid agonists that WA banned, the
New South Wales government banned AM-694 (Drug Misuse &
Trafficking Act, 1985, New South Wales). Tasmania outlawed four
cannabinoid agonists (CP 47,497, JWH-018, JWH-073, and JWH-
250), and also introduced an analogues clause into their Misuse
of Drugs Acts (Misuse of Drugs Order, 2011 (S.R. 2011, No. 74)
– Reg 4, Tasmania). The Northern Territory banned 18 synthetic
cannabinoid agonists (Misuse of drugs amendment (synthetic
cannabinoids) regulations 2011 (No. 33 of 2011), Northern Terri-
tory), while the Queensland government has proposed banning a
total of 22 cannabinoid agonists and redefining the definition of
what is considered a dangerous drug (Criminal & Other Legislation
Amendment Bill, 2011, Queensland; Drugs Misuse Amendment
Regulation (No. 1) 2011, Queensland; Drugs Misuse Amendment
Regulation (No. 2) 2011, Queensland). The new definition states
that a dangerous drug includes anything that is intended to “have a
substantially similar pharmacological effect” to an illicit substance
(Criminal & Other Legislation Amendment Bill, 2011).
The Australian Therapeutic Goods Agency (TGA, 2011) received
a request fromtheWAgovernment to review the status of synthetic
cannabinoid agonists, and subsequently scheduled eight cannabi-
noid agonists in July 2011. This made their possession a federal
offence.Most Australian state drug acts refer to the Standard for the
Uniform Scheduling of Medicines and Poisons (SUSMP) or Poisons
Standard, which is the legislative instrument over which the TGA
has authority. Consequently, products containing any of these eight
cannabinoid agonists were by default illegal in states that had not
specifically scheduled these chemicals.
It might be suggested that the Australian legislative response
to synthetic cannabis has been reactive and piecemeal rather than
evidence-based. Some have suggested that banning each chemical
as it emerges is like a dog chasing its own tail (Fattore & Fratta,
2011). Other commentators have described this approach to legis-
lation as a merry-go-round – as one new drug gets discovered and
banned, another one emerges purporting to be ‘legal’ (Dargan et al.,
2011; Evans-Brown, Bellis, & McVeigh, 2011; Measham, Moore,
Newcombe, & Welch, 2010). So why has Australia’s legislative
response to synthetic cannabis not been evidence-based?
It is possible that media reports concerning synthetic cannabis
created a moral panic that contributed to a legislative reaction.
Early descriptions of moral panic, such as Cohen’s (1972) analy-
sis of “Mods” and “Rockers” in the UK, have noted that moral panic
first involves a person, group, episode, or situation being framed by
themedia as a threat to society. Sometimes themoral panic quickly
dissipates, while othermoral panics reach criticalmasswith signif-
icant and long lasting repercussions, such as changes in policy. In
this respect, Brosius and Weimann (1996) have suggested that the
media sets the agenda for policy debate.
McArthur (1999, p. 151) has stated that the media “shape[s]
not only the public profile of [drug] problems but also the polit-
ical response to them”. Forsyth (2012) has proposed that once
media reports concerning the emergence of a new drug break in
the mainstream press, they will draw on the ‘drug scare’ narra-
tive that constructs the new drug as dangerous and the need for
urgent action. In turn, a media campaign against the drug develops
that recruits politicians, researchers and themorally righteous. The
subsequent moral panic leads to a perception that urgent legisla-
tive action is required and is likely to result in policy that is reactive
rather than responsive.
Moral panic occurs within the context of the dominant dis-
courses that exist within a society. For example, Cohen (1972)
stated that “by thrusting certain moral directives into the universe
of discourse” the media can create drug problems “suddenly and
dramatically” (p. 10). Dominant discourses are linguistic frame-
works inherent to any given culture that develop in symbiotic
relationships with those institutions with power (Burr, 2003).
They constrain what can be rationally said, written, and thought
about drugs. Each discourse provides specific subject positions
that demarcate the narratives that are coherent within the dis-
course (Burr, 2003). These narratives, such as the ‘drug scare
narrative’, are perceived by individuals within the culture from
which the dominant discourse emanates to hold the most ‘truth’
value. Nonetheless, there are competing dominant discourses with
some being more privileged than others, and it is in the interest
of any given institution to promote those discourses that maintain
the institution’s version of reality as ‘truth’ since this provides the
institution with power.
Bright, Marsh, Bishop, and Smith (2008) undertook an analy-
sis of the dominant discourses within Australia that frame Alcohol
and Other Drugs (AOD). They examined newspaper reports of AOD
over a 12 month period, and then triangulated this analysis with a
sample of newspaper reports from five years prior and a televised
Author's personal copy
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Table 1
Description of the dominant AOD-related discourses in Australia, as reported by Bright et al. (2008).
Discourse Subject positions Narrative
Economic Consumers and businesses Alcohol and other drugs (AOD) are something that are made, bought, and sold, in the same way as
any other product or service (e.g. bread or a taxi fare)
Medical Patients and experts Using AOD is like having a disease and health professionals can cure it
Moral Irresponsible/deviants and morally righteous Using drugs is wrong because of the negative effect they have on a person’s behaviour
Legal Law breakers, law abiders and law enforcers Using drugs is against law and people who use them should be arrested
Political Constituents and politicians People cannot make the right decisions about drugs so we need to help them by making policies,
thus protecting society
Glamour Celebrities Drugs are mysterious and that is why we like to hear about famous people who use them
debate on AOD. Bright et al. (2008) determined that in Australia, six
dominant discourses framed AOD-related issues: medical, moral,
legal, political, economic, and glamour (see Table 1). Within med-
ical discourse, for example, drug use is often pathologised such
that drug users are sick. This limits the degree to which ‘recre-
ational drug use’ can be considered since any drug use is defined as
inherently unhealthy. Within this discourse, experts are afforded
a subject position that has significant authority and typically sup-
port the pathogenic narrative. Further, since medical discourse is
paternal, thepathogenic narrative supports prohibition-baseddrug
policy.
The methodology used by Bright et al. (2008) might not be
appropriate for understanding the discourses that framed the
emergence of synthetic cannabis in Australia given its rapid emer-
gence and the subsequent constant flux. Rather, methodologies
that have explored the rapid emergence of new drugs might have
more utility. In this journal, Forsyth (2012) has recently described
the phenomena of the ‘drug scare’ using the UK experience with
Mephedrone as a case study. He proposed thatmedia reports about
the emergence of a new drug that are fuelled by ‘moral panic’ are
unhelpful since theymight divert attention fromothermore signif-
icant public health concerns (e.g. alcohol, diabetes, cardiovascular
disease, cancer, etc.), and also provide free advertising through
creating increased public awareness of the drug. Through exam-
ining online media, Forsyth was able to demonstrate that interest
in buying mephedrone increased following sensationalist media
coverage.
The present study draws from Forsyth’s (2012) methodology
using Australian online media and self-reports from a sample of
Australian synthetic cannabis users to understand how synthetic
cannabis emerged as a drug of concern in 2011. In doing so, we
aim to explore how the media, legislative change, and drug-related
harm intersect. Discursive analysis was used to help disentangle
this complex intersection. Such analysis is particularly useful here
given the dynamic and rapid social changes that occurred in 2011,
since it allows for subjective interpretations of the available anec-
dotal evidence given limited empirical data.
Method
Drawing from Forsyth’s (2012) methodology, Google Trends was
first used to produce time-trend graphs detailing the number of
stories being published online about synthetic cannabis and Kro-
nic, and also the amount of traffic searching for these terms. Google
Trends also generated links to media reports at key milestones.
Forsyth has noted some limitations in using this application since
Google is not the only search engine; however, it is the most widely
used. Further, Google Trends are normalised so the graphs do not
represent the absolute number of searches conducted or the num-
ber of media stories. Additionally, the media volume reported is
dependent on the parameters that Google uses to determine if text
is a ‘news story’.
It is reasonable to assume that the ways in which the Aus-
tralian online media was able to frame the emergence of synthetic
cannabiswas limitedby theavailabledominantdiscourses. As such,
the discourse and narrativeswere examinedwithin the key reports
generated by Google Trends. This examination was conducted by
the first author (SB). It was iterative and involved consideration of
the various subject positions that were available within the text, in
addition to the way in which synthetic cannabis was constructed.
As each discourse emerged, it was considered within the context
of the institutions that support and maintain the discourse. Finally,
the discourse was considered within the context of Bright et al.’s
(2008) delineation of the dominant discourses available for AODs
in Australia.
To ensure credibility (Lietz, 2010), the data were triangulated
with radio media. Two episodes of the Australian Broadcasting
Commission’s (ABC) Triple J show“Hack” that reportedon synthetic
cannabis were analysed. The first show, entitled “Cheating work-
placedrug tests”, airedonMay10 (Quartermaine, Tilley, Barrington,
& Kaitlyn, 2011). The second show was entitled “National Kro-
nic ban” and aired on July 7 (Tilley & Sawrey, 2011). Purposeful
sampling of media reports and social media was also conducted to
reconstruct a timeline of the emergence of, and response to, syn-
thetic cannabis. In addition, thick descriptions were provided of
each text that used direct quotes to ensure that the analysis stayed
true to the original text.
Rigour was ensured through an audit trail that documented the
analysis and the reasoning that underpinned the emergent dis-
courses (Morse, 1994). Thoughtful consideration of the discursive
researcher’s (SB) standpoint and opinions was documented in the
audit trail to ensure reflexivity. This can be summarised in the fol-
lowing disclosure statement:
I dislike paternalism since I value freedom of choice and believe
that drugusers can rationallyweighup thepros and consof drug
use in the context of the available evidence regarding harm. I
believe that drug policy is rarely developed in the context of the
available evidence and is often reactive in nature.
By including this statement, we acknowledge that it is impos-
sible for the researcher to be ‘objective’ or ‘neutral’ in the
production of knowledge. Subjectivity, while once seen as neg-
ative or as bias to be eliminated, can be used as a fruitful path
to greater understanding of the subject matter and our role in
its construction. Instead, readers should interpret our paper with
knowledge of the discursive researcher’s positioning as stated
above.
Finally, two pieces of previously unpublished data were
included in this paper from a study by the final author and col-
leagues (Barratt, Cakic, & Lenton, in press): (a) month and year of
first use of synthetic cannabis, and (b) where synthetic cannabis
users first reported hearing about the drug. A purposive sample of
316 Australian synthetic cannabis users answered these questions
as part of an online survey. A description of the sample and the
Author's personal copy
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survey methodology has been published elsewhere (Barratt et al.,
in press).
Findings and discussion
Figs. 1 and 2 contain graphs produced using Google Trend. The
lower line in each figure depicts the volume of media stories being
published online that referred to Kronic and synthetic cannabis
respectively. The upper line in each figure indicates howmanypeo-
ple were searching for “Kronic” and “synthetic cannabis”. As can
be seen in Figs. 1 and 2, the first online media stories about syn-
thetic cannabis and Kronic began to emerge in March, with a sharp
increase in the number of stories in May and June.
The first key story concerning Kronic was from The Age on June
8 (indicated by ‘A’ in Fig. 1) andwas entitled “Roadtesting Kronic: Is
fakegrassworth thehype?”. This ‘gonzo journalism’piecedescribes
the author’s experience of smoking Kronic and is framed within
neo-liberal and economic discourse. For example, the author states
that “so many people were having fun with [Kronic] that the anti-
fun brigade had no choice but to swing into action” and compared
the effects of Kronic to “two glasses of champagne”. Bright et al.
(2008) note that within the dominant Australian discursive land-
scape, only alcohol, tobacco, and caffeine can typically be framed
within economic discourse, which means that this story is framed
outside of the dominant discourses.
Similarly, the individuals who were interviewed as part of
the first radio report on Kronic in May (Quartermaine et al.,
2011) framed their use of Kronic outside of dominant discourses.
Again, use of Kronic was framed within neo-liberal and economic
discourse. For example, interviewees stated how they made an
informed choice to use Kronic in which the harms associated with
failing a drug test outweighed the unknown harms associated
with using chemicals with little to no toxicology data. Further,
they described responsible use of Kronic, such as not using it
before or during work, which also falls outside of the dominant
discourses.
Such initial framing was possible without widespread concern
regarding synthetic cannabis and is consistentwithForsyth’s (2012,
p. 198) observation that initial reports regarding a new drug are
generally published in alternative publications such as music press
(e.g. Triple J Radio) “or equivalent specialist sections of mainstream
titles” (e.g. The Age). For example, in the UK a report preceding
the moral panic regarding Mephedrone appeared in the Telegraph
by a prominent medical personality entitled “I took Mephedrone
and I liked it” (Pemberton, 2010). Despite being situated outside of
the dominant discursive frameworks, such early stories increase
the public’s awareness and might provide an advertisement for
the emergent drug. Indeed, as can be seen from the upper line in
Fig. 1, the number of Australian’s searching for Kronic on Google
began increasing significantly around this time. It is interesting to
note that “Kronic” was more searched than “synthetic cannabis”,
perhaps highlighting the effect that the media had on ‘branding’
synthetic cannabis. This is similar to the way in which MDMA was
branded as Ecstasy in the early 1980s, perhaps since the latter term
created additional public interest and may have contributed to the
moral panic that precipitated the prohibition of MDMA in the USA
(Eisner, 1989).
The increased awareness also provides an impetus for a ‘moral
panic’, with subsequent stories framed within the dominant dis-
courses. The second key story concerning Kronic was published
by the Sydney Morning Herald on 16 June and was entitled “WA
becomesfirst statewithKronic ban” (see “B” in Fig. 1). Interestingly,
the first and only relevant key story concerning synthetic cannabis
was also about legislative change – this time the South Australian
government’s intention to ban synthetic cannabis (see “A” in Fig. 2).
Both stories were framed within dominant discourses. Specifically,
they were framed within legal, medical and moral discourse.
Withinmedical discourse synthetic cannabiswas constructed as
a pathogen with similar (or greater) dangers to cannabis. Such con-
structions were typically reinforced by experts attesting to these
dangers. Within this discursive framework, primacy is given to
those individuals assuming the subject position of expert. This sub-
ject position is highly regarded in contemporary society, and might
be considered to have subsumed the role of the priest as the figure
of authority. Like the priest, the information provided by a medical
expert is not necessarily ‘true’ despite it being perceived as holding
the greatest ‘truth’ value. Indeed, there are often little to no toxicity
data for most emergent drugs. For example, Forsyth (2012) noted
that it was the news of a Mephedrone-related death that was later
found to be false, which provided the impetus for the UK govern-
ment to refer the matter to the Advisory Council on the Misuse of
Drugs.
Similarly, the second ABC radio show that aired in July focused
on the national legislative changes. Here, the federal secretary for
health assumed the subject position of expert. From this position
she was able to authoritatively declare that synthetic cannabis
is “just not safe”, causing hallucinations and heart palpitations.
While there have been increasing reports of synthetic cannabis
harms, a recent survey of 316 Australian community-based syn-
thetic cannabis users found that while such effects were reported
by around one third of the sample, very few respondents reported
that their symptoms were serious enough to seek help and many
respondents did not report experiencing these harms (Barratt et al.,
in press). Barratt et al.’s (in press) survey results also indicate that
a desire to use a legal recreational drug was one of the main rea-
sons for first trying synthetic cannabis. Consistent with medical
discourse, there was no available subject position for recreational
drug users with the secretary stating that there “is no therapeutic
reason to be using [synthetic cannabinoid agonists] and that is why
they have been banned”.
Within moral discourse, users assume the subject position
of an irresponsible deviant. For example, the South Australian
Attorney-General expresseda concern that “users aredrivingunder
the influence, posing a serious danger to themselves and others”.
Such constructions, alongside the pathogenic narrative available
within medical discourse, indicate a need for urgent legislative
intervention. In turn, these discourses provided a fertile environ-
ment for ‘moral panic’.
This moral panic is likely to have contributed to the first wave
of bans that occurred in June and July of 2011 since Australian gov-
ernments had a moral imperative to take urgent legislative action.
Such urgent action was naturally reactive and led to a number of
bansplacedon individual synthetic cannabinoid agonists. Although
authorities may be well-intentioned as they prohibit emerging
drugs like synthetic cannabinoid agonists, the unintended conse-
quences of these policies may have increased harm to some users
since the reporting of each scheduling decision creates increased
awareness. Such increased awareness could lead to increased use
of synthetic cannabis.
Indeed, as can seen be from the lower lines in Figs. 1 and 2,
online media interest first increased in the lead up to the first wave
of bans in June and July. There was also an increase in the number
of Australians searching for “Kronic” and “synthetic cannabis”, as
indicated by the lower lines in Figs. 1 and 2, which tracks in relative
accordance with the increased volume in media. It is reasonable
to assume that many of these individuals would not have previ-
ously been aware of synthetic cannabis. The first hit for a Google
search for ‘Kronic to be banned’ that we conducted in June was an
Australian-based online Kronic shop, andGoogle advertisements at
the end of many commercial online media reports were for online
shops selling synthetic cannabis. Kronic could not have asked for
Author's personal copy
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Fig. 1. Google Trends data for ‘Kronic’ in Australia for 2011. Note. The letters indicate the publication of key stories. The headlines for these are: (A) Roadtesting Kronic: Is fake
grass worth the hype? (B) WA becomes first state with Kronic ban, (C) NZ importer admits Kronic contaminated, (D) WA Police query banned drug Kronic link to man’s death,
and (E) Tall Black slapped with one-year ban for Kronic use. The lower line represents the volume of stories being published about Kronic and the upper line represents the
number of searches for Kronic.
better advertising. For example, Green (2011) reported on a man
who “saw [Kronic] on the news and thought...holy smoke, I’m going
to order this”.
Barratt et al.’s (in press) survey collected as-yet-unpublished
data on the month that respondents first used synthetic cannabis.
Reported in Fig. 3, these data appear to be indicative of two distinct
cohorts ofAustralianswho initiated synthetic cannabis use in2011:
(i) those whose initial use preceded media reporting, and (ii) those
who initiated use at around the same time as reports about Kronic
peaked in the media. A statistical analysis of the data indicated that
those who used synthetic cannabis for the first time in 2011 or
2012, whichwaswhenmedia interest began to heighten, were also
significantly more likely to have reported to have heard about it
through the media, whereas those used synthetic cannabis for the
first time before 2011 were significantly more likely to have heard
about it through other means (e.g. social media, friends, vendors,
etc.), 2 (1, N=273) =15.7), p<0.001.
In the lead up to the bans, people reportedly tried to stock-
pileKronic (Rickard, 2011), andKronicmanufacturers endeavoured
to sell any remaining stock. Kronic distributors used social media,
especially Facebook and Twitter, to engage their customers. These
technologies provided a unique way of monitoring drug-related
social interactions in real-time. For example, a post on the Kronic
Facebook page from June reads:
we only found out about the ban today so just clearing out the
last of our stock. It has to be gone by 2mmorow close of business
so we have 2 options. . . give heaps away for free or just dispose
of it tomorrow. I know what we’d prefer!
Hundreds of Facebook users ‘liked’ and commented on this and
other posts. For example, ‘James’ stated “I want some, no money
but I’ve already bought heaps from yas [sic] so give me it for free”.
The announcement by the WA government to ban seven syn-
thetic cannabinoid agonists also led to a “smoke ‘em party” that
was shut down by police as a matter of public safety. The party
was moved to another venue, but then cancelled following further
police intervention (“Kronic Party Plans up in Smoke”, 2011).
The next key Kronic story according to Google Trends was pub-
lished in The Brisbane Times on June 30. Entitled “NZ importer
admitsKronic contaminated”, this storydescribes thefindings from
an analysis of Kronic conducted by the New Zealand governments
that found traces of a novel benzodiazepine. This story was primar-
ily framed within medical discourse, with the incident constructed
as a “contamination”.
Just days after the WA government banned seven synthetic
cannabinoid agonists, new products were released that claimed to
circumvent the legislative changes. One such product was Kronic
“Black Label”. The final key Kronic-related story, which was pub-
lished on August 5 in The Australian, described how a man who was
“believed” to have been smoking Kronic “Black Label” was rushed
to hospital after “suffering a suspected heart attack”. He later died.
Entitled “WApolice query banned drug Kronic link toman’s death”,
this storywas framedwithinmedical and legal discourse. Again, the
Fig. 2. Google Trends data for ‘synthetic cannabis’ in Australia for 2011. Note. The letters indicate the publication of key stories. Only story A was included in the analysis as
the other stories were from New Zealand. The lower line represents the volume of stories being published about Kronic and the upper line represents the number of searches
for Kronic.
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Fig. 3. Month and year that participants from Barratt et al.’s (in press) survey respondents who reported first trying synthetic cannabis in 2011 versus the volume of Kronic
and synthetic cannabis media reports, as indicated by Google Trends. Note. As Google Trends does not provide raw data, the volume of media reports is only an approximation.
Further, the data is normalised and does not represent the absolute number of media stories.
potential harms associated with Kronic indicated an urgent need
for legislative intervention. In response to this death, the WA gov-
ernment banned an additional 14 cannabinoid agonists (Poisons
(Appendix A Amendment) Order (No. 2) 2011, Western Australia).
Again,media interest and internet traffic searching for “Kronic” and
“synthetic cannabis” increased in the lead up to these bans, as can
be seen in Figs. 1 and 2.
Conclusions
By examining the emergence of synthetic cannabis as a drug of
concern in Australia, the present paper aimed to help understand
howthemedia, legislative change, anddrug-relatedharm intersect.
The notion of dominant discourses was proposed to be helpful in
understanding this relationship since they will demarcate how the
media constructs the emergence of a new drug, how policy mak-
ers are able to frame the debate, and in turn, people’s drug using
behaviour.
The pre-existing Australian dominant discourses, as outlined by
Bright et al. (2008), appear to have led to the construction of syn-
thetic cannabis as a dangerous pathogen. This construction may
have contributed to a ‘moral panic’. The moral panic appears to
have been fuelled by experts highlighting the potential dangers
of the new drug. Whilst such claims are presumably intended
to reduce the likelihood of people using these substances, they
might not be completely accurate given an absence of toxicological
data and do not appear to be a deterrent. For example, Forsyth
(2012) found that the most significant increases in interest in pur-
chasing Mephedrone occurred following each report of an alleged
Mephedrone-related death. A similar trend has been reported by
Dasgupta,Mandl, and Brownstein (2009), who found that the num-
ber of overdoses from prescription opiates increased significantly
two to six months after major stories concerning prescription opi-
ates broke in the media.
Given the truth value of these expert statements within the
dominant discourse, governments have a moral imperative to ban
the new drug. This can lead to reactive polices that may have a
negative impact on drug-related harm since: (i) further aware-
ness is created which could increase harm as more individuals try
synthetic cannabis, and (ii) once banned, newer, less-understood
psychoactiveproducts enter themarket to replace thebanneddrug.
Thus, while the availability of the newly illegal drug decreases
following prohibition, other similar drugs with unknown health
harms become more available in their place. Even if the new prod-
ucts donot containnew legal chemicals, and in fact contain recently
scheduled chemicals, consumers are then at heightened risk of
prosecution for possession of a product they believed to be legal.
The possession of synthetic cannabinoid agonists could be treated
more severely than the possession of cannabis in Australia since
individuals charged with possession of synthetic cannabinoid ago-
nists might not be eligible to participate in cannabis diversion
schemes.
An alternative approach would have been to have regulated
this market. Regulation would mandate the provision of accurate
information, purity and strength. There is currently a disincen-
tive for companies to provide information to potential users about
the active ingredients or about safer ways to consume synthetic
cannabis. To avoid litigation, most brands of synthetic cannabis
state that they are “not for human consumption”, misrepresent
what they contain, or provide obscure instructions for use. For
example, a packet of Kronic’s Pineapple Express stated that it “con-
tains a unique blend of all natural organic extracts” and it “emits
a pleasant, relaxing smoke when burned”. The lack of quality con-
trol is evident in the recall of this particular brand of Kronic due
to it containing a novel benzodiazepine (Couch & Madhavaram,
2012).
Restrictions on where and to whom synthetic cannabis could
be sold would also be easier to manage in a regulated environ-
ment. Some (e.g., Evans-Brown et al., 2011; Hughes & Winstock, in
press) suggest that emerging psychoactive substances be regulated
as medicinal products as a pragmatic compromise to the current,
arguably unsustainable, approach.WebelieveAustralia should also
consider alternative models of regulation, based on careful exam-
ination of the likely intended and unintended consequences. The
recently regulatory scheme proposed by the New Zealand govern-
ment provides an example of such alternative models (Office of
the Associate Minister of Health, 2012). It will be interesting to
see how this new model affects the synthetic cannabis market and
drug-related harm.
Evidence-based policy development must consider a psychoac-
tive substance within the complex interrelationships between
state and federal legislation, media reporting and dynamic
webs of supply and demand. The unpredicted and unintended
outcomes of drug policy typically result from inadequete con-
sideration of these factors. For example, workplace drug testing
is a well-intentioned policy that aims to reduce drug-related
harm, but has had the unintended effect of producing a market
for synthetic cannabis as a substitute for cannabis which, until
recently, was unable to be detected by workplace drug testing
technologies.
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However, it is unlikely that Australia’s response to synthetic
cannabis will consider alternative models of regulation. In May
2012, eightbroadchemical groupswere scheduledby theTGA:ben-
zoylindoles, cyclohexylphenols, dibenzopyrans, naphthoylindoles,
naphthylmethylindoles, naphthoylpyrroles, naphthylmethylin-
denes, and phenylacetylindoles (TGA, 2012). In addition, they
scheduled “synthetic cannabinomimetics”, though no definition of
this term has been provided. Only time will tell what effects (both
intended and unintended) this latest legislative actions will have
on drug-related harm.
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There are a limited number of dominant discourses
available to frame drug use within Australia. These
dominant discourses play an important role in policy
debate and development, and also drug use behav-
iour. We describe the development of a psychomet-
ric instrument that is hypothesised to measure the
degree to which individuals internalise dominant
drug discourses. Sixty items were developed to
reflect six dominant discourses of drug use. A
substantive validity analysis was conducted. The
highest loading items were included in a 27-item
measure that was administered to 370 people
seeking substance use treatment in Perth, Western
Australia. In addition, participants completed the
Locus of Control of Behaviour Scale. Confirmatory
Factor Analysis tested the fit of a predicted six factor
model, in addition to three other plausible models.
The best fitting model was the predicted model.
Internal locus of control was correlated with medical
and legal discourse. The Dominant Drug Discourses
Scale appears to measure internalisation of six
dominant discourses. The tool has utility in research
examining policy development and drug use behav-
iours. To establish the construct validity of the tool
and better understand the constructs being mea-
sured, further research is required.
Keywords: Psychology, sociology, dominant discourses,
psychometrics, drugs
Drugs can be conceptualised as social constructions.
That is, while drugs have distinct objective pharmaco-
logical properties, a person’s understanding of drugs is
influenced by various institutional and individual
actors within that person’s culture, each of whom
have particular interests and ideologies (Dingelstad,
Gosden, Martin, & Vakas, 1996). This process can be
understood through the role of discourses, which have
been broadly defined as linguistic frameworks that
provide specific subject positions and demarcate what
narratives are coherent (Burr, 2003). Dominant dis-
courses develop through symbiotic relationships with
those institutions that hold power within a culture.
Narratives that are coherently framed within the
dominant discourses of a culture are perceived
by individuals within that culture to hold the most
‘truth’ value. As such, dominant discourses limit what
can be rationally thought, spoken and understood
about drugs.
The dominant discourses within which drugs are
framed in Australia typically only allow for patholo-
gical narratives. They are constructed as dangerous
(Room, 2006), harmful (Lancaster & Ritter, in press;
Moore, 2008), corruptive and criminogenic (Stevens,
2007). Certain drugs might be ascribed more patho-
genic agency than others. For example, Moore (2004)
has highlighted how each drug is constructed as a
subject with a distinct personality, or ‘drugality’. Thus,
while alcohol might be thought of as a larrikin, heroin
is oppressive and crack is perverse. Within these
pathogenic narratives, people who use drugs are
afforded limited subject positions that typically provide
minimal agency. For example, Barratt (2012) has
highlighted how drug users in Australia are often
incorrectly constructed as ignorant, irrational and
irresponsible. Meanwhile, Fraser and Moore (2008)
have shown how drug users are constructed as chaotic
and disordered.
Bright, Marsh, Bishop, and Smith (2008) undertook
an analysis of Australian discourse through examining
media reports involving alcohol and other drugs
(AODs). They found that there were six dominant
discourses available to frame AODs (an overview of
































































these dominant discourses can be seen in Table I).
Medical, moral, legal and political discourses each
provided space for specific pathological narratives.
For example, Bright et al. (2008) noted that within
medical discourse drugs are constructed as pathogens
that reduce a drug user’s agency, which can only be
restored through relinquishing control to experts.
While the dominant culture is protected against the
pathogenic effects of alcohol, there are a minority of
individuals who have some underlying vulnerability
(e.g. indigenous, youth, etc.). In contrast, moral
discourse was described as constructing drugs as
corruptive and those that use them as deviants who
are somehow weak-willed. Only economic and
glamour discourses provided an opportunity for non-
pathological narratives; however, Bright et al. noted
that within the dominant culture, economic discourse
was limited to framing alcohol while glamour
discourse was only available to frame celebrity drug
use.
It is essential that the dominant drug discourses be
better understood for three reasons. First, drug research
has a symbiotic relationship with dominant discourses.
Research that most conforms to dominant discourses
will attract the most funding. Consequently, most drug
research has focused on the pathology of drug use,
providing a skewed perspective of drugs and drug use
(Mugford, 1991). In turn, this research reinforces the
dominant discourses.
Second, a number of researchers (e.g. Bright,
Bishop, Kane, Marsh, & Barratt, 2013; Dingelstad
et al., 1996; Duff, 2004; Elliott & Chapman, 2000;
Lancaster & Ritter, in press; Lawrence, Bammer, &
Chapman, 2000; Stevens & Ritter, 2013) have demon-
strated the influence of dominant discourses on drug
policy. For example, the focus of any given policy
debate is limited by the available dominant discourses.
This is illustrated by the debate regarding cannabis,
which tends to focus on its legal status based on
varying accounts of its harm potential. The research
that is used to develop policy is often conducted within
the context of dominant discourses. Further, dominant
discourses limit the scope of drug policy development.
For example, because pathogenic narratives cannot
coherently acknowledge pleasure, the notion of mod-
eration (or controlled drug use) cannot be rationally
discussed since any drug use is undesirable. In turn,
this precludes strategies encouraging moderate drug
consumption being implemented.
Third, dominant discourses influence people’s drug
use behaviour and treatment seeking. This occurs
indirectly through the implementation of policies that
are necessarily developed within the context dominant
discourses, and also directly through a process of
internalisation. By doing so, drug users’ attributions
regarding their drug-related behaviours are framed by
the available narratives and subject position in a similar
manner to the self-stereotyping originally described by
Hogg and Turner (1987). For example, internalisation
of moral discourse would lead drug users to identify
with the deviant subject position and perhaps increase
the degree of stigma that they perceive. Perceptions of
stigma among drug users have been found to be
associated with reduced access to health care, increased
experiences of discrimination and poorer mental health
(Ahern, Stuber, & Galea, 2007).
Similarly, individuals that internalise medical
discourse will identify with the subject position of
the ‘addict’ and thus might be more likely to have
an external locus of control. Therapists from a range
of perspectives (e.g., Beatch et al., 2009; Teyber,
1997; Yalom, 2002) have contended successful
behaviour change requires individuals to take
personal responsibility for their behaviour. Hence,
internalisation of medical discourse by individuals
experiencing problems associated with their sub-
stance use could hinder their behaviour change
efforts. However, Keene and Raynor (1993) found
that internalisation of medical discourse, as evi-
denced by the degree to which participants endorsed
the disease model of addiction, was associated with
positive treatment outcomes in a 12-step program.
Similarly, Hammer, Dingel, Ostergren, Nowakowski,
and Koenig (2012) found that many of the
participants that they interviewed who were engaged
in treatment believed that a genetic/medical under-
standing of their behaviour had utility in assisting
their efforts to change their behaviour. Hammer
et al. (2012) noted a range of narratives that had
diverse outcomes. Perhaps then, people who inter-
nalise certain dominant discourses might have better
outcomes when they are matched to a particular
treatment that shares this understanding of addictive
behaviour.
To better understand the role of dominant
discourses regarding drugs, we sought to develop a
psychometric instrument that measures the degree to
which individuals internalise those discourses found
by Bright et al. (2008) to be dominant within
Australian society. Such an instrument might be
used to further our understanding of how discourses
are structured, and how they influence drug policy
and clinical processes in treatment settings. Since
some might consider the use of psychometric
measurement to be incompatible with social con-
structionism, it is important the paradigmatic
assumptions herewith are defined:
(i) The ontological perspective is that of critical
realism, where multiple methods are necessarily
utilised to capture an approximation of an
unascertainable single objective reality
(Nightingale & Cromby, 1999; Parker, 1998).
(ii) The epistemology is pragmatic, such that the
pursuit of knowledge is problem-focused and is
directed by the anticipated consequences of pre-
existing knowledge (Cherryholmes, 1992).
































































In accordance with the procedure for psychometric
item development outlined by Oppenheim, 60 items
expressing ‘a point of view, a belief, a preference, a
judgement, an emotional feeling, or a position for or
against something’ (1992, p. 174) were formulated for
each of the six dominant discourses outlined by
Bright et al. (2008). Each of the items included (either
implicitly or explicitly) at least one of the subject
positions inherent to the relevant discourse outlined
by Bright et al. Given the neo-liberal nature of
economic discourse, a personal subject position was
trialled for some of these items. Each of the items
additionally reflected a potential narrative that con-
structed drugs in a manner that would be congruent
with the relevant discourse. Because more narratives
were available within certain discourses (e.g. moral)
than others (e.g. glamour), more items were generated
for some discourses than others. In developing items,
we aimed to minimise redundant items and statements
susceptible to response bias (Murphy & Davidshofer,
2005). The content validity of the items was
established through refinement by a psychometrician
and individuals working within the AOD field. The
final 60 items that were developed are outlined in
Table I.
Substantive validity of the refined items was
ascertained using the procedure outlined by Anderson
and Gerbing (1991). Specifically, the 60 items were
randomly placed in a questionnaire with the six
discourses randomly assigned a number and briefly
described at the start of the questionnaire. Twenty
people seeking treatment at a Perth residential
substance use treatment agency were provided with
an information letter and the instrument (Anderson and
Gerbing recommend a sample size of between 12 and
30 participants). Participants were instructed to parti-
cipate they would be required to assign a number to
each item that best reflected the corresponding
discourse description (see Table II). Consent to
participate was implied through the anonymous return
of the completed instrument. All instruments were
returned completed.
Table I. Initial item set that was developed.
Medical discourse
1. People who use drugs are unwell
2. Drug use makes people unwell
3. Drug use is spreading like a plague
4. Doctors know what is best for drug users
5. People who use drugs need to seek treatment
6. Drug use is unhealthy
7. People who use drugs are unwell
8. It is important that you listen to your doctor
9. Drug use puts you at risk of HIV
10. Unhealthy people use drugs
11. Drugs are dangerous
12. Drug use kills
Legal discourse
1. Drug use leads to crime
2. Punishment for drug dealers is not harsh enough
3. People who use drugs are criminal
4. Drug users should be punished
5. Laws are an effective way of stopping people from using
drugs
6. You shouldn’t use drugs because they’re illegal
7. Drug dealers prey on the weak
8. Drugs should be prohibited
Moral discourse
1. People who use drugs are lazy
2. Using drugs is wrong
3. People who use drugs are stupid
4. People can’t control their own drug use
5. It is not normal to use drugs
6. Drug users are untrustworthy
7. People who use drugs lie
8. Normal people don’t use drugs
9. Drug use causes you to betray other people
10. People who use drugs steal
11. Drugs take control of people’s lives
12. People who use drugs can’t be trusted
13. Drug users are irresponsible
14. People who use drugs don’t know when to stop
15. Drug use destroys families
16. Drugs should be condemned
17. Successful people don’t use drugs
Political discourse
1. Only the minority use drugs
2. Drug use harms society
3. Drugs are a threat to society
4. It’s the governments job to protect us from drugs
5. Drug use is a big problem that we need to fix
6. Drug use needs to be regulated
7. Drugs cost taxpayers a lot of money
8. We need to control people’s drug use
Glamour discourse
1. Most rock stars take drugs
2. It’s okay for famous people to use drugs
3. Drug use makes people interesting
4. Drugs are fascinating
5. Supermodels use drugs
6. Drug are intriguing




1. People are free to choose what drugs they buy
2. Paying for drugs is like paying to see a movie
3. I like some drugs, but not others
4. Spending money on drugs is my choice
5. I should be able to spend my money on drugs if I want to
6. I make an informed choice about whether or not I use
particular drugs
7. Drugs are just another way of having fun






























































Each item was analysed using Anderson and
Gerbing’s (1991) substantive-validity co-efficient:
csv¼ nc no/N, where nc represents the number of
participants who endorse the presupposed dimension
and no represents the maximum number of participants
who endorse a different dimension. The extent to which
an item reflects a dimension can then be examined by
performing a binomial test of significance. Items
measuring the intended dimension are reflected by a
probability of less than 0.05, although Anderson and
Gerbing note that in practice the items retained will
often reflect those having the highest csv values. At least
four items were retained for each dimension. The
retained items (see Appendix) were used to construct
the Dominant Drug Discourses Scale (DDDS).
Participants in the scale development
The sample consisted of 192 males and 156 females
aged between 16 and 75 years (M¼ 37.50, SD¼ 10.78)
who were seeking treatment at one of several substance
use agencies in the northern suburbs of the Perth
metropolitan area, in addition to 23 individuals who did
not disclose their age or gender. The most common drug
for which people were primarily seeking treatment was
alcohol (39%) followed by amphetamines (22%),
opiates (18%), cannabis (5%) and benzodiazepines
(2%). Fourteen percent of participants did not disclose
the drug for which they were seeking treatment.
Measures
The level of agreement for each of the 27 items within
the DDDS was rated on a five-point Likert scale. In
addition to the DDDS, participants were provided with
Craig, Franklin and Andrews’s (1984) Locus of
Control of Behaviour Scale (LCBS). Since
Confirmatory Factor Analysis (CFA) has shown the
non-reverse scored ‘internal items’ are more robust
than the reversed scored external items (Bright, Kane,
Marsh, & Bishop, 2013), only the internal items were
included.
Procedure
Several Perth treatment agencies (excluding the agency
involved in the substantive validity analysis study)
were asked if they could provide clients with the
measures and an information letter. Given that no
identifying information was obtained, informed con-
sent was implied by the anonymous return of the
completed measures. Ethics approval was gained from
both the Curtin University Human Research Ethics
Committee (HREC) and the HRECs attached to each of
the treatment agencies.
Data analysis and model testing
There were missing data for a total of 128 items across
the 371 cases. Results from Little’s Missing
Completely At Random test, performed using SPSS
19, indicated that the pattern of missing item values did
not statistically deviate from randomness. Missing
values were subsequently imputed using the SPSS
expectation maximisation algorithm.
CFA, as implemented through LISREL 8.8
(Jo¨reskog & So¨rbom, 2007), was used to test and
compare the predicted factor model (consisting of six
factors) to two other plausible factor models. The
factor models are described in Table III.
The item data violated multivariate normality. As a
consequence, the chi-square statistic that is normally
used to test model fit will be inflated. In these
circumstances, Jo¨reskog and So¨rbom (2007) recom-
mend testing model fit with a chi-square statistic
that corrects for the inflation. The Satorra–Bentler
Table III. Description of the three models.
Factor model
Number of
factors Names of factors
Model 1a (correlated factors) 6 Medical, moral, political, legal, economic, glamour
Model 1b (uncorrelated factors)
Model 2a (correlated factors) 2 Pathological (as measured by the medical, moral, political and legal items) and
alternative (as measured by the economic and glamorous items)Model 2b (uncorrelated factors)
Model 3a (correlated factors) 3 Pathological, economic, glamour
Model 3b (uncorrelated factors)
Model 4 7 One higher order factor (pathological) driving three of the six lower order
correlated factors (medical, moral, legal); there is no higher order factor
driving economic and glamour
Table II. Description of dimensions used in the substantive
validity analysis.
Discourse Subject positions Narrative
Economic Consumer, dealer Drugs are commodities
Medical Sick, expert Drugs are pathogens









Glamour Celebrities Famous people who use
drugs are interesting






























































chi-square provides such a statistic and was therefore
used to derive fit statistics for all the factor models.
Five fit statistics were used to evaluate model fit: the
Satorra–Bentler chi-square divided by its degrees of
freedom (2/df) (Kline, 2005), the Comparative Fit
Index (CFI) (Hu & Bentler, 1999), the Non-Normed Fit
Index (NNFI) (Hu & Bentler, 1999), the Standardised
Root Mean square Residual (SRMR) (Bentler, 1990)
and the Root Mean Square Error of Approximation
(RMSEA) (Browne & Cudeck, 1993; Steiger, 1990).
Each of the fit statistics evaluates model fit from a
slightly different perspective. The suggested criteria for
a good fit is a 2/df statistic less than or equal to 3
(Kline, 2005), a CFI and NNFI value greater than or
equal to 0.9 (Benet-Martı´nez & Karakitapoglu-Aygun,
2003), an SRMR less than or equal to 0.1 (Marsh &
Hau, 2004) and an RMSEA less than or equal to 0.08 or
a 90% CI for RMSEA that encompasses 0.08 (Benet-
Martı´nez & Karakitapoglu-Aygun, 2003).
RESULTS
The fit statistics for the factor models are reported in
Table IV. The predicted model consisting of six
correlated factors (Model 1a) was tested first, and
was found to fit the data better than an alternative
version of the model in which the factors were
uncorrelated (Model 1b). The removal of Item 21
from Model 1a, the lowest loading item, produced a
better fitting model (Model 1c) that reached threshold
for all five fit statistics. Four additional factor models
(Models 2a to 3b) were tested but did not fit the data as
well as Model 1c. The correlations among the six
factors in Model 1c are reported in Table V.
The high correlations between some of the factors
within Model 3c (e.g. r¼ 0.909 between legal and
moral) suggests that while the six constructs are
conceptually distinct, they might load on a higher
order factor. Hence, a final model (Model 4) was
examined in which the three highest correlated factors
(moral, medical and legal) were indicated by a higher
order factor, while the glamour and economic factors
were not indicated by a higher order factor. This model
was not found to be a better fit than Model 3c.
Correlations between each of the six of the DDDS
factors and locus of control were examined, since the
internalisation discourses that limit agency (e.g.
medical discourse) should be associated with low
levels of internal locus of control, while other
discourses that provide increased agency (e.g. eco-
nomic) might be associated with increased levels of
internal locus of control. Only significant correlations
were found between with the internal items of the
LCBS and the medical (r¼ 0.296, p< 0.001) and legal
(r¼ 0.146, p¼ 0.004) scales of the DDDS.
DISCUSSION
We have described the development of the DDDS, a
psychometric instrument proposed to measure the
degree to which individuals internalise the dominant
discourses regarding drugs in Australia. Construct
validity of the scale is supported by the current
research, in which the DDDS data was found to be a
good fit with the proposed factorial model.
The DDDS could have significant utility in research
examining policy debate and development, and also
help understand how the internalisation of certain
dominant discourses influences drug users’ identities
and behaviours. Some researchers (e.g. Rodner, 2005;
Sonn & Fisher, 1998) have shown that certain people
are resilient to internalising dominant discourses that
are pathogenic. Such resilience could be beneficial to
drug users’ psychological wellbeing. As such, some of
the DDDS scales might be useful in studies examining
interventions to reduce drug-related stigma.
Table IV. Fit statistics for CFAs of DDDS.
Model Description 2/df CFI NNFI SRMR RMSEA
1a Six correlated factors 1038.52/309¼ 3.36 0.913 0.901 0.080 0.080 (90% CI: 0.075, 0.085)
1b Six uncorrelated factors 1921.24/324¼ 5.94 0.808 0.792 0.197 0.116 (90% CI: 0.111, 0.121)
1c Six correlated factors without Item 21 873.746/309¼ 2.83 0.914 0.901 0.078 0.075 (90% CI: 0.069, 0.081)
2a Two correlated factors 917.71/208¼ 4.41 0.894 0.882 0.98 0.096 (90% CI: 0.090, 0.103)
2b Two uncorrelated factors 927.11/209¼ 4.44 0.889 0.878 0.111 0.097 (90% CI: 0.090, 0.103)
3a Three correlated factors 849.38/206¼ 4.12 0.904 0.893 0.089 0.092 (90% CI: 0.086, 0.099)
3b Three uncorrelated factors 909.05/209¼ 4.35 0.892 0.881 0.112 0.095 (90% CI: 0.089, 0.102)
4 Higher order factor model 793.90/203¼ 3.64 0.908 0.896 0.087 0.089 (90% CI: 0.082, 0.095)
Bold value represents the best fitting model.
Table V. Correlation matrix of latent variables (N¼ 370).
ECON MED MORAL LEGAL POLIT GLAM
ECON 1.000
MED 0.385 1.000
MORAL 0.246 0.880 1.000
LEGAL 0.513 0.896 0.909 1.000
POLIT 0.281 0.850 0.842 0.767 1.000
GLAM 0.153 0.422 0.441 0.318 0.333 1.000
Note: p< 0.001 for all correlations, except for GLAM and
ECOM, where p¼ 0.081.






























































However, several authors (e.g. Davies, 1997;
McCullough & Andersen, 2013) have noted that the
internalised narrative of lost agency through addiction
might assist individuals change addictive behaviour or
seek treatment. Indeed, this understanding of drug use
behaviour might be particularly helpful for successful
outcomes within 12-step programs (Keene & Raynor,
1993) and pharmacological interventions. The medical
scale of the DDDS could be helpful in matching
treatments with individuals’ beliefs about the nature of
their behaviour.
Contrary to prediction, internalisation of medical
discourse was associated with increased internal locus
of control. This could be construed as evidence against
the validity of the medical discourse scale, or that the
concerns about medical discourse limiting agency may
be unfounded – or at least the relationship is more
complex than first thought. Interesting, the economic
discourse scale, which was hypothesised to provide
individuals with increased agency, was negatively
correlated with the medical, moral, legal and political
discourse scales. This could be considered further
evidence of construct validity of the DDDS. There is a
need for further research into the role of discourse on
agency and treatment outcomes.
Since the DDDS was designed to be used among a
range of populations, the subject positions within the
items were not personalised (excluding items 13 and 19
within economic discourse scale that refer to ‘I’).
Rather, the items refer to ‘people’ and ‘you’. It is
possible that individuals who endorsed items in the
medical scale, and indeed the other scales, might apply
these narratives to others but not themselves. As such,
it is recommended that items 13 and 19 be reworded so
they are impersonal for consistency and a user-specific
form of the DDDS be developed in which the subject
positions within the items are personalised. This form
could be compared with the DDDS to better understand
the processes inherent to the internalisation of domi-
nant discourse.
While a users’ form of the DDDS would have
limited applicability in general settings, it might have
greater utility in treatment settings. Such a form of the
DDDS might also consider the more addiction-specific
narratives that medical discourse encompasses, such as
the brain disease narrative that has become so salient in
addiction research and treatment (Hammer et al.,
2013). This form would necessarily exclude the
glamour discourse since it only provides a subject
position for celebrities.
The present research also furthers understanding of
the structure of discourse. Despite medical, moral,
legal and political discourse providing space for
pathological narratives of drug use, the data did not
support a single pathological discourse latent factor.
This suggests that the four discourses are discrete and
supports the way in which discourse is generally
conceptualised (Burr, 2003; Dingelstad et al., 1996).
However, this research was conducted on a clinical
sample seeking treatment. Further research should
examine the DDDS, or other quantitative measures of
discourse, using non-clinical samples.
Given the cultural-specificity of discourse, the
validity of the DDDS might be limited outside of
Australia. Nonetheless, there is significant cultural
overlap between Australia and some other Western
countries such as the USA and the UK. Consequently,
to some the dominant discourses that the DDDS
measures might be generalisable.
In conclusion, the DDDS is a unique tool that has
been shown to have some validity. We are not aware of
any other psychometric instruments that have been
developed to examine dominant discourses.
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Australian Dominant Drug Discourses Scale
Economic discourse items
1. People are free to choose what drugs they buy
7. Paying for drugs is like paying to see a movie
13. Spending money on drugs is my choice
19. I should be able to spend my money on drugs if I
want to
Medical discourse items
2. It is important that you listen to your doctor
8. Doctors know what is best for drug users
14. People who use drugs need to seek treatment
20. People who use drugs are unwell
25. Drug use kills
Moral discourse items
3. People who use drugs lie
9. Drug use causes you to betray other people
15. Drug users are irresponsible
21. Using drugs is wrong
26. Drug users are untrustworthy
Legal discourse items
4. Laws are an effective way of stopping people from
using drugs
10. You shouldn’t use drugs because they’re illegal
16. Drug use leads to crime
22. Drug users should be punished
Political discourse items
5. It’s the governments job to protect us from drugs
11. Drug use is a big problem that we need to fix
17. Drug use needs to be regulated
23. Only the minority use drugs
27. Drug use harms society
Glamour discourse items
6. Supermodels use drugs
12. It’s okay for famous people to use drugs
18. Drugs are intriguing
24. Most rock stars use drugs
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Psychometric Properties of the Locus of Control of Behaviour
Scale (LCBS) among Australians Seeking Alcohol and Other Drug
(AOD) Treatment
Stephen J Bright, Robert Kane, Ali Marsh, and Brian Bishop
School of Psychology, Curtin University of Technology
Despite a paucity of studies evaluating the psychometric properties of the Locus of Control of Behaviour Scale (LCBS), it continues to be widely
used in behavioural research. The present study sought to redress this gap in the literature. The 17-item LCBS was administered to 373
Australians attending Alcohol and Other Drug (AOD) treatment agencies in the northern metropolitan region of Perth. Confirmatory factor
analyses were conducted in order to determine which of several plausible measurement models provided the best fit for the data. A unidimen-
sional model, recommended by the authors of the LCBS, and a two-dimensional (Internal Locus of Control vs External Locus of Control) model
provided poor fits. Other multidimensional models, differing only in the dimensionality of the externality factor, were also tested. A multidimen-
sional model consisting of an Internal Locus of Control factor and four component External Locus of Control factors provided the best fit;
however, the fit is probably best described as “reasonable” rather than “good.” A subsequent exploratory factor analysis using parallel analysis
indicated a cohesive internality factor; however, the externality factor showed a tendency to fragment into smaller components. Results were
discussed in terms of the problematic externality factor.
Key words: alcohol and other drugs; confirmatory factor analysis; locus of control; locus of control of behaviour scale; psychometrics;
substance use.
What is already known on this topic
1 Locus of control has been proposed as both a unidimensional
and multidimensional construct.
2 The Locus of Control of Behaviour Scale (LCBS) has been used
extensively in clinical research.
3 The authors of the LCBS propose that it is a unidimensional
measure of locus of control, although a confirmatory factor
analysis (CFA) has not been conducted to determine the facto-
rial structure of the scale.
What this paper adds
1 Despite being proposed to be unidimensional measure, a
confirmatory factor analysis indicated that the LCBS is actually
multidimensional.
2 The factorial structure of the internality dimension appeared to
be robust compared to the externality dimension, which frag-
mented into smaller subdimensions.
3 Researchers and clinicians should use the LCBS with caution
until further factor analytic research is conducted, though it
appears that the internality dimension of the LCBS might have
the most robust psychometric properties.
Originally defined by Rotter (1966) as the degree to which
individuals perceive themselves to have personal control over
their environment, locus of control (LOC) has become one of
the most widely researched constructs in psychology. Indeed, a
PsycINFO search using “locus of control” as a key word returned
over 15,000 citations identifying the construct as a moderating
or mediating variable in everything from depression (Clark,
2004) to mortality (Rodin & Langer, 1977).
There are many disagreements within the literature over
the operational definition of LOC. For example, Rotter (1990)
maintains that LOC is a unidimensional construct reflecting the
degree to which reinforcements are perceived to be contingent
upon personal agency; while Levenson (1973, 1974) has pro-
posed that LOC is a multidimensional construct in which
internality and externality are orthogonal components. Indeed,
Lefcourt (1991) has noted that correlations between internality
and externality are often low. Levenson has broken down
the external component into subcomponents that distinguish
between the external influences of chance and other people.
Furthermore, while Rotter has maintained that LOC is a gener-
alised, global and stable construct, others (e.g., Saltzer, 1978;
Spector, 1988; Wallston, Wallston, & DeVellis, 1978) have sug-
gested that it is domain specific, and thus, amenable to change
over the lifespan.
Within clinical research, it might be suggested that a domain
specific measure of LOC would be more useful than a global
measure. Developed by Craig, Franklin, and Andrews (1984),
the Locus of Control of Behaviour Scale (LCBS) provides such
a measure. Specifically, Craig et al. (1984) proposed that the
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LCBS measures the degree to which individuals perceive that
they have agency over their clinical problems. The scale consists
of seventeen 6-point Likert scale items anchored by “strongly
disagree” and “strongly agree” (see Appendix). Craig et al. pro-
posed that, following the reverse coding of seven items, the total
score provides a unidimensional measure of an individual’s
LOC with regard to their clinical problems; the higher the score,
the greater the externality.
The LCBS has been frequently used in the clinical psychology
literature to investigate a range of issues including, but not
limited to: anxiety (Hofmann, 2005), chronic fatigue (Samaha,
Lal, Smaha, & Wyndham, 2007), chronic illness (Elfstrom &
Kreuter, 2006), compassion fatigue (Nordtugab, Krokstadcd,
& Holenb, 2011), personality disorders (Fosse & Holen, 2007),
post-traumatic stress disorder (Dyb, Holen, Steinberg, Rod-
riguez, & Pynoos, 2003), stuttering (for review, see Susca,
2006), and suicide (Beautrais, Joyce, & Mulder, 1999). In par-
ticular, the LCBS has been extensively used in research con-
cerning psychotherapeutic treatment outcomes (Hook & Page,
2002, 2006; Hunt & Andrews, 1998) and Alcohol and Other
Drug (AOD) use (Haynes & Ayliffe, 1991; Poikolainene, 1997;
Rabinowitz et al., 1998).
Despite the popularity of the LCBS within the clinical
research, the psychometric properties of the scale do not appear
to have been adequately evaluated, with most studies simply
citing the original work by Craig et al. (1984) as evidence for the
scale’s reliability and validity. They provided some evidence of
reliability (12-month test–retest reliability of 0.76) and conver-
gent validity (a 0.66 correlation with Rotter’s [1966] original
LOC scale). They also demonstrated discriminant validity by
showing that LCBS scores were significantly higher among clini-
cal populations than a control group, and they provided some
evidence that the LCBS had predicative validity with regard to
relapse among stutterers. However, Craig et al. (1984) did not
provide any convincing evidence for the factorial validity of
the scale. They only conducted an exploratory factor analysis,
which indicated a two-factor solution. The authors proposed
that the second factor was simply a result of the wording of the
items, but was essentially meaningless, and thus reverted to a
one-factor solution.
Apart from the study by Elfstrom and Kreuter (2006) in
which the LCBS was examined within the context of a struc-
tural equation model, it would appear that no confirmatory
factor analysis (CFA) has been conducted on this measure. This
is particularly concerning, given the number of studies that have
used this measure. Indeed, even the results of Elfstrom and
Kreuter should be interpreted cautiously since the items were
translated into Swedish. Nonetheless, in their measurement
model, Elfstrom and Kreuter had to exclude 12 items due to low
loadings.
The aim of the present study was to conduct a CFA on an
English version of the LCBS. Given the salient use of this scale
in treatment research and AOD research, individuals seeking
treatment at an AOD agency should represent an appropriate
population on which to test the factor structure of the LCBS.
In addition, given the debate concerning the dimensionality of
LOC, two types of measurement models were tested: A unidi-
mensional model, recommended by the authors of the LCBS, in
which all 17 items are “driven” by a general LOC factor; and a
series of multidimensional models, all of which include an inter-
nal LOC factor and a separate external LOC factor, with some of
the models breaking down the external LOC factor into com-
ponent external LOC factors (e.g., Levenson, 1973, 1974).
Method
Participants
Participants consisted of 373 individuals who were seeking
services at several AOD treatment agencies in Perth, Western
Australia. Participants were recruited from both inpatient and
outpatient facilities. They were aged between 16 and 75 years
(M = 37.51, SD = 10.49). Of the participants who disclosed their
gender, 55% (n = 193) were male, and 45% (n = 158) were
female.
Procedure
Individuals seeking treatment for alcohol and other drug-related
problems at two inpatient facilities in Perth, Western Australia
were personally invited to take part in the study by the first
author. Interested individuals read an information letter
explaining that participation was voluntary, would involve
completing a short questionnaire, and their responses would be
anonymous. They were then given the LCBS to complete along
with a questionnaire that collected basic demographic informa-
tion. In addition, posters advertising the study were placed on
the walls of waiting areas within outpatient facilities alongside
copies of the aforementioned information letter, the LCBS, and
the demographic questionnaire. Participants recruited in this
way were instructed to place their completed surveys in a secure
drop box located nearby. Only those participants who provided
their written consent and stated that they understood the infor-
mation letter were included in the study. Ethical approval to
conduct this research was provided by Curtin University’s
Human Research Ethics Committee and the ethics committees
of the individual inpatient and outpatient services that partici-
pated in the study.
Results
In accordance with Craig et al.’s (1984) instructions, seven
items were reversed scored. There were missing data for a
total of 40 items across the 373 cases. Results from Little’s
Missing Completely at Random (MCAR) test, performed using
SPSS (Chicago, IL, USA), and indicated that the missing cases
did not statistically deviate from randomness. Missing values
were subsequently imputed using the SPSS expectation max-
imisation algorithm. Ten individuals with Mahalanobis values
greater than 40.75 (i.e., the critical chi-square value for 17 dfs
and an alpha-level of 0.001; see Tabachnick & Fidell, 2001,
p. 68) were classified as a multivariate outlier and eliminated
from the analyses, reducing the sample size to 363. A number
of inpatient respondents indicated to the first author that
they did not understand what item 6, “My problem(s) will
dominate me all my life,” was referring to. As such, item 6
was removed from the analysis.
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Confirmatory Factor Analysis (CFA)
There are three key assumptions underlying the CFA model.
First, the CFA assumes that the 16 items being analysed are
multivariate normal (Kline, 2005). If the assumption is violated,
as it was in this case (c2 = 425.890, p < 0.001), the chi-square
statistic that is normally used to derive the fit statistics will be
inflated (Jöreskog & Sörbom, 2004). In these circumstances,
Joreskog and Sorbom recommend deriving the fit statistics from
a version of chi-square that corrects for the inflation. The
Satorra–Bentler chi-square, available through LISREL, provides
such a statistic (Jöreskog, 2005). The Satorra–Bentler chi-square
was therefore used to compute all fit statistics. Second, CFA
assumes that the bivariate relationships among the 16 items are
linear rather than curvilinear. The most straightforward way to
test for linearity is to randomly select a sample of the scatter
plots of the bivariate relationships. If there are no obvious cur-
vilinear trends, then we can assume that the linearity assump-
tion has been met. No serious departures from linearity were
observed in a random selection of the 153 scatter plots derived
from the 17 LCBS items. Third, CFA assumes that no item is
multicollinear (i.e., highly correlated) with other items. It has
been suggested that multicollinearity may be a problem for a
particular item whenever its tolerance value is less than 0.1
(e.g., Bowerman & O’Connell, 1990, p. 447; Stevens, 2002). In
the present study, tolerance values ranged between 0.618 and
0.906 indicating that multicollinearity was not a problem.
The present study used five fit statistics to evaluate model
fit: The Satorra–Bentler chi-square divided by its degrees of
freedom (c2/df; Kline, 2005), the comparative fit index (CFI;
Bentler, 1990), the non-normed fit index (NNFI; Bentler, 1990;
Hu & Bentler, 1999), the standardised root mean square residual
(SRMR; Bentler, 1990), and the root mean square error of
approximation (RMSEA; Browne & Cudeck, 1993; Steiger,
1990). Each of the fit statistics evaluates model fit from a slightly
different perspective. The suggested criteria for a good fit is a
c2/df statistic less than or equal to 3 (Kline, 2005), a CFI and
NNFI value greater than or equal to 0.9 (Benet-Martínez &
Karakitapoglu-Aygun, 2003), an SRMR less than or equal to 0.1
(Marsh & Hau, 2004), and an RMSEA less than or equal to 0.08
or a 90% CI for RMSEA that encompasses 0.08 (Benet-Martínez
& Karakitapoglu-Aygun, 2003).
Several factor models were tested. First, we tested a 1-factor
model in which LOC is conceptualised as a unidimensional
construct. We then tested a 2-factor model which proposes
that LOC is best understood in terms of an internality and an
externality factor. The final three models—consisting of 3, 4,
and 5 factors respectively—all recognised the integrity of the
internality factor but differed in terms of how they conceptual-
ised the externality factor.
The 3-factor model partitioned the externality factor into
what appeared to be a powerful others factor (items 4, 11, 12,
and 14) and a luck/chance factor (items 2, 3, 9, 10, and 17). In
the 4-factor model, item 12 and 14 broke away to define a third
externality factor. Because items 12 and 14 appeared to measure
physiological symptoms, this factor was named physiological
symptoms. Finally, the 5-factor model identified a fourth exter-
nality factor by dividing the luck/chance factor into two sepa-
rate factors: luck (items 2, 3, and 17) and outside forces (items
9 and 10).
Fit statistics for the one-factor model and the four multifac-
tor models are reported in Table 1. The one-factor model can be
immediately dismissed as providing a poor fit for the data.
Although the correlated factor versions of the two-factor, three-
factor, four-factor, and five-factor models provided progressively
better fits for the data, the first three models met the recom-
mended “good fit” criteria on just one of the fit statistics (SRMR
<0.1). The five-factor model faired a little better by meeting the
“good fit” criteria on two of the fit statistics (SRMR <0.1, a 90%
CI for RMSEA that encompassed 0.08).
The correlated five-factor model appears to fit the data better
than the othermodels, which perhaps is no surprise since it is the
most complexmodel. The question is: Does the five-factor model
provide a significantly better fit than the other models? Because
the factor models are non-nested, this is a difficult question to
answer. Non-nestedmodels can, however, be compared with the
Akaike Information Criterion (AIC; Akaike, 1974). The model
with the lowerAIC provides the better fit. AIC values ranged from
1001.62 for the one-factor model to 415.02 for the correlated
five-factor model, providing further evidence for the superior
Table 1 Fit Statistics for Five LCBS Measurement Models






Root mean square error of
approximation (RMSEA)
1 Factor 937.62/104 = 9.02 0.62 0.57 0.150 0.150 (90% CI [0.140–0.160])
2 Factor
Correlated 558.59/103 = 5.42 0.77 0.73 0.091 0.110 (90% CI [0.100–0.120])
Orthogonal 563.39/104 = 5.42 0.77 0.73 0.094 0.110 (90% CI [0.100–0.120])
3 Factor
Correlated 449.45/101 = 4.45 0.81 0.78 0.085 0.098 (90% CI [0.089–0.110])
Orthogonal 488.81/104 = 4.70 0.78 0.74 0.110 0.010 (90% CI [0.092–0.110])
4 Factor
Correlated 418.64/98 = 4.27 0.84 0.80 0.080 0.086 (90% CI [0.089–0.100])
Orthogonal 549.22/104 = 5.28 0.75 0.71 0.120 0.110 (90% CI [0.100–0.120])
5 Factor
Correlated 331.02/94 = 3.52 0.87 0.83 0.075 0.083 (90% CI [0.074–0.093])
Orthogonal 613.10/104 = 5.89 0.70 0.66 0.140 0.120 (90% CI [0.110–0.130])
LCBS, Locus of Control of Behaviour Scale.
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fit of the correlated five-factor model. A path diagram of the
five-factormodel is presented in Figure 1. The five factors had the
following internal consistencies: internal (seven items: 0.67),
powerful others (two items: 0.57), physiological symptoms (two
items: 0.56), luck (three items: 0.70), and outside forces (two
items: 0.66). All things being equal: The fewer items in the scale,
the smaller the internal consistency. Internal consistencies of
0.6 are generally considered acceptable for scales consisting
of between five to nine items (Loewenthal, 2001). The present
internal consistencies, therefore, appear to be acceptable.
Exploratory Factor Analysis (EFA)
Although a five-factor correlated model comes closest to
meeting the criteria for a “good fit,” its fit is probably best
described as “reasonable” rather than “good.” It was therefore
decided to conduct an EFA with the aim of obtaining converging
evidence for a multidimensional model. We used parallel analy-
sis to determine how many factors should be extracted for the
final rotated solution (O’Connor, 2000). Parallel analysis gen-
erates random datasets with the same dimensions (participants
x items) as the main analysis, and then conducts an EFA on each
dataset. For each of the initial 16 factors, eigenvalues are rank
ordered across the EFAs and the eigenvalue at the 95th percen-
tile is specified. Comparison of eigenvalues from the main
analysis with those at the 95th percentile in the parallel analysis
indicates how many factors should be extracted. Results of the
parallel analysis showed that three factors should be extracted.
A final EFA was conducted forcing a three-factor solution,
which was then rotated using the promax procedure. The three-
factor solution explained 46% of the inter-item variability. The
pattern matrix revealed the ubiquitous internality factor and the
two externality factors of “powerful others” and “luck/chance.”
This is the three-factor solution that was previously tested with
CFA and proved to be a poor fit for the data.
Discussion
Despite being a well-established domain-specific measure of
locus of control within the clinical research, the psychometric
properties of the LCBS have not been adequately described. The
aim of the present study was to examine the underlying factor
structure of the LCBS. This is important since it provides infor-
mation about the construct validity of the LCBS.
The developers of the LCBS (Craig et al., 1984) state that this
has a single-factor structure, which is consistent with Rotter’s

































































Figure 1 Path Diagram of the 5-Factor Locus of Control of Behaviour Scale LCBS Model.
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(1990) unidimensional conceptualisation of locus of control.
However, the single-factor model that we tested appeared to
fit the data poorly. This suggests that contrary to Craig et al.
(1984), the LCBS items do not load on a single locus of control
factor. As such, several alternate models were examined.
Excluding the two-factor model, which was also found to be
a poor fit, the additional models that were examined were
consistent with Levenson’s (1973, 1974) multidimensional con-
ceptualisation of locus of control. Specifically, Levenson has
proposed that internal and external loci of control are not two
ends of a continuum but separate orthogonally related variables.
In addition, Levenson has suggested that external locus of
control consists of two separate components: chance and pow-
erful others. The three-factor model that we tested was consist-
ent with this conceptualisation. While this model was found to
be a better fit than the single-factor model, it was still unsatis-
factory so two additional models were considered.
A four-factor model was subsequently examined that
included an additional factor that was indicated by two items
that appear to be measures of physiological symptoms. A five-
factor model was also examined, which extended the four-
factor model by further dividing the luck/chance factor into two
separate factors: luck and outside forces. This model was found
to be the best fit, although the solution is best described as
reasonable rather than good.
While the best fitting model was multidimensional, contrary
to Levenson’s (1973, 1974) conceptualisation, the dimensions
were not orthogonally related but correlated. This finding is also
inconsistent with the low correlations between internality and
externality that have been reported (for review, see Lefcourt,
1991).
It is not surprising that the five-factor model was the best
fitting solution given that it was the most complex model exam-
ined. To determine whether the five-factor model was a better
fit than the other models, the AIC values were additionally
examined. The five-factor model had the lowest AIC value,
which provided further evidence for the superior fit of the
correlated five-factor model.
Finally, an EFA was conducted that provided further evidence
that the factorial structure of the LCBS is multidimensional. In
particular, the EFA indicated a three-factor model. While this
model was already tested with CFA and provided a poor fit, the
fragmentation of the externality dimension is consistent with
the CFA results—as the externality dimension is divided into
smaller components, the fit improves.
Overall, these findings raise questions about the validity of
the LCBS. Our data did not fit the one-factor model proposed
by Craig et al. (1984). While a multidimensional model was
found to fit the data best, this model was correlated rather than
orthogonal. Further, while the internality dimension appeared
to be robust and cohesive, the externality dimension appeared
to fragment into smaller components. These finding are signifi-
cant given the number of studies that have used the LCBS. Prior
to being used in future clinical research, additional factor ana-
lytic research needs to be conducted on the LCBS. Indeed, there
are some limitations in the present study.
First, despite having a reasonable sample size to conduct CFA,
a larger sample size would have allowed for further analyses.
In particular, a larger sample could have been split into two
allowing for a second CFA. This would have provided further
evidence regarding the underlying factor structure of the LCBS.
Second, participants in this study were all seeking treatment for
AOD use. It is reasonable to assume that the degree to which
these individuals were able to concentrate on the task of com-
pleting the LCBS could have been impaired as a consequence
of withdrawal or even acquired brain injury. In turn, this
would increase the amount of measurement error and reduce
the degree to which the data fits the factorial model that under-
pins the LCBS. Nonetheless, to have utility as a clinical tool, the
LCBS should be robust against such influences, which would be
observed in a range of clinical settings outside of an AOD treat-
ment service. Finally, the best fitting model was only a reason-
able fit, thus provided only limited evidence for the underlying
factor structure of the LCBS.
In conclusion, the present study provides evidence that the
factorial structure of the LCBS is not that originally proposed
by Craig et al. (1984). This finding could threaten the validity of
the LCBS and research that has used the tool in accordance with
Craig et al.’s instructions. Specifically, it appears that the overall
LCBS score is not a unidimensional measure of locus-of-control
and thus using this score might not be meaningful. As such, it is
not clear what research using the LCBS has measured. Conse-
quently, we recommend that researchers are cautious in using
this tool until further factor analytic research is conducted that
better elucidates the factorial structure of the LCBS.
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Appendix
Locus of Control of Behaviour Scale
(LCBS) Items
1 I can anticipate difficulties and take action to avoid them
2 A great deal of what happens to me is probably just a matter
of chance
3 Everyone knows that luck or chance determines ones’ future
4 I can control my problem(s) only if I have outside support
5 When Imake plans, I am almost certain that I canmake them
work
6 My problem(s) will dominate me all my life
7 My mistakes and problems are my responsibility to deal with
8 Becoming a success is a matter of hard work, luck has little or
nothing to do with it
9 My life is controlled by outside actions and events
10 People are victims of circumstance beyond their control
11 To continue to manage my problems I need professional help
12 When I am under stress, the tightness in muscles is due to
things outside my control
13 I believe a person can really be the master of his/her fate
14 It is impossible to control my irregular and fast breathing
when I am having difficulties
15 I understand why my problem(s) varies so much from one
occasion to the next
16 I am confident of being able to deal successfully with future
problems
17 In my case maintaining control over my problems is due
mostly to luck
SJ Bright et al. Locus of control of behaviour scale
Australian Psychologist 48 (2013) 172–177
© 2013 The Australian Psychological Society
177
Discussion 
The use of psychoactive substances has been estimated to cost the Australian 
community $55 billion annually as a result of decreased health, accidents and 
injuries, legal enforcement, AOD treatment, property damage and lost productivity 
(Collins & Lapsley, 2008). In addition, there are social costs attributable to the use of 
AOD, including:  assaults, domestic violence, family breakdown, reduced quality of 
life and early mortality. Consequently, there continues to be ongoing debate within 
the Australian community regarding AODs that are often poignant and polemic. 
Such debates are limited by the available dominant discourses that provide the ‘rules 
for engagement’. Dominant discourses demarcate how the ‘problem’ itself is 
constructed and the arguments that have the most ‘truth’ value. In turn, each 
dominant discourse produces solutions that privilege the institution/s with which it is 
associated.   
The research reported in this thesis suggests that there are at least six 
dominant discourses within which AODs can be framed: medical, moral, legal, 
political, economic and glamorous. Each discourse was shown to construct AODs 
differently and provide specific subject positions for people who use AODs. In turn, 
this limits the narratives that are available within each discourse. Narratives framed 
within medical, moral, legal and political discourse were revealed to be primarily 
pathogenic, in which limited space was provided for legal psychoactive substances. 
Conversely, economic discourse framed AODs within a neoliberal narrative, though 
illegal drugs were excluded from such narratives. Meanwhile, glamorous discourse 
was shown to provide an opportunity for a range of AOD narratives; however, these 
are limited to celebrities who use AODs. The specificity of these individual 
dominant discourses was demonstrated in the factor structure of the DDDS, which 
was developed as part of the research.  
The way in which these dominant discourses constrain the narratives of AOD 
use in Australia is consistent with Tupper’s (2012) observation that Drugs are 
demarcated from Non-drugs within dominant discourses. Hence, despite licit 
substances contributing to more overall social and economic burden for Australian 
society than illegal drugs (Collins & Lapsley, 2008), it would appear that the ‘drug 
problem’ in Australia has been primarily constructed as one that excludes legal 
substances through constructing these substances as Non-Drugs. Indeed, over half of 
60 
the newspaper articles that were analysed in Paper 1 referred to illegal psychoactive 
substances.  
Constructing the drug problem 
Within medical discourse, the pathogenic narrative pertains to the 
physiological and psychological harms (or diseases) to which exposure to AODs 
contribute. Illegal drugs (or Drugs) are often constructed as having more pathogenic 
agency than legal psychoactive substances (Non-drugs), particularly with regard to 
the disease of addiction. This is noteworthy since the conceptualisation of addiction 
as a disease first emerged in relation to problematic alcohol use in the 18th (Levine, 
1978) and 19th century (Valverde, 1998). By 1956 the American Medical 
Association (AMA) had declared that alcoholism was a medical illness (Keller, 
1976), and more recently addiction has been defined as a disease of the brain 
(Courtwright, 2010; Hammer et al., 2013). Alcoholics Anonymous, which was 
established in the decades preceding the AMA’s declaration, defined alcoholism as 
an affliction (or disease) of the soul. While this conceptualisation of addiction as a 
disease might be better framed within moral discourse, Miller and Kurtz (1994) note 
that the two conceptualisations of addiction as a disease are often erroneously 
conflated.  
AODs are typically demarcated from psychoactive drugs that are constructed 
as Medicines within medical discourse; however, some drugs can be constructed as 
medicines. This has mainly been evident for alcohol and caffeine, which have been 
constructed as having some health benefits when used in moderation. Such 
constructions serve to further differentiate these Non-drugs from Drugs. More 
recently there have been attempts to construct some illegal drugs such as MDMA, 
LSD and Cannabis as Medicines (Griffiths & Grob, 2010), though the success of 
such positioning is likely to take significant effort to reduce the existing pathogenic 
construction of these Drugs (Bright & Williams, 2013; Tupper, 2008). Further, the 
pharmaceutical industry has a vested financial interest in rejecting illegal drugs as 
Medicines since these drugs cannot be patented. However, medical discourse does 
provide space for some legal drugs to be constructed as Drugs with regard to 
physiological harms. This is particularly evident for tobacco, and to a lesser degree 
alcohol, since the harms associated with alcohol use are confined to people who 
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drink more than ‘normal’. Consequently, there are subject positions available within 
medical discourse for ‘abnormal’ drinkers. 
Medical discourse has previously been identified as a particularly privileged 
discourse in Australia (e.g., Fraser et al., 2004). The information that medical experts 
provide regarding AODs has significant ‘truth’ value. Consequently, through 
perpetuating the Drug/Non-drug dichotomy, medical discourse plays a substantial 
role in constructing the drug problem as one that excludes most legal drug users. In 
doing so, it also provides a solution to the drug problem. People who use Drugs and 
‘abnormal’ Non-drug users are positioned as sick or disordered, requiring 
paternalistic interventions that are guided by medical experts. This narrative serves 
to maintain the power of medical institutions, which gain funding to research and 
disseminate interventions, such as those involving Medicines, to treat the sick 
population. Hence, it is in the interest of medical institutions to emphasise the harms 
associated with Drugs and epidemics of drug use and ‘abnormal’ drinking.    
While arguably less privileged than medical discourse, legal discourse also 
clearly perpetuates the construction of the drug problem in Australia as one that 
excludes legal drugs through constructing AODs using a legal/illegal dichotomy that 
is analogous to the Drug/Non-drug dichotomy. Since the pathogenic narrative within 
legal discourse pertains to the criminality associated AODs, illegal drugs are 
necessarily problematic since they are legally prohibited. However, illegal drugs are 
also constructed as having additional criminogenic agency than legal drugs. This is 
consistent with Hughes, Lancaster and Spicer (2011), who found that the content of 
59.9% of 4,397 newspaper articles about illegal drug use focused on the legal 
problems associated with their use. In contrast, legal drugs are only constructed as 
problematic within legal discourse when people engage in illegal behaviours while 
using these drugs (e.g., drink driving). Such people are positioned as criminals and 
demarcated from the majority of law abiding citizens who use legal drugs. These 
constructions of AODs within legal discourse reinforce the rationale for the 
prohibition of illegal drugs, which serves to elevate the importance of law 
enforcement as the solution to the drug problem. Criminals have limited agency and 
require law enforcement to dissuade them from engaging in illegal behaviour 
through penalties that result from using illegal drugs and engaging in illegal 
behaviours associated with legal drug use. 
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Moral discourse produces narratives that are concerned with ethics. Within 
this discourse ethical ideologies are used to construct what is considered right or 
wrong. A particularly privileged ethical ideology within Australian society is 
Christianity. Moral discourse that is underpinned by Christianity often constructs 
alcohol as a Non-drug given the role of wine within the Bible. For example, Christ’s 
first reported miracle was to turn water into wine, and transubstantiation means that 
wine is analogous to the blood of Christ. Further, it is likely that alcoholic beverages 
were safer to drink in biblical times than water. Meanwhile, use of Drugs is 
constructed as wrong (or a sin) because this behaviour is typically illegal and 
potentially harmful. Within this narrative, people who use drugs are positioned as 
deviants who have some agency, albeit negative. This subject position is consistent 
with those that have emerged from previous analyses exploring media 
representations of Australian heroin users (Elliott & Chapman, 2000; Lawrence et 
al., 2000).  
Alternatively, moral discourse was also found to construct AODs as 
corruptive agents. This is consistent with the findings of a recent analysis of media 
representations of Cannabis in Canada that cited Paper 1. Haines-Saah et al. (2014) 
found that implicit to many descriptions of non-drug-related crimes was “the idea 
that marijuana smoking disinhibited individuals, reduced their moral threshold, and 
facilitated their criminal activity” (p. 9). A consequence of such constructions is that 
people who use AODs and engage in immoral behaviour are positioned as passive 
victims who have limited agency. This is particularly true with regard to vulnerable 
populations (e.g., young people, Indigenous Australians, etc.). Ekendahl (2012) 
notes that the media have often used this binary opposition between victims and 
villains to demarcate those drug using populations who deserve help from those who 
should be denied it.      
In contrast to these pathogenic narratives, economic discourse constructs 
AODs as commodities. Within this discourse, consumers are positioned as neoliberal 
subjects who are able to make rational decisions about their drug use. It is in the 
interest of manufactures and retailers of legal drugs to normalise the use of these 
drugs in order to maintain profits associated with sales. Hence, economic discourse 
perpetuates the Drug/Non-drug dichotomy since any increase in the demarcation 
between the two categories, including that created through further pathologising 
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Drugs, increases the normalisation of Non-drug. While it is conceptually possible for 
people who use an illegal drug to be positioned as consumers within an economic 
narrative, the aforementioned vested interest of manufacturers and suppliers of legal 
drugs ensures that such space is only available within the dominant discourse for 
Non-drug users. Hence, economic discourse also decreases the salience of legal 
drugs in the construction of the drug problem in Australia. 
The pathogenic narrative inherent to political discourse pertains to the threat 
that the use of AODs by the out-group, positioned as the ‘them’, poses to the in-
group, positioned as the ‘us’. This process, in which those that are different from the 
majority are identified and marginalised has been referred to by Haines-Saah et al. 
(2014) as ‘othering’. Political discourse serves to reinforce the importance of 
governments whose role it is to develop policies that protect the ‘us’ from the AOD 
problems caused by the ‘them’. Such policies are limited by the other dominant 
discourses that both construct the problem and limit the available solutions that can 
be implemented to protect the ‘us’. Since the us/them dichotomy replicates the Non-
drug/Drug dichotomy, AOD policy that is framed within political discourse will tend 
to maintain the status quo. Such policy is unlikely to be effective in reducing AOD-
related harm. 
Responding to the drug problem 
Australia has a policy of harm minimisation to respond to AOD-related 
problems. Harm minimisation consists of three areas of intervention: supply control, 
demand reduction, and harm reduction (Ministerial Council on Drug Strategy, 2011). 
Supply control involves regulating people’s access to legal drugs and attempts to 
preclude the availability of illegal drugs. Demand reduction involves reducing the 
amount of a psychoactive substance that people consume through mechanisms such 
as treatment, education and increased costs through taxation. Harm reduction 
involves any effort to ameliorate the economic, social, legal and health consequences 
associated with the use of a psychoactive substance. Examples of effective harm 
reduction interventions include: (i) needle and syringe exchange programs to reduce 
the incidence of HIV (Kimber et al., 2010; MacDonald, Law, Kaldor, Hales, & Dore, 
2003); (ii) mandating that thymine be included in bread products to reduce alcohol-
related encephalopathy (Harper et al., 1998), and; (iii) drug diversion schemes to 
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reduce the effect that a criminal conviction can have on a person’s developmental 
trajectory (Gottfredson, Najaka, & Kearley, 2003; Wilson, Mitchell, & MacKenzie, 
2006).  
Supply Control 
While there is evidence that supply control mechanisms can be effective in 
reducing the harms associated with the use of legal substances, there is growing 
evidence that supply control interventions are ineffective at managing illegal drugs. 
Using a number of international databases, Werb et al. (2013) consistently found that 
over the past 20 years the purity and potency of illegal drugs have significantly 
increased, while price has decreased. This is despite an increase in the amount of 
illegal drugs that have been seized. Further, by tweaking the chemical structure of 
illegal drugs a plethora of new psychoactive substances have recently become 
readily available that are often more potent and harmful than the illegal drugs that 
they were developed to mimic (for review, see Appendix A). Notwithstanding this 
evidence, most of the Australian Government’s resources that are used to manage 
AODs are allocated to controlling the supply of illegal drugs (Ritter, McLeod, & 
Shanahan, 2013).  
There is a symbiotic relationship between many of the dominant discourses 
that perpetuates a policy response to AODs in which the focus is placed on efforts to 
control the supply of illegal drugs and the implementation of alternative policy 
solutions is limited. In doing so, the power of the dominant institutions associated 
with each discourse is maintained. Legal institutions are required to control the 
supply of illegal drugs, so it is in their interest to support the preservation of the 
prohibition of these drugs since this ensures that future funding is secured. The 
rationale for the prohibition of illegal drugs is supported by evidence of harm that is 
provided through medical discourse. Medical institutions have a vested interest in 
perpetuating the construction of certain drugs as harmful since this provides 
opportunities for further research funding. Further, medical institutions implicitly 
support the prohibition of any drug that is deemed too harmful to be regulated, or of 
limited therapeutic value, since this maintains their control over the supply of 
psychoactive substances and also the demarcation between Drugs and Medicines. 
Moral discourse constructs the use of Drugs as intrinsically wrong, and thus also 
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supports their prohibition; in the same way that murder is wrong and thus should be 
illegal. Further, since Drugs could corrupt vulnerable populations, moral discourse 
can be used to frame a consequentialist argument wherein any means that are 
necessary should be used to control the availability of illegal drugs (Brook & 
Stringer, 2005). However, legal discourse also supports moral institutions in that the 
use of some Drugs is constructed as wrong because they are illegal.  
The way in which dominant discourses limit policy responses to AOD issues 
is evident in the way in which the Australian Government reacted to the emergence 
of a rapid increase in the availability of novel new psychoactive substances. In 2011, 
products containing these substances became available to purchase from Australian 
tobacconists and adult stores. Such products have often been professionally 
packaged and promoted as legal. Paper 2 focused on one particular type of product 
that has been termed synthetic cannabis. Synthetic cannabis refers to a product 
containing a herbal mixture that is laced with synthetic cannabinomimetics. The 
most well-known brand of synthetic cannabis was Kronic and initially contained 
synthetic cannabinoid agonists such as JWH-018, JWH-073, JWH-122 and JWH-
250 (Couch & Madhavaram, 2011).    
Synthetic cannabis was initially constructed by the media within economic 
discourse as Non-drugs. However, through the juxtaposition of synthetic cannabis 
and other new and emerging drugs with the illegal drugs that they mimicked, these 
new drugs were soon constructed as a Drug within the media. In doing so, medical 
discourse constructed the drugs as harmful, often with minimal empirical evidence. 
However, because medical discourse provides the availability for such objects to be 
constructed in this way (i.e., as Drugs), and is so privileged within Australian 
culture, this construction had significant ‘truth’ value. Further, the binary that was 
created between natural and synthetic served to strengthen this construction such that 
synthetic cannabis was intuitively considered more harmful than natural cannabis. 
This was particularly apparent when synthetic cannabis was conflated with other 
new and novel drugs such as NBOMe so that the problem became defined as that 
involving ‘synthetic drugs’ (Bright & Barratt, 2013).  
Moral and political discourse subsequently constructed synthetic cannabis as 
a threat to society given its legal availability, which created a moral panic. In 
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response to this moral panic, the Australian Government had a political imperative to 
implement policies to protect society from the perceived threat. Such policies were 
reactive and led to several chemicals being banned across multiple jurisdictions. In 
turn, this led to increased awareness and use of these new psychoactive substances, 
and the emergence of new synthetic cannabinomimetics that replaced the recently 
banned substances, such as AM-2201 and RCS-4 ("Poisons (Appendix A 
Amendment) Order (No. 2) 2011, Western Australia,"). These newer chemicals are 
more potent and might be associated with more harm than the earlier chemicals. 
Research in Germany has found that these newer synthetic cannabinomimetics have 
been associated with more severe and complex presentations at emergency 
departments (Hermanns-Clausen (Hermanns-Clausen, Kneisel, Szabo, & Auwarter, 
2012). Further, Winstock and Barratt (2013) found that use of synthetic cannabis is 
now more likely to lead to an emergency department presentation than use of any 
other AOD.  
The iterative interface between media, policy and drug-related behaviour 
highlights how dominant discourses can limit policy responses to AODs. The media 
sets the agenda for policy through constructing the problems of concern within 
society (Brosius & Weimann, 1996). For example, Beckett (1994) has shown that 
public concern about a drug can be influenced more by the media than statistics 
regarding the actual severity of the problem associated with that drug. In setting the 
agenda regarding AODs, the media is limited by the available dominant discourses 
such that oftentimes moral panic is created. Since policies that are implemented in 
response to these moral panics are reactive and also limited by the available 
dominant discourses, they are typically ineffective and perpetuate the status quo.  
Lancaster et al. (2011) have expressed concern that policies which are 
reactive to moral panic divert resources away from larger and more pressing AOD-
related problems. For example, while Australian AOD policy has focused on 
controlling the supply of illegal drugs, the prevalence of some alcohol-related harm, 
such as emergency department and ambulance presentations, hospitalisations, night-
time assaults and domestic violence has been found to have steadily increased 
(Foundation for Alcohol Research and Education, 2013; Livingston, Matthews, 
Barratt, Lloyd, & Room, 2010). Through maintaining the status of alcohol as a Non-
Drug, many of the dominant discourses preclude alcohol being constructed as 
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problematic. When alcohol is considered problematic, it is only considered 
problematic for certain vulnerable populations. Subsequent policies aim to reduce 
this problem through controlling the supply of certain beverages that are associated 
with use among them populations (e.g., alcopops), or through interventions target the 
vulnerable populations (e.g., Indigenous Australians). Yet more alcohol-related 
harms have been found to occur within middle-class communities than Indigenous 
and low income communities (Foundation for Alcohol Research and Education, 
2012). 
Tobacco provides an example of how a Non-Drug has been reconstructed as 
a Drug such that effective policy has been developed and implemented leading to a 
steady decrease in the incidence and prevalence of tobacco use. Such policies have 
focused on supply control (e.g., restrictions on sales, advertising and packaging) and 
demand reduction (e.g., taxation and education). However, these effective policies 
have only been possible since the government has regulation over the market. It 
logically follows that the regulation of some other drugs could also provide the 
opportunity for more effective policies; however, such change is limited by the 
dominant discourses. It is anticipated that the DDDS, which has been developed as 
part of this thesis, will allow further research into the way in which dominant 
discourses interact with evidence-based policy development. Such research might 
provide opportunities for the implementation of more effective AOD policy.   
Demand Reduction 
Supply control mechanisms have little effect on reducing people’s demand to 
use AODs. While some people might not use illegal drugs for fear of breaking the 
law, Miron and Zwiebel (1995) have stated that this effect is small. MacCoun and 
Reuter (2011) note that the effects of the law on deterring of drug use are complex. 
For example, the perceived degree of certainty of sanctions resulting from illegal 
drug use and the perceived stigma attached to use influences rates of use. 
Consequently, the effects of the law are likely to have the least impact on the 
demand to use those drugs for which the prevalence of use is higher, such as 
Cannabis and Ecstasy (AIHW, 2011), since there will be more opportunities to 
witness people use these drugs without receiving legal sanctions. Further, use of 
these drugs will be perceived as more normal. Meanwhile, the effects of the law 
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might have more effect on the use of drugs such as heroin since the prevalence of use 
is much lower (AIHW, 2011). Nonetheless, the recent decriminalisation of all illegal 
drugs in Portugal has not resulted in any significant increase in use of any drugs 
(Hughes & Stevens, 2010). Given this complex interaction between law enforcement 
and demand to use drugs, effective AOD policy needs to directly reduce people’s 
demand to use AODs. The internalisation of certain dominant narratives might 
directly increase or decrease people’s demand to use AODs and also have effects on 
the efficacy of interventions that are implemented to reduce demand. 
For example, the internalisation of neoliberal narratives, which are framed 
within economic discourse, could influence people’s perception of AODs such that 
they become more resistant to education campaigns. That is, since economic 
discourse positions the object as a Non-drug, and people who use AODs as 
neoliberal subjects, people who internalise this discursive framework will be less 
likely to perceive their own use of AODs as problematic. While the analysis of 
dominant AOD discourse provided in this thesis indicates that the constructions of 
Non-drugs within economic discourse is limited to legal drugs, a number of 
participants who completed the DDDS in Paper 4 endorsed items associated with the 
economic narratives. This suggests that while illegal drugs cannot be rationally 
framed within economic discourse in the broader community, individuals are able to 
apply narratives that are framed within this discourse to their own illegal drug use. 
Future research could use the DDDS to examine the role that the internalisation of 
economic discourse has on attitudes towards drugs and subsequent drug use 
behaviour. Such research could also examine the impact that the internalisation of 
this discourse has on the efficacy of educational campaigns.   
Glamour discourse was found to provide an alternative narrative that is 
neither pathogenic nor neoliberal. Rather, this discourse constructs AODs as objects 
that provide an interesting dimension to a celebrity’s status. While there is no subject 
position available for a non-celebrity drug user within glamorous discourse, 
Bandura’s (1977) social learning theory suggests that exposure to some narratives 
framed within this discourse could lead to increased drug use. For example, 
celebrities such as Ben Cousins model that a person is able to use illegal drugs and 
also excel at his profession. Consequently, the United Nations have expressed 
concern that “celebrity drug offenders can profoundly influence public attitudes, 
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values and behaviour towards drug abuse, particularly among young people” 
(International Narcotics Control Board, 2008, p.11). This statement appears to be 
framed within moral discourse, such that the term ‘drug’ refers to Drugs, which are 
constructed as having corruptive agency within this discourse. Such constructions 
create a moral imperative to protect vulnerable individual from these agents such as 
young people. However, in a focus group conducted by Shaw, Whitehead, and Giles 
(2010), young people were found to be critical of Amy Winehouse’s drug use and 
speculated that the media reported exaggerated her behaviour. Shaw et al.’s (2010) 
findings suggest that the impact of the glamorous narrative of AODs on young 
people’s attitudes and behaviour might be more complex than that stated by the 
United Nations. Indeed, the lack of positioning for non-celebrity drug users is likely 
to limit the internalisation of the glamorous narratives.    
Those dominant discourses that create pathogenic narratives of AODs (i.e., 
legal, medical, moral and political) are likely to be internalised by individuals since 
they provide a range of accessible subject positions. It might be assumed that the 
internalisation of these discourses influence people’s attitudes regarding the use of 
Drugs such that they are less likely to use Drugs. This could be considered a natural 
demand reduction mechanism.  
In an effort to leverage the veracity of the message being disseminated, 
AOD-related education campaigns are often framed within medical, moral and legal 
discourse. It would be expected that campaigns that are framed within the dominant 
discourses would be more effective; however, the effects of such education 
campaigns on the use of Drugs and drug-related harm have been found to be 
equivocal (for review, see Fletcher, Calafat, Pirona, & Olszewski, 2010; Midford, 
2007). For example, the “faces of meth” campaign, which involved advertisements 
in which people who use methamphetamine were depicted as committing violent 
crimes, leaving friends to die and engaging in prostitution to fund their use of 
methamphetamine, has been shown by Erceg-Hurn (2008) to decrease the perception 
of risk associated with methamphetamine use among the target audience and 
increase their perceived acceptability of the drug. Such findings might suggest that 
people perceive such campaigns as over-exaggerating the harms of the drug that are 
inconsistent with the target audiences’ experiences. It would be interesting to 
examine whether the degree to which people have internalised the pathogenic 
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narratives of AODs influences the effect that campaigns have on their attitudes and 
behaviour. Perhaps campaigns that are framed within a single discourse that is 
consistent with a particular narrative that has been internalised by an individual 
would be more effective for this person. In contrast, people who have internalised 
the neoliberal narrative of AODs might be more resistant to campaigns that are 
framed within dominant discourse. The DDDS might be a useful tool for conducting 
research to explore these interactions. 
The specific pathogenic narratives associated with each of the dominant 
discourses are also likely to impact on the way in which treatments for people with 
AOD-related problems are designed and disseminated. For example, treatment that is 
framed within moral discourse would necessarily be abstinence-oriented since any 
drug use is conceptualised as inherently wrong. Further, Brooke and Stringer (2005) 
highlight that moral discourse precludes the possibility of regulated and controlled 
use since people who use AODs are constructed as weak-willed and their “ability to 
control drug use can only be demonstrated through abstinence” (p. 318). Through 
achieving abstinence, treatment that is framed within moral discourse is typically 
referred to as recovery. Miller and Kurtz (1994) note that recovery is “not a 
treatment but a way of living and being” (p. 161). It involves an element of 
redemption following the actualisation of the person’s true self that had been 
possessed by the substance. This weakness of will and dislocation of self (or 
delusion) positions people who use AODs as helpless and provides justification for 
them to be governed by others since they require rescuing. Not only does this limit 
their agency through eliminating any rational voice, it justifies the use of therapeutic 
strength to subvert them into changing since this is in their best interest. Such 
positioning is likely to also perpetuate stigma and shame among people who use 
AODs.  
Alternatively, the aim of treatments that are framed within medical discourse 
is a reduction in harms that result from the use of AODs. This allows for a broader 
range of acceptable treatment outcomes that include, but are not limited, to 
abstinence. For example, reductions in alcohol use could be considered appropriate 
treatment goals for individuals who experience harm from alcohol use, through have 
not developed the disease of addiction. However, such treatment goals might be 
considered more tenuous for individuals who experience harm from Drug use, since 
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Drugs are constructed by medical discourse as being inherently harmful. Like moral 
discourse, individuals who use Drugs and abnormal drinkers are positioned within 
medical discourse such that their agency is limited; however, rather than being weak-
willed and deluded, within medical discourse these individuals are constructed as 
sick. Some (e.g., Brook & Stringer, 2005; Hammer et al., 2013) have noted that the 
medical conceptualisation of addiction as a brain disease might foster more dignified 
treatment of people who use AODs, thus reducing shame and stigma. However, it 
privileges medical experts over the experiences and needs of people who use AODs. 
Medical experts deem who are sick. Ironically, people who are dependent on 
Medicines such as Selective Serotonin Reuptake Inhibitors (SSRI) are not classified 
as addicted to the medication, but rather experience SSRI discontinuation syndrome 
if they cease taking the SSRI. By defining what constitutes addiction, medical 
experts also control who can access treatments and what treatments these individuals 
can access. In doing so, medical discourse also legitimatises the use of 
pharmacotherapies by medical experts as preferred treatments, whereby: (i) 
Medicines are prescribed substituted for Drugs, (ii) Medicines are prescribed to 
prevent the effects of Drugs, or (iii) Medicines are prescribed to reduce the severity 
of the disease (e.g., anti-craving medication).  
Despite addiction being conceptualised as biological in origin within medical 
discourse, addiction does not have a clear and consistent aetiology and there are few 
biological indicators that can be used to diagnosis the disease. Rather, most 
diagnostic criteria (e.g., ICD-10, DSM-V) refer to behavioural symptoms. 
Courtwright (2010) has also been critical of the inattentiveness of the addiction as a 
disease framework to the social determinants of AOD-related behaviour. While 
biological mechanisms might maintain addictive behaviours, social factors increase 
people’s predisposition to experience problems associated with AODs. For example, 
rats provided with an enriched environment are less likely to develop morphine 
addiction than those that are enclosed in a normal cage (Alexander, Coambs, & 
Hadaway, 1978). Similarly, people living in supportive environments that provide 
opportunities for growth will be more resilient to developing addictions (Alexander, 
2008; Hart, 2013). Further, experiencing stress has been shown to precipitate 
increased use of AODs (Rose & Bond, 2008). Through privileging the biological 
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determinants of AOD-related behaviour, medical discourse could limit the scope of 
interventions to those that reduce prevalence rather than incidence.  
Psychotherapeutic interventions for addiction could be considered to be 
consistent with medical discourse since they are also treatments for people with 
addictions, albeit less privileged than pharmacotherapies. While psychotherapy often 
conceptualises addiction as a learned behaviour, this conceptualisation is not 
necessarily inconsistent with the brain disease framework since learning involves 
neurological changes. However, psychotherapy tends to position people as agents of 
their own change (Beatch et al., 2009; Teyber, 2000; Yalom, 2002). That is, 
psychotherapy aims to increase people’s internal locus of control with regard to their 
behaviour. This seems to be incompatible with the reduced agency that is inherent to 
the subject position available for people who use Drugs within medical discourse. 
Rather, the limited agency associated with positioning of subjects who use Drugs 
within dominant discourses that produce pathogenic narratives suggests that 
individuals who use Drugs and internalise these dominant narratives would have an 
external locus of control.  
However, the research contained in this thesis suggests that the interaction 
between internalisation of pathogenic narratives and locus of control might be more 
complex. Contrary to prediction, the medical scale of the DDDS was associated with 
increased internal locus of control, and no relationship between locus of control and 
internalisation of narratives associated with other pathogenic narratives was 
observed. Several authors (e.g., Davies, 1997b; McCullough & Andersen, 2013) 
have noted that the internalised narrative of lost agency through addiction might 
provide an increased sense of control over their behaviour. For example, Hammer et 
al. (2013) have suggested that the addiction as a disease narrative simultaneously 
allows a person to own and yet disown their behaviour. This understanding of drug 
use behaviour might be particularly helpful for successful outcomes within 12-step 
programs (Keene & Raynor, 1993) and pharmacological interventions. In contrast, 
McCullough and Andersen (2013) have proposed that individuals with lower 
internalisation of this narrative might be more likely to benefit from 
psychotherapeutic approaches such as motivational interviewing. As such, the 
DDDS could be helpful in matching treatments with individuals’ beliefs about the 
nature of their behaviour.  
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Harm Reduction 
While harm reduction is a well-established concept within academia, and 
numerous harm reduction strategies have been successfully implemented within 
Australia, the research contained in this thesis suggests that there is limited space to 
frame harm reduction within the available dominant discourses. The solution of 
abstinence that is inherent to moral discourse is incongruent with the harm reduction 
philosophy that better social and health outcomes are possible without necessarily 
requiring a reduction in AOD use. Harm reduction accepts that some people will use 
AODs and does not take a moral position on this behaviour. Legal discourse 
provides space for harm reduction strategies involving legal drugs since use of these 
drugs is sanctioned; however, legal discourse is incongruent with harm reduction 
strategies regarding illegal drugs due to the binary between deterrence and 
promotion. That is, through consideration of the harms that arise as a result of 
prohibition (e.g., unknown purity), harm reduction is framed within legal discourse 
as not being committed to the deterrence of illegal drug use, and is instead framed as 
promoting the use of these drugs.  
While harm reduction could be suggested to be consistent with medical 
discourse since there is a focus on reducing harm, it might be considered a ‘weaker’ 
solution within this discourse. For example, Ekendahl (2012) has highlighted how 
the binary opposition between treatment and harm reduction leads to harm reduction 
being conceptualised as non-treatment. Put simply, the dominant discourses 
predispose professionals and the community to see treatment as the most appropriate 
solution to AOD-related problems leading to harm reduction being perceived as an 
inferior solution. The use of the DDDS as part of training for healthcare 
professionals could help to increase their awareness of the role of dominant 
discourses on shaping their understanding of AODs. This, in turn, could conceivably 
enhance their willingness to work with people who use AODs, and their openness to 
the appropriateness of a broader range of interventions for such individuals. Given 
that there is a lack of tools available to teach critical reflection (Smith, 2011), the 
DDDS might have significant utility as a teaching aide. 
Medical discourse might also be limited in framing harm reduction since 
harm reduction constructs people who use AODs as rational and able to make 
decisions to reduce harm when provided opportunities to do so. However, people 
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who are constructed as sick have limited agency and might be deemed irrational. 
Moore (2008) has stated that this inequality in status between people who use drugs 
and medical experts has precluded the legitimacy of the experiences and knowledge 
of people who use AODs, such as their experience of pleasure.  
Understanding the benefits that can result from using AODs is important 
since they are central to the reasons for using AODs. In addition to pleasure, 
researchers have found a range of benefits that people have identified that they gain 
from their use of certain psychoactive substances. Lende, Leonard, Sterk, and 
Elifson (2007) found that methamphetamine was reported to increase participants’ 
ability to work, draw and have sex, while  a participant in Pennay’s (2012) study 
stated that the drug was helpful since “if we’re too pissed we’d usually have it to 
straighten us out. I never go anywhere without my little vial, just in case ... 
somebody gets too fucked on ecstasy or too pissed” (p. 413). Meanwhile, use of 
cannabis has been reported by users to reduce stress (Boys, Marsden, & Strang, 
2001; Morgan, Noronha, Muetzelfeldt, Fielding, & Curran, 2013) and recent 
randomised controlled trials have shown that psychedelic drugs such as psilocybin 
increase personal insight and facilitate spiritual experiences (Griffiths, Richards, 
Johnson, McCann, & Jesse, 2008; Griffiths, Richards, McCann, & Jesse, 2006; 
MacLean, Johnson, & Griffiths, 2011).  
By not acknowledging the benefits of AOD use, the credibility of demand 
reduction efforts is reduced and the efficacy of harm reduction interventions could be 
diminished. Consequently, some (e.g., Mackenzie, 2011; Moore, 2010) have 
suggested that researchers need to move ‘beyond harm reduction’. That is, even 
harm reduction tends to confirm to the pathological paradigm first described by 
Mugford (1991), in which the focus of research is on harm. As an example of 
moving beyond harm reduction, Müller and Schumann (2011) have proposed a 
model in which Drugs are conceptualised as instruments through highlighting the 
functional adaptation that the use of Drugs can provide. However, the benefits of 
Drugs cannot be considered within the dominant discourses. For example, extending 
on Paper 1, McKenna (2011) conducted a discursive analysis of popular fiction to 
examine how the enhancement that amphetamine can produce was constructed. 
McKenna found that despite the social context actually encouraging the use of 
amphetamine to meet social expectations, the enhancement that amphetamine use 
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provided was often “glossed over or joked about” (p. 92). Perhaps the neoliberal 
subject position that is available within economic discourse might be leveraged to 
more effectively frame harm reduction and consider the benefits that Drugs can 
provide.  
Limitations 
Since discourse is situated within a specific socio-cultural context, the results 
of this research, including the DDDS, might have limited validity outside of 
Australia. Nonetheless, there is significant cultural overlap between Australia and 
some other Western countries such as the USA and the UK. Consequently, some of 
the dominant discourses that have been described will likely be similar to those in 
these countries. The utility of the DDDS might be limited given that there is much 
overlap between the dominant discourses and symbiotic relationships between them. 
Further, since the DDDS was designed to be used among a range of populations, it 
could be improved through creating additional forms that are specific to the 
population that is being sampled. The DDDS currently contains two items that were 
personalised (i.e., referred to “I” rather than “people”). Consequently, endorsement 
of the impersonal items of DDDS might be indicative that the individual applies 
these narratives to others but not themselves. It is recommended that a user-specific 
form of the DDDS be developed in which the all of the items are personalised, and a 
general form of the DDDS be developed in which all of the items are impersonal. 
These forms could be compared to better understand the processes inherent to the 
internalisation of dominant discourse. Further, a combined version of the form could 
have therapeutic utility since it allows a comparison between self and others.  
Conclusion 
The research contained in this thesis extends our understanding of dominant 
discourses regarding AODs in Australia. It would appear that at least six separate 
dominant discourses are available to frame AODs use in Australia: Medical, Legal, 
Moral, Political, Economic and Glamorous. Each dominant discourse has symbiotic 
relationships with particular institutions and ideologies. The narratives associated 
with the first four dominant discourses are primarily pathogenic in which the 
subjects positions for people who use AODs have limited agency. Through 
influencing people’s understanding of AODs, these dominant discourses limit policy 
76 
development, the implementation of strategies to reduce drug-related harm 
(including treatment) and affect people’s AOD-related behaviour. The development 
of a scale to measure the degree to which people internalise dominant narratives of 
AODs will provide opportunities for further research to understand the complex 
interaction between discourse, policy, treatment and AOD-related harm. 
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1. New drugs are emerging 
at an unprecedented rate as 
manufacturers of legal high products 
use new chemicals to replace 
those that are banned. There are 
two primary categories of product 
available in Australia: powders/
pills and synthetic cannabis. Both 
are being marketed and sold on 
the internet as well as in Australian 
tobacconists and adult stores.
2. While it is unclear how many 
Australians use new and emerging 
drugs due to limitations in 
monitoring, some indicators suggest 
that use is increasing. These drugs are 
highly accessible, touted as legal and 
perceived as safe. They may evade 
drug testing and are inadvertently 
promoted through media attention.
3. Because there is little information 
about the pharmacology and toxicity 
of new and emerging drugs, it is 
difficult to establish their harm 
potential, however: 
 a.  Some of the chemicals contained 
in the powder/pill products may 
increase the risk of psychosis, 
dependence and brain injury. It is 
unclear how these harms compare 
to traditional illicit drugs such as 
methamphetamine or cocaine. 
 b.  Synthetic cannabis may be more 
harmful than natural cannabis, 
and has been linked to psychosis, 
seizures and heart problems.
4. Given the rapidly changing market, 
a new drug could emerge that has the 
potential to cause widespread harm. 
Early monitoring systems are required 
to identify such drugs, and warn 
clinicians and AOD workers as well as 
individuals who use these drugs. 
 a.  The Psychonaut Web Mapping 
Project provides an exemplar of 
a monitoring system. It might 
be further enhanced by analysis 
of wastewater and of products 
available in Australian stores. 
5. Typically, individuals will not 
spontaneously admit to using 
new and emerging drugs and 
traditional assessment tools do not 
elicit this information.
 a.  Allied health and youth workers 
need to assess for the use of new 
and emerging drugs, and provide 
harm reduction and treatment 
where appropriate. 
 b.  Clinicians working in acute and 
treatment settings need to be 
aware that some presentations 
may relate to the use of new and 
emerging drugs. These patients 
should be treated similarly to 
presentations of the drug that the 
new substance is mimicking. 
6. Online user-driven forums and 
educational resources such as 
Erowid can be used to gather 
useful information about new and 
emerging drugs.
7. Banning individual chemicals  
as they emerge does not appear to 
create any meaningful change in 
the availability of emerging drugs. 
It may also inadvertently increase 
harm by raising awareness of the 
products and by encouraging 
people to access newer and lesser-
known chemicals. Innovative policy 
responses need to be implemented 
to address this challenging issue:
 a.  A model that regulates the sale 
of new and emerging drugs 
is being implemented in New 
Zealand and may provide a 
useful template for Australia.
 b.  At this time policy makers should 
focus on early monitoring systems 
and gathering toxicological data 
on new and emerging drugs. 
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What are new and emerging drugs? 
A range of terms have been used to describe new and emerging 
drugs, including legal highs, herbal highs, party pills, emerging 
psychoactive substances, novel psychoactive substances, or 
simply synthetics*. Products containing these new and emerging 
drugs have been available in some Australian adult stores and 
tobacconists, in addition to being sold from overseas and local 
websites, for the past two years. They are often professionally 
packaged and labelled ‘not for human consumption’ (see Figure 1). 
Such pre-packaged products have been sold as nutritional 
supplements, herbal ecstasy, plant food, bath salts, party pills, 
room deodorisers, incense and synthetic cocaine. Some people 
have bought the active chemicals that these products have been 
speculated to contain from online vendors 4. These are often sold 
as research chemicals.
Most new and emerging drug products are promoted as legal, 
however the complexity of Australian law means such claims 
are often tenuous (see Box 1). Most reportedly produce marked 
psychoactive effects resulting from the various chemicals in 
them. However, when analysed, some products have been found 
to include only caffeine or no active ingredients at all 5, 6. 
There is a broad array of new and emerging drugs available in 
Australia, but they will be classified into two basic categories 
for the purposes of this paper: 
• powders/pills 
• synthetic cannabis.
* The term ‘synthetics’ is problematic since many traditional 
drugs such as amphetamine, ecstasy and LSD are synthetic.
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 introduction 
New recreational drugs are being developed at an 
unprecedented rate. In 2011, 49 new drugs were detected 
by the European Centre for Monitoring Drugs and Drug 
Abuse (ECMDDA); double the number of new drugs that 
the ECMDDA detected in 20091. An interaction between 
the multi-million dollar international legal highs industry 
and policy makers appears to be fuelling this increase. 
Each time an existing chemical 
is banned, a new drug enters 
the market to replace it. 
Some of these emerging recreational drugs are professionally 
packaged and aggressively marketed on the internet. Online user-
driven drug forums are also enabling the rapid dissemination of 
information about these new drugs.
New and emerging drugs are initially highly accessible. Overseas 
some have become as popular as more traditional illicit drugs 2. 
The potential harms associated with these new drugs are difficult 
to quantify as there is virtually no human testing conducted 
prior to them being released into the market. There is therefore 
little information about whether the substances are toxic or even 
carcinogenic. We have no idea what the long-term effects might 
be. Most informants that contributed to the development of 
this paper were concerned that the next new drug might cause 
significant widespread harm. Is this a potential public health crisis 
waiting to happen?
Professor Farrell, Director of the National Drug and Alcohol Research 
Centre, stated that emerging drugs represent one of the biggest 
challenges in the alcohol and other drugs (AOD) field in 2013 3. This 
paper addresses what clinicians, allied health and youth workers, 
researchers and policy makers need to know about new and 
emerging drugs to make effective assessments and reduce harms. It 
will also discuss the need for early monitoring systems to detect the 
emergence of potentially dangerous new drugs, and recommend 
that policy makers consider innovative options to minimise harm.
Get your ePub version of this issue of 
Prevention Research at druginfo.adf.org.au
...article continued page 5
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Products have been 
available in some 
Australian adult stores 
and tobacconists for 
the past two years.
 the law
There is a complex relationship between state 
and federal laws in Australia. While importation 
falls under federal legislation, most drug laws are 
state-based and unique to each state. This means 
that although a chemical may be illegal to import 
under federal law, outside of federal jurisdictions 
(e.g. universities, airports, international mail and 
other border controls) it might be legal to possess 
in one state, yet illegal to possess in another.
Existing federal government laws
At the federal level, the Therapeutic Goods Administration 
(TGA) has a legislative document called the Poisons Standard. 
The Poisons Standard contains schedules that determine the 
degree of restriction that is placed on a substance. For example, 
Schedule 3 substances can only be purchased from a pharmacy 
(though don’t require a prescription), while substances in 
Schedule 4 can only be accessed with a prescription. 
Changes to the Poisons Standard occur four times each 
year following a public consultation process. In addition to 
making decisions about which schedule is most appropriate 
for any given medicine, the TGA can place a substance in 
Schedule 9, meaning that it is an illegal substance with no 
approved medical use. 
While the relevant legislation in some states, such as Victoria, 
refers to the TGA’s legislation 76, drug laws in other states, such 
as New South Wales, do not 77. In these states, prosecution 
using the TGA’s legislation can only occur in federal 
jurisdictions and requires the involvement of federal agents. 
Federally, there is also the Criminal Code Act 1995, which 
includes an analogues clause. The clause bans chemicals 
based on their structural similarity to chemicals that are 
already scheduled. For example, mephedrone could be 
considered an analogue of the illegal drug methcathinone, 
or even amphetamine (see Box 2). Individuals prosecuted 
for importing mephedrone have typically been convicted 
under this Act. 
State government legislative response 
Most states have banned a range of chemicals contained 
in synthetic cannabis and pills/powders. Some states have 
also added analogue clauses to their drug legislation. 
The Queensland Government has proposed banning any 
product that is intended to ‘have a substantially similar 
pharmacological effect’ to an illicit substance 78. From a legal 
perspective, this means that selling a product containing 
only caffeine that is marketed as a substitute for ecstasy, 
could be treated in the same way as selling ecstasy. As such, 
an individual carrying a pill containing only caffeine could 
potentially be charged with possession of a dangerous drug. 
Federal government  
legislative response 
In May 2012, the TGA placed MDPV and eight broad 
synthetic cannabinoid agonist chemical groups in 
Schedule 9 11. This has effectively banned thousands of 
chemicals based on their chemical structure at the federal 
level, and in those states that refer to the TGA’s legislation. 
Many chemicals that will be considered illegal under 
these changes have not yet been synthesised. In addition, 
the TGA scheduled synthetic cannabinomimetics, which 
means any synthetic product that has similar effects to 
cannabis, though no formal definition is provided in the 
legislation and it has not yet been tested in court. 
Most recently, new laws have been introduced by the federal 
government to allow for emergency scheduling. Under this 
new law, the Attorney-General or Minister for Justice will 
not have to introduce legislation to amend the Criminal 
Code Act. Instead, a minister can simply issue an emergency 
determination that can last 18 months. Barrister Greg Barns 
has stated that this “will not curtail in any way the demand for 
drugs and the ability of the market to supply them to millions 
of Australians” 79. Indeed, despite all of the aforementioned 
legislative changes, new and emerging drug products remain 
widely available in many Australian states.
Matthew Wielenga, owner of the company that 
manufactured Kronic, was arrested in Melbourne on 7 
December 2012 after he was found with more than 100kg of 
Kronic and 1kg of white powder reported to be a synthetic 
cocaine 80. It will be interesting to see how the case proceeds 
in this new legislative environment.
Box 1: in DePth
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 What are new and emerging drugs? 
Powders/pills 
Party pills 
In the early 2000s, the legal high/party pill industry emerged 
in the United Kingdom (UK) and New Zealand (NZ) where legal 
piperazines, such as benzylpiperazine (BZP), were professionally 
packaged and marketed as a harm reduction strategy by the 
industry. Following some health concerns, BZP was banned in 
NZ and the UK in 2008 and 2009 respectively. In an endeavour to 
continue selling party pills, the legal high manufacturers sought 
to develop new BZP-free products. Unlike BZP products, which 
were already prohibited in Australia, these new products were 
alleged to be legal and marketed to Australians. 
BZP-free products were often 
mislabelled as plant food in 
an attempt to conceal the 
product’s intended use. 
For example, a London Underground packet stated that the pills 
are ‘best suited for tropical plants. Use one … per square meter 
around garden beds. For potted plants less than one metre in 
height, half to a quarter... should be sufficient’ (see Figure 1). Such 
products contained a range of cathinone analogues such as 
mephedrone (see Box 2 ).
Bath salts/synthetic cocaine
In 2010, mephedrone was banned in both the UK and Australia. 
New products subsequently emerged containing a range of 
new chemicals, including naphyrone (naphthylpyrovalerone), 
MDPV (methylenedioxypyrovalerone) and flephedrone 
(fluromethcathinone) 7-10. These new products have been sold as 
powders intended to be snorted. At first, they were imported from 
Europe and the USA where they were sold as bath salts. However, 
it appears that they are increasingly being manufactured in 
Australia and sold as synthetic cocaine in adult stores. Some 
popular overseas brand names include Ivory Wave, Bubble Bliss 
and Vanilla Sky. Local brands have included Sharman’s Dust, White 
Bull and Smokin’ Slurrie.
Because some of the chemicals contained in these new 
products, such as MDPV, are active at very low doses, the pre-
packaged products are often cut with fillers to ensure that the 
dose is similar to that of the illicit substances that they mimic. 
Many also contain numbing agents to replicate the subjective 
experience of using cocaine 5. 
In May 2012, MDPV was banned federally in Australia 11. However, 
other synthetic cocaine products are currently available in 
Australia. These second generation bath salt products may 
contain the range of chemicals that were found in synthetic 
cocaine available in the USA after MDPV was banned. These 
new chemicals include α-pyrrolidinovalerophenone (α-PVP) and 
methyl-α-pyrrolidinopropiophenone 12. Anecdotal evidence from 
a few presentations in Victorian acute settings indicates that 
some products might also contain methoxetamine – a ketamine 
analogue that has recently been banned in the UK. 
Research chemicals
Once information about the active ingredient of a new drug 
becomes widely available, there have been anecdotal reports of 
people ordering the pure chemical directly from overseas online 
chemical vendors. For example, after mephedrone was identified 
as an active ingredient in a popular legal highs product, people 
began to seek the pure chemical 4. Such demand for a specific new 
chemical in the recreational drug market has not been seen since 
MDMA (or ecstasy) emerged in the late 1980s. 
Synthetic cannabis 
Synthetic cannabis refers to products containing an herbal 
mixture that is laced with a range of synthetic chemicals to mimic 
tetrahydrocannabinol (THC), the primary psychoactive chemical 
contained in cannabis. Kronic is the most well-known brand of 
synthetic cannabis in Australia. Kronic has produced a range of 
blends, including Skunk, Purple Haze, Tropical, Pineapple Express 
and Black Label.
In April 2011, Western Australian (WA) media began reporting the 
use of Kronic by workers on mine sites to evade drug screening 13. By 
June, the WA Government had banned seven chemicals that Kronic 
was thought to contain 14. In the lead up to this ban, the manufacturer 
of Kronic endeavoured to sell its remaining stock 15. Customers 
reportedly stockpiled Kronic after the company used social media, 
especially Facebook and Twitter, to engage its customers. The night 
before the bans took effect, a ‘smoke ‘em party’ was organised in Perth 
for people to consume their remaining Kronic 16. 
Facebook had never before been used to 
sell drugs so openly in Australia, nor had 
there been such organised efforts to use 
drugs in a social setting prior to a ban.
Other states, including Victoria, soon followed WA’s lead. However, 
new synthetic cannabis blends have appeared that claim to 
contain new unscheduled chemicals. This is consistent with the UK 
experience where analysis of synthetic cannabis blends available after 
bans have found the presence of a new range of chemicals 17. Even 
if these new synthetic cannabis products contain new chemicals, 
consumers could be charged with possessing prohibited drugs.
Figure 1: Professionally packaged party pill product 
displaying information that obscures its intended use.
...continued from page 3
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After BZP was banned in the UK and NZ, legal high 
manufacturers began marketing new products. The 
first analysis of such products by Camilleri et al.70 found 
a range of novel chemicals, including several cathinone 
analogues. Cathinone, a chemical contained in the 
khat tree which is native to North East Africa, is just 
one atom different to amphetamine. While the legal 
status of the khat tree is state-dependent in Australia 
(see Box 1), cathinone is banned both federally and in 
all states and territories. Methcathinone is a synthetic 
cathinone analogue that has effects that are similar 
to methamphetamine and has been banned in most 
countries, including Australia, for many years. 
One of the cathinone analogues identified by 
Camilleri et al. was phthalimidopropiophenone. This 
cathinone analogue is a pro-drug, which means it is 
an inactive, legal substance until it is broken down by 
stomach acids into cathinone which is an illegal and 
active compound. 
In effect, this means the 
drug is legal outside of 
the body but becomes 
illegal once ingested.
Mephedrone, or 4-methylmethcathinone, was another 
cathinone analogue identified by Camilleri et al.70. Once 
identified, there was a rapid increase in its popularity. 
Mephedrone was dubbed miaow miaow by the media, 
and people began seeking out the raw chemical 
rather than products alleged to contain mephedrone. 
Significant media coverage quickly developed 74 with 52 
mephedrone-related fatalities reported in the UK alone 
by July 2010. However, only two or three cases were 
ever confirmed, and it was discovered that 12 of these 
people had not consumed mephedrone 81. Nonetheless, 
in the midst of this media coverage, governments 
worldwide moved to quickly ban mephedrone and 
other cathinone analogues. Unfortunately this has led 
to a range of new chemicals being used in legal high 
products, including naphyrone (naphthylpyrovalerone), 
MDPV (methylenedioxypyrovalerone), flephedrone 
(fluromethcathinone), α-pyrrolidinovalerophenone 
(α-PVP) and methyl-α-pyrrolidinopropiophenone.
Box 2: in DePth
how prevalent is 
the use of new and 
emerging drugs  
in Australia? 
While the use of new and emerging drugs has been 
identified as significant in the USA and Europe 2, the 
exact degree to which these drugs are being used in 
Australia is unclear. Nonetheless, some indicators 
suggest an increasing trend. For example, the 
Australian Federal Police has noted a significant 
increase in the quantity of non-traditional drugs 
seized18, and there have been numerous Australian 
media reports about new and emerging drugs19-21.
In 2010, the Australian Ecstasy and Related Drugs Reporting 
System (EDRS), an annual national survey of regular ecstasy 
users, identified the use of mephedrone among a number of 
informants22. Between 2011 and 2012, there was an increase in 
the number of EDRS participants reporting use of other new 
and emerging substances. However, the people that the EDRS 
is sampling from (i.e. regular ecstasy users) are not necessarily 
representative of the population using new and emerging drugs 
and therefore cannot be used to estimate the prevalence of use 
among the general Australian population.
Analysis of wastewater provides more objective evidence for 
the use of emerging drugs. Chen et al. have shown a peak in the 
level of mephedrone detected in Adelaide wastewater during 
2010, and an increasing trend in the level of MDPV detected 
between 2009 and 201123. However, because there is little data 
on the metabolism of new drugs, there are no algorithms to 
determine the prevalence of use based on the amount of any 
chemical detected in samples. It is also unclear whether the 
chemicals identified in the waste analysis originated from pre-
packaged products, were acquired as research chemicals, or 
were contained in products sold within the illicit market.
The Australian Federal 
Police has noted a 
significant increase in 
the quantity of non-
traditional drugs seized.
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how harmful are new and emerging drugs? 
Powders/pills 
The potential harms associated with powder/pill products 
are difficult to establish. Each product may contain different 
chemicals with varying toxicity profiles, and analyses of products 
have found that a product may also contain different chemicals 
at different points in time 5. For example, the dose for MDPV 
is almost 100 times smaller than mephedrone, which means 
there is an increased risk of overdose. Like methamphetamine 
and cocaine, MDPV is also a potent dopaminergic agent, which 
means that there is an increased risk of psychosis and compulsive 
re-dosing 24, 25. It is unclear how comparable these risks are to 
those associated with the use of methamphetamine/cocaine. 
Chemicals containing chlorine or fluorine atoms are called 
halogenated chemicals and are generally neurotoxic. Some 
powder/pill products have been found to contain halogenated 
chemicals 5, 7, 8, 26-29. Such products might increase the risk of an 
individual experiencing a brain injury – particularly if the product 
is used frequently and in high doses. 
Synthetic cannabis 
The harm potential of a synthetic cannabis product will 
depend on the specific chemicals that it contains, and many 
products contain more than one chemical. Generally speaking, 
synthetic cannabis might be more harmful than cannabis for 
a range of reasons. THC, the primary psychoactive ingredient 
in cannabis, has a very low toxicity profile and does not tend 
to interact with many other drugs. There is very little data on 
the toxicity of the chemicals contained in synthetic cannabis 
and their metabolites. In addition to THC, cannabis contains a 
host of other chemicals, such as cannabidiol (CBD), which have 
antipsychotic and anticonvulsant properties. The absence of 
chemicals such as CBD in synthetic cannabis might increase 
the likelihood of psychotic symptoms or possibly seizures 
30. Finally, the effects of synthetic cannabis are shorter than 
those of natural cannabis, which may increase the likelihood of 
addiction through reinforcement of use from frequent dosing 31. 
While there are anecdotal reports of people successfully using 
synthetic cannabis to reduce their dependence on cannabis, 
others have reported significant withdrawal symptoms. 
Hospital presentations 
It is unclear how many people have presented to Victorian 
hospitals with problems resulting from the use of new and 
emerging drugs as hospitals have no way of coding such 
presentations. At least two unverified Australian deaths 
associated with the these drugs have been reported by the 
media 21, 32. The media has also reported on other Australian 
deaths that may have resulted from such drugs being sold as 
traditional drugs such as LSD 33. 
Staff at call centres such as DirectLine and the Drug and Alcohol 
Clinical Advisory Service (DACAS), report that they have received 
calls about new substances. However, limitations in the amount 
of information that is recorded prevents any quantitative 
analysis. Nonetheless, 17 per cent of calls received by the 
Victorian Poisons Information Centre (VPIC) about ‘street drugs’ in 
2012 were coded as ‘other’. Jeff Robinson, Manager of VPIC, was 
able to confirm that a number of these calls concerned new and 
emerging drugs. These are the only indicators currently available 
about the incidence of new and emerging drug-related harms.
Why do people use new and emerging drugs? 
Increased awareness and publicity  
Unlike previously available legal high products, new and 
emerging drugs reportedly produce marked psychoactive effects. 
Greater awareness of this fact, disseminated through the media 
and online user forums (see Box 3), is likely to have increased 
demand for the products. This was particularly evident with the 
emergence of synthetic cannabis in Australia during 2011. Bright 
et al. 19 have shown that there was a strong connection between 
the volume of media coverage and the number of internet 
searches for Kronic and synthetic cannabis. Many of the initial 
online newspaper articles about the ban on Kronic contained 
Google advertisements that linked directly to online vendors. A 
Queensland newspaper quoted one man as saying, “I saw Kronic 
on the news and thought... holy smoke, I’m going to order this” 34. 
Legality 
Some people are attracted by the alleged legal status of new 
and emerging drugs 35. There may also be a perceived degree 
of safety attached to a product that is professionally packaged 
(see Figure 1) and apparently legal 36. 
Avoidance of positive drug screens 
Synthetic cannabis became widely known in Australia when the 
media reported that mine workers in WA and Queensland used 
the drug to avoid positive drug urine screening tests 37. Perrone 
et al. have found similar motivation among users of synthetic 
cannabis in the USA 38. Most of their sample of synthetic 
cannabis users were attending abstinence-only drug treatment 
programs under community corrections orders, or were seeking 
a career in the US military, and were therefore motivated to use 
synthetic cannabis to avoid positive drug tests. 
Availability 
Increased availability of any drug is positively associated with 
increased use, and emerging drug products are highly accessible 
in adult stores and online. This should be considered in the context 
of a reported worldwide decline in the purity of ecstasy tablets.  
As such, some people who are dissatisfied with the quality of 
ecstasy might be inclined to purchase legal highs39, 40. Finally, some 
people might consume new and emerging drugs unwittingly – 
there have been reports of the drugs being detected in samples  
of ecstasy and LSD (www.ecstasydata.org).
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Example discussion from an  
online user forum 
TABle 1
#1 Original Poster
Hi I received a sample yesterday of the latest LU 
'Doves Love'. According to the packet it contains a 
compound "2β-(3-(4-Methylphenyl)isoxazol-5-yl)-3β-(4-
chlorophenyl)tropane", allegedly a dopamine reuptake 
inhibitor. http://en.wikipedia.org/wiki/(-)-2%C...phenyl)
tropane. Just wondered if anyone had tried these yet or 
had any other info on them, and if they could post a trip 
report. I will probably post one after this weekend. 
#2 Person A
The Admin of the Aussie herbal incense forum imported 
some and said they were all right. He reviewed them.
#3 Person B
Interesting, might have to try some. The LU Doves 
ive tried have always tested up to be a Beta Ketone 
substance – My guess butylone or methylone. 
perhaps a mix. 
#4 Person A
Does anyone know what the legality of this 
compound is? These are being imported.
#5 Person C
tried these three times. Im from the USA. These are the 
bomb. Honestly can say one of the best legal pills Ive 
tried. Started feeling full effects about an hour after 
taking it. So euphoric, Rushes, Very like MDMA. I took 
one and then two hours later took the Second. Total 
duration About 4-6 hours. But definately give them 
a try. I f***in love em. Ive ordered them three times 
already and Im waiting on a fourth order and I can't 
wait for them to come they are awesome.
#6 Person A 
Most of the online reviews for these are glowing. 
Someone on the other forum last night posted that 
they had a bad experience though. It will be good 
to see more reviews so that we can get a better idea. 
Apparently the Phenyl Tropane alkaloids should test 
yellow with the Mandelin reagent also.
#10 Person D   
(Originally posted by Person C) 
tried these three times. Im from the USA. These are the 
bomb. Honestly can say one of the best legal pills Ive 
tried. Started feeling full effects about an hour after 
taking it. So euphoric, Rushes, Very like MDMA. I took 
one and then two hours later took the Second. Total 
duration About 4-6 hours. But definately give them 
a try. I f***in love em. Ive ordered them three times 
already and Im waiting on a fourth order and I can't 
wait for them to come they are awesome.
shill much?
#12 Person E (Senior Moderator) 
Please do report if you have those suspicions.  
We always look into it, so it wont get anyone in 
trouble if it's unwarranted
Box 3
 Online user forums 
Social interactions involving drugs are increasingly 
occurring online. For over a decade, bulletin boards (or 
forums) such as Bluelight (www.bluelight.ru) and Drugs 
Forum (www.drugs-forum.com) have allowed people 
from around the world who use drugs to interact with 
one another with a degree of anonymity. 
Social interactions on drug forums may involve:
• Requests for information about a drug or route of 
administration 
• Posts that describe a person’s experience with a 
particular drug or pill (i.e. a trip report or pill report)
• Instructional information, such as how to reduce the 
likelihood of experiencing drug-related harm (e.g. pill 
testing or bad drug use combinations) 
• How to enhance the subjective drug use experience 
(e.g. a good setting for a trip) 82. 
Online user forums have the potential to both reduce 
and increase drug-related harms:
• Information provided by peers is likely to be perceived 
as more credible than that obtained from government 
websites or the mainstream media 83. However, the 
degree to which harm is reduced will depend on the 
information provided and the interpersonal dynamics 
that develop between participants. Fortunately, there 
are moderators that censor the content, provide 
additional information where appropriate, and remove 
posts that break forum rules. 
• In her study of 837 online drug forum participants, 
Barratt found that 80 per cent of participants said 
that their drug use was influenced by information on 
forums82. The most common behavioural influence was 
the introduction of a new substance, followed by dosage 
information, and then information about content/purity.
Monitoring new  
drugs through forums 
Interactions through online user forums provide allied 
health and youth workers, clinicians and researchers 
with an effective method for monitoring the emergence 
of drug use trends and accessing information about 
new and emerging drugs. This methodology comprised 
part of the Psychonaut Web Mapping Project, which led 
to a range of new drugs being identified 71 , however 
it does require a healthy level of scepticism. Table 1 
provides an example of a relatively recent thread on 
Bluelight, which suggests that a new legal high product 
called London Underground Dove Love contains a 
cocaine-like analogue, RTI-336. The fifth post from 
ludovelover appears to be somebody associated with 
the manufacture or distribution of the product. This 
participant has a history of three posts on the site 
promoting the product and is subsequently identified as 
a shill (i.e. a person who publicises or praises something 
or someone for reasons of self-interest).
Excerpt taken from Bluelight.ru. Identifying user names 
and dates have been removed for anonymity.
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how can allied  
health and youth 
workers respond? 
Most people who use emerging drugs will not 
experience harm 41, 42. Indeed, Barratt et al. found that 
less than one per cent of participants experienced 
problems associated with their use of synthetic 
cannabis that were severe enough to seek assistance35. 
Allied health and youth workers 
are uniquely placed to identify 
this hidden population. 
However, they will need to assess specifically for the use of 
new and emerging drugs (see Box 4) as people do not typically 
spontaneously admit to their use, and might not perceive these 
products to be drugs. If the use of new and emerging drugs is 
identified, workers can then provide education, harm reduction, 
brief intervention and referral to treatment if required.
Education about the potential harms associated with these 
drugs needs to be framed carefully and credibly as Australians 
can be sceptical of traditional drug education where harms 
are sometimes overstated. Workers must provide a balanced 
discussion that acknowledges the perceived reduction in harms 
associated with using these products in comparison to traditional 
illicit substances (e.g. reduced legal harms, not affiliating with 
illicit drug dealers), while also highlighting the potential harms 
that could arise from using products containing chemicals that 
we know little about. 
Assessment 
Clinicians working in mental health, AOD services 
and acute settings, as well as allied health and 
youth workers, need to be aware that some of their 
clients may be using new and emerging drugs. Most 
traditional assessments do not ask about these drugs, 
and clients may not spontaneously admit to their use 
as they may not be perceived as drugs. It is therefore 
important to ask the following questions: 
• Have you used anything that has been bought 
online or from adult stores? 
• Have you taken any herbal supplements, legal 
highs, party pills, herbal highs, research chemicals, 
bath salts or incense?
• What chemical or brand have you used?
• What were the effects of it (e.g. stimulant, 
depressant or hallucinogen)?
• Was it like any other substance you have used?
• Did you experience any negative health effects?
This information must be collected sensitively to 
prevent the process from increasing awareness and 
subsequent use of new and emerging drug products. 
If use of these drugs is established, further information 
about the specific substance can be obtained from 
online user forums. (An example of how forums can 
be used to obtain information is provided in Table 1.) 
Educational websites, such as Erowid (www.erowid.org), 
may also be useful. However, with the ever increasing 
number of brands, many of which may now be made 
locally, this approach might be less helpful.
Lastly, provide the individual who is using, or is 
potentially going to use these drugs, with the 
intervention appropriate to the setting. (For harm 
reduction see Box 5 and for acute settings see Box 6.)
Box 4
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how can clinicians 
in acute settings 
respond? 
The clinical presentation in acute settings varies depending 
on the chemical that has been consumed. Presentations 
associated with the use of powders/pills have included 
symptoms such as ataxia (loss of co-ordination), sweating, 
tachycardia (fast heart rate), arrhythmia (irregular heart 
beat), hypertension (high blood pressure), hyperthermia 
(over-heating), rhabdomyolysis (breakdown of muscle 
tissue), kidney failure, seizures, bruxism (clenched jaw/
teeth grinding), nausea, anxiety, agitation, confusion, 
paranoia and hallucinations 43-53. The most severe 
symptoms reported include stroke, cerebral oedema (brain 
swelling), cardiorespiratory collapse and death 51, 54-57. 
Synthetic cannabis presentations have included symptoms 
such as sweating, tachycardia, arrhythmia, hypertension, 
nausea, anxiety, agitation, seizures, confusion, paranoia 
and hallucinations 30, 31, 58-62.
Laboratory results are limited in identifying the 
contribution of new and emerging drugs to presentations. 
Tests are not yet available for 
many of these substances as 
the drugs are emerging faster 
than tests can be developed. 
In interpreting laboratory results, it is also important to 
note that many of these drugs can produce false positive 
results for other more traditional drugs. For example, 
mephedrone and MDPV can produce a false positive for 
amphetamine and/or cocaine use 63, 64. Therefore, it is 
essential to determine whether the person presenting has 
consumed any new and emerging drugs through careful 
questioning (see Box 4).
Box 5
 Harm reduction 
While the safest option is to abstain from consuming new and 
emerging drugs, some individuals will continue to use them. 
Information should be provided to these individuals that 
reduces their likelihood of experiencing harm:
• Avoid driving, swimming and operating machinery while 
under the influence of new and emerging drugs. 
• Only use new and emerging drugs with another person 
who is not using any AOD and who can call triple zero if 
things go wrong. If using alone, then at least tell somebody 
and write down the name of the product or chemical. 
• Conduct a test to ensure that no allergy exists by ingesting 
a minute quantity an hour or more before using the 
product. Given that the chemicals contained in products 
can vary over time 5 , this step is recommended even 
when a product has previously been used as there is no 
guarantee that the contents will be the same. 
• People with pre-existing mental health conditions should 
not consume these products. Most deaths from new and 
emerging drug products, such as suicides, have involved 
poly-drug use or underlying mental health conditions 41. 
As these drugs can lead to a reoccurrence of psychotic 
symptoms among people with a history of drug-induced 
psychosis, such individuals need to be given information 
about harms and dissuaded from use as the new drugs 
might be perceived as less problematic than the substance 
that originally caused the psychosis 30, 60. Further, it is 
recommended that these products are not consumed with 
AOD, including caffeine. Given caffeine is contained in many 
products, sometimes in high quantities, additional caffeine 
consumption could lead to toxic effects 6. 
• Older people and people with pre-existing cardiovascular 
conditions should avoid using new and emerging drugs. The 
chemicals contained in some products might be cardiotoxic, 
lead to hypertension, or cause fast/irregular heartbeats. 
• Injection of pre-packaged products is highly discouraged 
given the unknown contents of the products. Not only 
are the active chemicals unknown, many products also 
contain a range of fillers and even numbing agents that 
could lead to health problems if injected. A number of 
needle and syringe program workers in Victoria have 
reported negative outcomes from attempts to inject 
pre-packaged powders/pills and this has reportedly led 
to at least one Australian death 21. Dorairaj et al. reported 
a recent rise in soft tissue complications associated with 
injecting new and emerging drug products in Ireland, 
including extensive abscess formation 84.
• People using research chemicals must be aware that 
packaging can be misleading. A package stating that 
it contains chemical ‘a’ active at 250mg, may actually 
contain chemical ‘b’ active at 1mg and so ingesting 
250mg will lead to an overdose. Use of scientific scales 
is encouraged as it is impossible to visually identify 
differences of 1mg or even 10mg. 
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how can clinicians and workers  
in AoD settings respond? 
Presentations to AOD treatment services primarily for new 
and emerging drugs appear to be limited. For example, the 
Victorian Earlier Identification of Drug Harms Project (EIDHP), 
which interviews AOD workers from approximately 20 services 
six times a year to identify changing and/or emerging drug 
use patterns and behaviours, has not noted an increase in 
presentations related to these drugs. This might be because the 
use patterns for new and emerging drugs are similar to those for 
other party drugs such as ecstasy. Despite a higher incidence of 
ecstasy use than drugs such as heroin in Australia 65 , relatively 
fewer individuals present to AOD services seeking treatment for 
ecstasy. Nonetheless, a number of people who present in an AOD 
setting have used ecstasy. This may also be the case for new and 
emerging drugs. Workers therefore need to ask whether these 
drugs are being used to get a more accurate understanding of 
the patient’s drug use (see Box 4).
Where use of new and emerging drugs is identified as 
the secondary cause of a patient’s presentation, this drug 
use should also be addressed in the treatment plan. For 
example, education and harm reduction can be provided to 
some individuals, while for others, treatment might include 
abstaining from the use of new and emerging drugs. If the use 
of new and emerging powders/pills is the primary presenting 
problem, Winstock and colleagues advise that AOD workers 
should provide those evidence-based treatments that are 
recommended for amphetamine dependence 41. Similarly, 
AOD workers can provide individuals presenting with concerns 
about their synthetic cannabis use with those evidence-based 
treatments that are recommended for cannabis dependence. 
Workers need to ask 
whether these drugs are 
being used to get a more 
accurate understanding of 
the patient’s drug use.
Box 6
Acute clinical 
treatment of new  
and emerging drugs 
When consumption of a new and emerging drug is 
suspected to have contributed to an acute medical 
presentation, most clinicians recommend that the patient 
be treated as though they have consumed the prototype 
drug that the new drug has been developed to mimic. For 
example, adverse symptoms from ingesting powders and 
pills can generally be treated in a similar fashion to those 
caused by amphetamine and cocaine intoxication since most 
have similar effects on the central nervous system25, 85, 86. 
Mas-Morey et al. recommend that acute severe medical 
complications arising from drug toxicity such as 
hyperthermia be treated through aggressive cooling using 
ice, while kidney injury and rhabdomyolysis should be 
treated with intravenous saline and other resuscitative 
measures. Psychosis, agitation, seizures and adverse 
cardiovascular effects associated with pills and powders 
should be treated with benzodiazepines87. Where psychotic 
symptoms and agitation do not diminish, Mas-Morey et al. 
recommend subsequently administering an antipsychotic 
agent. Oral therapy is preferred over intravenous or 
intramuscular administration of medications to manage 
acute symptoms. Castellanos and Thornton recommend 
similar intervention for individuals presenting with 
agitation and psychosis associated with acute synthetic 
cannabis intoxication31.
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how can policy makers respond? 
The emergence of new drugs has presented a 
significant challenge for policy makers worldwide. 
To date, the Australian policy response has 
primarily focused on supply control. Individual 
substances have been banned and analogue laws 
introduced (see Box 1), however this approach has 
not been successful in reducing the availability of 
new and emerging drugs. Innovative approaches 
will be required to effectively reduce harm.
Banning individual chemicals 
The legal appeal of new and emerging drugs is reduced by 
banning their component chemicals as they are identified. 
However, this approach renders legislators and service providers 
playing ‘catch up’ to an ever increasing array of new substances. 
It may also contribute to increased harm by driving newer and 
lesser known products onto the market. Further, the notoriety 
that some emerging substances gain by their prohibition, such 
as mephedrone, can prompt increased demand that is met by 
the illicit market – sold as either the chemical itself or used in 
other illicit drugs such as ecstasy 66. 
Analogue laws 
Analogue laws ban broad categories of substances. Chemicals 
have been banned based on their structural similarity to other 
prohibited drugs. Similarly, substances that activate the same 
brain systems as other prohibited drugs have been banned 
(e.g. cannabinomimetics). However, this assumes that drugs 
of a similar category, or that act on similar parts of the brain, 
have similar harm profiles, which is not necessarily the case. To 
date, many of these broader laws have not been successfully 
prosecuted, and the USA’s Drug Enforcement Agency recently 
recommended that this approach be avoided 67. Some 
researchers have also expressed concern that analogue laws 
might impede the development of medicines 68, 69. 
Consumer/medicinal law 
Current Australian laws for the regulation of consumer and 
medicinal products are unlikely to offer much control over new 
and emerging drugs. For example, the Therapeutic Goods Act 1989 
only applies to those chemicals already scheduled as medicines 
within the Poisons Standard (see Box 1) or to ‘therapeutic’ products. 
Either scenario would be difficult to establish when a product 
is labelled ‘not for human consumption’. Similarly, prosecution 
under consumer law would be difficult as it would require that 
the product be demonstrated to fail to work for the purposes 
advertised (e.g. plant fertilisers, bath salts). 
Regulation 
New Zealand has established a specific regulatory regime 
for new psychoactive substances that will come into effect 
this year. Under this system, distributors will be required to 
determine the safety of their products at their own expense 
before they may legally be sold. This new regulatory regime 
offers an alternative policy response to mitigate the harmful 
cycle of new, untested drugs being sold as legal highs. This 
policy also restricts the sale and marketing of products to 
minors, and contains labelling requirements. A recent UK 
inquiry into new and emerging drugs recommended that 
this model be implemented 67. 
While the efficacy of the NZ 
model is yet to be established, it 
might provide a good framework 
for developing Australian policy 
given the absence of evidence-
based options. 
Demand reduction 
In addition to supply control, Australian policy must target a 
reduction in demand for new and emerging drugs. Campaigns to 
reduce demand for traditional drugs are not necessarily helpful 
as they may inadvertently raise awareness of new and emerging 
drugs. Hence, novel approaches must be considered. 
In the case of synthetic cannabis, initial demand for the product 
was fuelled by efforts to avoid positive drug urine screening 
tests, which detect the presence of THC metabolites for up to 
three months after an individual’s last use. The move to saliva 
screening, which has been designed to detect only recent 
cannabis use, may reduce demand for an undetectable synthetic 
substance over cannabis. 
The aforementioned UK inquiry into new and emerging drugs 
also noted that they ‘are substitutes for similar and possibly 
less dangerous traditional drugs’. The inquiry suggested that 
decriminalisation of these traditional drugs would reduce 
demand for new and emerging drugs 67, p. 9, and recommended 
a model similar to that which has been implemented in 
Portugal. Indeed, it would be interesting to compare the 
prevalence of new and emerging drug use in countries that have 
decriminalised or regulated the use of drugs, with countries 
that prohibit drug use through criminal sanctions. Such analysis 
might provide the impetus, both in Australia and internationally, 
to reconsider the current overarching legislative frameworks.
13PreventionResearch
the need for early 
warning systems 
Given how rapidly new drugs are entering the 
market, there is the potential for one to emerge that 
could cause significant harm. In this environment, 
early warning systems could prevent a potential 
public health crisis. 
Survey-based systems such as the EDRS are responsive – 
researchers need to be aware of a new drug to be able to 
question participants about it – so they have limited use as 
an early warning system. For example, mephedrone use was 
occurring in Australia as early as 2007 yet the EDRS did not 
identify it until 2010. This was despite an Australian analysis of 
products containing mephedrone being published on Bluelight 
– an online forum for drug-related harm reduction – in 2007 
70. This limitation of the EDRS has been addressed by including 
an open-ended question asking participants whether they 
have used any new drugs not included in the survey. However, 
the accuracy of the responses is questionable, particularly in 
relation to the contents of pre-packaged blends. 
Monitoring of acute presentations, such as hospital 
emergency department presentations or ambulance statistics, 
could be helpful in providing early identification of potentially 
harmful new drugs. However, given the aforementioned 
limitations in coding procedures, trends are unlikely to be 
identified at an early stage unless large numbers present at 
one site. The use of biochemical testing, such as urine drug 
screens, by hospital emergency departments to identify types 
of drugs used is also inconsistent and limited by clinician 
awareness and laboratory capabilities.
As Australia’s traditional monitoring systems struggle to detect 
the emergence of new and potentially dangerous drugs, there 
is a need to develop more effective early warning systems. 
One potential methodology is that used by the European 
Psychonaut Web Mapping Project 71-73 (see Box 7). 
Raimondo Bruno, Senior Lecturer at the University of Tasmania, 
proposes a combination of approaches to develop an effective 
early warning system in Australia. He recommends using the 
Psychonaut Web Mapping Project methodology to identify 
new trends that can be verified using surveys and wastewater 
analysis. In addition, samples of products from adult stores 
and Australian online vendors should be sought for analysis to 
provide further verification and to identify new substances as 
they emerge. 
Communication of warnings 
Once a drug has been identified, the dissemination of this 
information needs to be carefully managed. The Australian 
media has played a significant role over the past two years 
in framing the emergence of new drugs as problematic – 
sometimes fuelling a moral panic 19. The information is often 
provided by experts who highlight the potential dangers of 
the new drug. While such assertions are presumably intended 
to reduce the likelihood of individuals using these substances, 
they may be inaccurate given an absence of toxicological data, 
and they do not appear to act as a deterrent. For example, 
Forsyth found that the most significant increases in interest in 
purchasing mephedrone occurred following each report of an 
alleged mephedrone-related death 74. As such, it is important 
that information about potentially harmful products be 
targeted to specific networks, such as AOD and mental health 
services, emergency departments, outreach workers, peers and 
user-based forums.
Box 7
An exemplar of 
monitoring: the 
Psychonaut Web 
Mapping Project  
The Psychonaut Web Mapping Project provides a useful 
model for developing early warning systems. It involves 
monitoring the web for new and emerging drugs using 
scanning software. Key word searches are also monitored. 
Yin and Ho have identified a strong connection between 
specific search terms and the number of calls to a US 
poisons centre about new and emerging drug products 88. 
Once a new drug is identified, further information about 
the drug is gathered through purposeful website sampling, 
including online user forums 71. A technical report on the 
newly identified substance is then developed and passed 
on to the EMCDDA for validation. 
Raimondo Bruno, Senior Lecturer at the University of 
Tasmania, and PhD candidate Rosalie Poesiat, are currently 
conducting an Australian replication of the Psychonaut 
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glossary
Analogue: A chemical that is similar in 
structure to another chemical.
Benzylpiperazine (BZP): A 
psychostimulant that was contained in 
many of the first generation legal highs. 
Cathinone: A naturally occurring 
psychostimulant that is contained in the 
khat tree. Many of the second generation 
legal highs were cathinone analogues.
Dopaminergic agent: A chemical that 
leads to increased dopamine in the brain. 
Dopamine is implicated in reinforcing 
behaviour and also psychosis.
Legal highs: Psychoactive products that 
are sold as legal alternatives to illegal 
drugs. Unlike legal highs that were 
available in the past, many of today’s 
legal highs are pre-packaged products 
containing novel psychoactive chemicals 
that produce pronounced effects. These 
chemicals might not necessarily be legal.
Metabolites: The chemicals that are 
produced as the body breaks down a 
drug that has been ingested. 
Mephedrone (4-methyl-methcathinone): 
The most popular cathinone analogue that 
was contained in the second generation 
legal highs. Also called miaow miaow.
Research chemicals: Raw active 
chemicals, as opposed to those contained 
within pre-packaged products. 
Synthetics: A term often used to describe 
new and emerging drugs. It is not very 
accurate as many traditional drugs, such 
as LSD and amphetamines, are also 
synthetic as opposed to naturally derived. 
 





A case study of the emergence of Kronic as the most 
popular brand of synthetic cannabis demonstrates how 
policy, media and drug-related harm intersect. The 
story of its rise and ineffective legal demise involves 
several characters: entrepreneurial businessmen, 
medical experts, mining companies, policy makers, 
media and, of course, people interested in using 
synthetic cannabis. 
Kronic’s story began here when its owner, Matthew 
Wielenga, expanded his synthetic cannabis business from 
New Zealand to Australia in 2010. By late April 2011, the 
Australian media were reporting that workers on Western 
Australian (WA) mine sites were using Kronic to evade drug 
testing. Since Australian mining companies must meet strict 
occupational health and safety regulations, the WA mining 
lobby quickly persuaded the WA Government to respond. On 
13 June 2011, it was announced that seven of the chemicals 
that Kronic was suspected to contain would be banned 
in WA from 17 June, prompting strong support from the 
Australian Medical Association.
The announcement also created significant publicity for 
Kronic, with most media headlines referring to the brand. The 
manufacturers of Kronic endeavoured to sell their remaining 
stock ahead of the ban, using social media to engage their 
customers. On the evening of 16 June, a party was organised 
in Perth encouraging people to smoke their remaining Kronic, 
which was quickly shut down by police.
Soon after the June 2011 bans came into effect, similar products 
became available that were alleged to contain new chemicals. 
Kronic released a Black Label blend for its WA customers.
The Kronic brand was further publicised when, on 30 June, the 
media reported that a novel benzodiazepine had been detected 
in Kronic by New Zealand authorities. Wielenga asserted that 
this benzodiazepine was not intended to be in Kronic, and that 
the company importing the chemicals that he used in Kronic 
must have been at fault. This company, Stargate International, 
established the ‘legal highs’ industry in New Zealand.
On 4 August 2011, a man with a pre-existing heart condition 
died after apparently smoking Kronic Black Label. The 
WA Government reacted promptly, banning another 14 
chemicals from 6 August and other states quickly followed 
WA’s lead. New South Wales banned eight chemicals on 1 
July, while Tasmania and the Northern Territory took action 
in early August. Later in 2011, Queensland and Victoria also 
scheduled several chemicals, while the federal government 
banned eight chemicals in July 2011 and eight broad 
chemical categories in May 2012.
The Kronic chronicles demonstrates the piecemeal response 
to synthetic cannabis in Australia, which has essentially been 
reactive and ineffective. There is little evidence that these 
changes have significantly reduced the availability of synthetic 
cannabis. In fact, each legislative action has raised awareness 
of it through the media, and manufacturers have responded 
to legislative actions by bringing new and lesser-known 
chemicals onto the market. While Wielenga’s company is no 
longer producing Kronic in Australia, a number of others have 
capitalised on the Kronic brand, selling their own synthetic 
cannabis products as Kronic.  
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...continued from page 3
So, what can be done?  
While coordinated global monitoring of these new 
drugs exists via such bodies as the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), Focal 
Point Network and the UN SMART project, monitoring of 
a drug’s existence does not protect consumers without 
some awareness of its risk and effect profile. Legislators 
in Australia could consider supporting an independent 
risk assessment unit for new and emerging drugs, which 
integrates data from universal and targeted public health 
surveillance, subjective user effect and risk profiles, police 
and emergency health services data, and basic scientific 
information. By supporting a flexible and responsive unit, 
assessments could target the compounds of most concern. 
A useful framework for such a risk assessment strategy has 
already been developed by the EMCDDA in Lisbon.
Alternatives to control under the current drug legislation 
must also be considered, and the lessons learned from 
alcohol and tobacco control taken into account. We know 
that price, age and promotion restrictions work. We could 
consider the integration of familiar regulations for other 
consumables such as consumer protection, quality control 
and trading standards. Mandating producers to include 
dosing advice, contraindications, side effects and what to 
do in an emergency, would be an interesting approach. For 
example, including a warning such as, ‘May cause paranoia, 
psychosis and extreme mood swings’. A reporting system 
for side effects could also be set up, which is independently 
monitored by researchers and funded by manufacturers, to 
observe longer term harms and emerging complications. 
Other approaches might include requiring producers 
to demonstrate that their product is ‘safe for human 
consumption’ or that it is fit for purpose by applying for 
approval through the Therapeutic Goods Administration 
(TGA). Evaluating the ideas of New Zealand’s legislators may 
also be instructive, with the Advisory Council for the Misuse 
of Drugs in the UK calling for a similar review of how new 
drugs should be assessed and controlled. 
Finally, we need to explore the best ways to support 
informed decision-making by individuals, the majority of 
whom are interested in their own health and wellbeing. 
While there is much talk about harm reduction, there has 
been little research into what messages are most effective, 
how they are best communicated, and how acceptable 
currently recommended approaches are to users of new 
and emerging drugs. In the future, harm reduction will 
need to explicitly incorporate the maintenance, and 
possibly even the enhancement, of pleasure if we really 
want people who use drugs to see that harm reduction 








In the future, harm 
reduction will need to 
explicitly incorporate 
the maintenance, and 
possibly even the 
enhancement, of pleasure.
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Policy makers should take heed of the Kronic chronicles 
and consider alternative legislative responses that better 
mitigate harm than banning specific substances. As discussed 
by Dr Winstock, regulating markets for new and emerging 
psychoactive substances is one option. Yet, if only new or 
emerging drugs are regulated, we may just shift trends in 
drug consumption towards lesser-known drugs and away 
from traditionally prohibited drugs. Research indicates that 
the legal status of new and emerging drugs is attractive to 
drug consumers, who wish to alter their mind or experience 
drug-induced pleasure without breaking the law. In the case of 
Kronic, mounting evidence suggests that synthetic cannabis 
is more harmful than cannabis itself. If the goal of policy is 
to reduce drug-related harms in the community, ending 
prohibition of cannabis may achieve this goal by breaking the 
cycle of new and lesser-known products entering the market, 
and reducing the demand for a ‘legal’ cannabis-like alternative. 
The question shouldn’t be whether cannabis is regulated, but 
what model of cannabis regulation is most suitable.
Stephen Bright is Coordinator of Addiction Studies and 
Monica Barratt is Research Fellow at the National Drug 
Research Institute, both at Curtin University
The Kronic timeline
2010: Matthew Wielenga expands his 
business from New Zealand to Australia
Late April 2011: Media reports of Kronic 
being used by workers on WA mine sites
13 June 2011: WA Government announces 
impending ban on chemicals thought to be 
contained in Kronic
16 June 2011: Party held for Kronic users to 
consume remaining product ahead of bans
17 June 2011: Bans come into effect
June/July 2011: Kronic releases Black Label 
blend for WA customers
4 August 2011: Man dies after allegedly 
smoking Kronic Black Label
6 August: WA Government bans a further 
14 chemicals
July 2011-2012: Other state and territory 
governments and the federal government 
follow WA’s lead, banning a variety of chemicals
2012-2013: Newer versions of Kronic 
released into the market
Mounting evidence suggests 
that synthetic cannabis is 
more harmful than cannabis. 
Kronic
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Letters
NBOMe — a very different 
kettle of fish . . .
TO THE EDITOR: We are concerned 
that recent media reports about a 
17-year-old Sydney boy who died 
after allegedly consuming 25B- or 
25I-NBOMe might lead to an increase 
in the incidence of NBOMe toxicity 
among patients presenting to 
emergency departments. NBOMe 
was reported to be available online 
for as little as $1.50 per tablet.1 The 
subsequent media interest is likely to 
have increased public awareness of 
the availability of the NBOMe series 
of drugs; and increased awareness 
of psychoactive substances through 
media reporting is associated with 
their increased initial uptake.2 It is 
possible that the increased awareness 
of this cheap LSD (lysergic acid 
diethylamide)-like drug will prompt 
some individuals to buy NBOMe 
tablets and sell them as LSD in order 
to make a significant profit.
The NBOMe series are analogues 
of the 2C series of psychedelic 
phenethylamine drugs that include 
an N-methoxybenzyl (hence, 
“NBOMe”) substituent that 
has significant effects on their 
pharmacological activity. NBOMe 
drugs have been characterised 
in in-vitro receptor studies as 
remarkably potent agonists of the 
5-HT2A and 5-HT2C receptors,
3 
which may account for the powerful 
psychedelic effects at very low 
doses that have been reported by 
users.4 Unlike LSD, however, the 
NBOMe drugs have significant 
sympathomimetic effects and can lead 
to acute toxicity, in addition to the 
behavioural hazards associated 
with LSD use.4 This problem is 
compounded by up to six “effective” 
doses of an NBOMe drug being sold 
in a single tablet. Our observations 
of online marketplaces indicate that 
NBOMe tablets are available for 
purchase in Australia containing 
1200 g, yet as little as 200–1000 g 
may be considered an effective 
sublingual dose.5
The treatment of a patient 
presenting with LSD intoxication 
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typically involves supportive care 
and rarely requires pharmacological 
intervention other than sedation. 
Individuals presenting to emergency 
departments with acute NBOMe 
toxicity might experience 
cardiovascular complications, 
agitation, seizures, hyperthermia, 
metabolic acidosis, organ failure 
and death.5 Therefore, we would 
encourage medical and paramedical 
personnel involved in managing 
patients presenting with symptoms 
of psychosis who are presumed to 
be under the influence of illicit drugs 
to consider the diagnosis of an 
inadvertent NBOMe-type drug 
overdose, which mandates a higher 
level of care than they might 
otherwise assume is needed. 
Appropriate treatment might include 
aggressive cooling, pharmacological 
intervention and other high-level 
resuscitative measures.
David G E Caldicott Emergency Physician1
Stephen J Bright Psychologist and Senior Alcohol 
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Monica J Barratt Research Fellow3
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Appendix F: Information and consent forms 
Note: The actual letter was printed with a Curtin University letterhead 
Division of Health Sciences 
School of Psychology 
Project Title: Dominant Discourses and Narratives of Substance Use 
Dear Participant, 
As a PhD (Clinical Psychology) student, I am investigating how the use of illicit substances, 
particularly heroin, is a poignant issue in Australia. In developing policies pertaining to the use of 
these substances, and indeed interventions for illicit substance users, it is important that we 
understand peoples’ attitudes towards illicit substance use. 
Participation is voluntary, with no penalty resulting from you not wishing to take part, and I 
would be very appreciative of your assistance.  
In participating, you are requested to complete the attached questionnaire. This should take no 
longer than 5 minutes. The information is provided by you anonymously and will remain 
confidential, with only myself and my supervisors having access to the raw data. However, for 
this reason, you will only be able to withdraw from the study prior to submitting a completed 
questionnaire. 
The results of the study will be non-identifiable and used to complete PhD thesis, and possibly, 
future publications. Following the completion of my thesis, the raw data will be housed in a 
lockable filing cabinet in the school of psychology for five years, after which it will be destroyed. 
This project has gained ethical approval from the University Human Research Ethics Committee.   
If you have any further questions, please do not hesitate to ask for clarification.  
PLEASE RETAIN THIS INFORMATION LETTER.  
If you have any problems with my conduct during your participation in this research, or would just 
like some further information, please contact my supervisor, Ali Marsh on 9266 2468. Alternatively, if 
you would prefer to contact somebody independent of this study, please phone the Ethics Committee 
Secretary, Linda Teasdale, on 9266 2784.   
If you feel at all distressed following the completion of the questionnaire, please contact your 
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